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ABSTRACT 
Upper gastrointestinal tract (GIT) cancers usually receive neoadjuvant therapy prior 
to surgery. The histological assessment of this response and if this can be predicted 
on the pre-treatment biopsy are the subject of this thesis. 
The first study assessed the inter- and intra-observer variation amongst pathologists 
in evaluating the degree of regression using the Mandard scoring system. The results 
showed that the reproducibility of this system was only fair to moderate in both 
cases of inter- and intra-observer testing. 
The second study examined the levels of expression of selected tumour markers 
before and after neoadjuvant chemotherapy. These included markers monitoring 
apoptosis (p53 and bcl-2), proliferation (Ki-67), angio- and lymphangio-genesis 
(VEGF, CD-31 and LYVE-1). The levels of expression in these markers were 
measured in the pre-treatment biopsies, to monitor if they could predict the response 
to neoadjuvant therapy.  It was found that when the panel of chosen markers being 
used together, delivered a much higher power of prediction rather than adopting only 
one marker, where the collective power of prediction was 80.6%, whereas  
individually, the power of prediction ranged between 24.6% (VEGF) and 60.7% 
(Ki-67). 
The third study explored the use of digital image analysis in assessing the response 
to neoadjuvant therapy. It was found that while this technique paralleled the 
Mandard scoring system, it delivered a more objective and reproducible assessment. 
On the basis of these results I suggest that image analysis should be used to assess 
tumour regression especially in the context of clinical trials. In this retrospective 
study it has been shown that the pre-treatment biopsy can predict the degree of 
regression.   
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Gastric and oesophageal adenocarcinoma, even when clinically localized, continue 
to resist curative surgical management despite progressively more extensive 
operations, including oesophagectomy, subtotal gastrectomy, total gastrectomy, 
radical gastrectomy with splenectomy and distal pancreatectomy, as well as 
extended lymph node dissection. Current efforts are now focused on designing and 
testing multimodal, perioperative strategies with the aim of achieving the same 
encouraging effects observed with combined,  multidisciplinary therapies employed 
in the treatment of other solid tumours, such as colon and rectal cancers, anal cancer, 
and breast cancer. 
Since tumour response to preoperative systemic treatment is measurable, 
neoadjuvant therapy serves as an in vivo chemosensitivity assay. A significant 
response indicates that the drug regimen is appropriate and, in addition, may be 
useful postoperatively. Lack of significant measurable response indicates the need to 
choose another regimen or to proceed to surgery. Rapid progression of the disease in 
the face of neoadjuvant therapy may identify a tumour so aggressive that a patient 
can be spared non-therapeutic surgery and its concomitant morbidity. 
Relevant papers were identified by searches of MEDLINE and EMBASE with 
‘gastric adenocarcinoma’, ‘oesophageal adenocarcinoma’,  ‘predictive factors’, 
‘tumour regression’, ‘Mandard’, ‘Image analysis’, ‘p53’, ‘Bcl-2’, ‘Ki-67’, ‘VEGF’, 
‘CD-31’, and ‘LYVE-1’ as keywords. Additional reports were selected from 
reference lists of individual papers and searches of conference abstracts. Studies 
were preferentially selected when the subject was prediction of response, rather than 
prognostic importance of a marker. 
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1.1 Cancer of the Oesophagus 
1.1.1 Epidemiology 
Oesophageal carcinoma is still one of the most lethal malignancies. It grows 
relatively fast, and patients with this cancer generally have a worse prognosis than 
those with other types of gastro-intestinal tumours. Surgery is performed as standard 
treatment but prognosis for patients remains poor with 5-year survival rates of only 
10-20% 1. 
Recent UK data indicate that there are an estimated 7000 new diagnoses and 6700 
deaths from oesophageal cancer each year. The overall age standardized incidence 
has increased over recent decades especially among adenocarcinomas (ACA) close 
to the gastro-oesophageal junction. Data from the Office for National Statistics 
shows that the incidence for men and women in England and Wales is 12.6 and 5.9 
per 100.000, respectively. Oesophageal cancer is essentially a disease of older age, 
with two thirds of cases being diagnosed over 65 years of age. The aetiology of 
oesophageal cancer appears to be different for each histological subtype and 
independent of this for different geographical regions. The two major groups are 
squamous cell carcinoma (SCC) and adenocarcinoma (ACA) 2. 
Currently, most of the patients with adenocarcinoma of the oesophagus present with 
advanced disease. The poor prognosis for most of the patients is responsible for the 
development of new therapeutic strategies, including the use of a multimodal 
approach. None of the treatment protocols have managed to improve overall survival 
so far, which may be related to the wrong agents being used or the lack of survival 
factors linked with the treatment. The presence of distant metastasis, depth of 
tumour invasion, lymph node status, and complete tumour resection (R0 resection) 
are the most significant prognostic factors in patients with oesophageal 
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adenocarcinoma. In the recent years, biologic factors that may determine individual 
outcome in oesophageal cancer patients have been suggested 3. They include tumour 
suppressor genes (e.g., p53, p21, p16), proliferation markers (e.g., Ki-67), apoptosis-
related proteins (e.g. Bcl-2), adhesion molecules, growth factors [e.g., vascular 
endothelial growth factor/endothelial growth factor (VEGF/EGF)], and microvessel 
density. Most studies have investigated only small numbers of patients or have had 
methodological problems. Therefore, prediction of the true risk of tumour 
progression and metastatic spread and the relation between these factors and disease 
outcome remain varied and controversial 4-6. 
A meta-analysis by Greer et al. analysing 21 randomized trials of neoadjuvant 
radiochemotherapy prior to surgery for patients with oesophageal cancer, showed 
only a non-significant improvement in overall survival. It has been well established 
that only patients with a complete pathological response to neoadjuvant therapy will 
have a significant survival benefit. The prognosis of patients who do not respond to 
neoadjuvant therapy appears to be inferior to that of patients who had surgery alone. 
These data suggest the need for predictive markers to allow a customized 
radiochemotherapy to increase the number of complete pathological responses 
following neoadjuvant approaches 7. 
1.1.2 Pathological Changes involved in the development and spread 
of oesophageal cancer 
The development of cancer in general can be categorized in six essential alterations 
in cell physiology that collectively dictate malignant growth (Figure 1): 1. Self-
sufficiency in growth signals; 2. Insensitivity to growth-inhibitory (antigrowth) 
signals; 3. Avoiding apoptosis (i.e. programmed cell death); 4. Unrestrained 
replicative potential; 5. Sustained angiogenesis; and 6. Tissue invasion and 
metastasis 8.  
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Figure (1). The different pathways that gives cancer its capabilities 
 
In the table below (Table 1), a summary of the common changes found in the distal 
oesophageal, gastro-oesophageal junction (GOJ), and gastric adenocarcinoma is 
displayed. 
 
Mechanism of malignant growth Possible involved antigens and factors 
Self-sufficiency in growth signals Cyclin D1 and E, Ki-67, PCNA, EGFR, TGF-α, EGF, 
Her2/neu, integrins 
Insensitivity to antigrowth signals Rb, p16, p21, APC, TGF-ϐ, Smad4 
Avoidance of apoptosis P53, Bcl-2, Fas-fas ligand, NF-kB, COX-2 
Limitless replicative potential Telomerase 
Sustained angiogenesis VEGF 
Invasion and metastasis Cadherins, integrins, CD44, serine protease 
system, MMP, TIMP 
Other factors DNA-content, promoter hypermethylation 
multiple genes, TH1/TH2 balance, CRP, PTHrP 
Table (1). Hallmarks of adenocarcinoma of the distal oesophagus, gastroeosophageal junction 
(GOJ), and gastric adenocarcinoma 
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The reduced responsiveness of larger tumours may perhaps be related to acquired 
changes in tumour biology, where a combination of heterogenous tumour clones, 
tumour hypoxia and immune cell responses can alter the balance between 
proliferation and apoptosis. Despite variations in individual mechanisms of action, 
chemotherapy and radiotherapy ultimately bring about cancer cell death by 
activation of the apoptotic cascade. 
In oesophageal cancer, previous reports and studies indicated that spontaneous 
apoptosis occurs in all cases of oesophageal adenocarcinoma, that patients with a 
high apoptotic index have a better response to neoadjuvant therapy, and that 
apoptosis is significantly induced by chemoradiotherapy. Regulators of apoptosis 
include p53, the Bcl-2 protein family, and caspases, and other factors are implicated 
in the biology of chemoresistance. Loss of p53 function has been shown to disrupt 
apoptosis and accelerate tumour development in laboratory work on transgenic mice, 
and loss of p53 function correlates with multidrug resistance in many tumour types 
9. Bcl-2 proteins, which are a family of cytoplasmic proteins, may inhibit apoptosis. 
However, in one study, neither p53 over-expression nor Bcl-2 correlated with 
response to chemoradiotherapy 10. 
1.1.3 Histology of oesophageal cancer 
Oesophageal cancer is exceptional among the gastrointestinal tract malignancies 
because it embodies two distinct histopathological types, squamous cell carcinoma 
and adenocarcinoma. Which type of cancer predominates in a given patient or a 
geographic area depends on many variables, including individual lifestyle, 
socioeconomic status, and environmental factors. 
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The overwhelming majority (more than 90%) of oesophageal malignancies may be 
classified as either squamous cell carcinoma or adenocarcinoma. Squamous cell 
carcinomas account for approximately 40% of oesophageal malignancies diagnosed 
in the high-incidence areas throughout the world. Approximately 60% of these 
neoplasms are located in the middle third of the oesophagus, whereas 30% and 10% 
arise in the distal third and proximal third of the intrathoracic oesophagus, 
respectively. Typically, these tumours are associated with contiguous or non-
contiguous carcinoma in situ plus widespread submucosal lymphatic dissemination. 
Rarely, other carcinomas, melanomas, leiomyoscarcomas, carcinoids, and 
lymphomas may develop in the oesophagus as well. Around 75% of all 
adenocarcinomas are found in the distal oesophagus, whereas squamous cell 
carcinomas are more evenly distributed between the middle and lower third. The 
cervical oesophagus is an uncommon site of the disease 11. 
1.1.4 Current status of adenocarcinoma of the oesophagus 
Since 1970 the incidence and prevalence of oesophageal adenocarcinoma has been 
increasing at an alarming rate in North America and Western Europe 12 13. Most if 
not all adenocarcinomas in the distal oesophagus occur in patients with Barrett’s 
oesophagus 14. They may be of fungating or stenotic appearance. This premalignant 
lesion is due to clonal evolution of mucin-secreting epithelium from progenitor cells 
in the native squamous mucosa, mainly as a result of mucosal damage by gastro-
oesophageal reflux disease 15. The vast majority of the tumours are associated with 
intestinal metaplasia or dysplasia 16.   
Several rare cancers of the oesophagus have been characterised, including squamous 
cell carcinoma with sarcomatous features, as well as adenoid cystic and 
mucoepidermoid carcinomas. These neoplasms are impossible to tell apart clinically 
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and prognostically from the more common types of oesophageal carcinoma. Small 
cell carcinomas account for approximately 1% of oesophageal malignancies and 
arise from argyrophilic cells in the basal layer of the squamous epithelium. These 
neoplasms are usually located in the middle or lower third of the oesophagus and 
may be associated with ectopic production of a variety of hormones, including 
parathormone, secretin, granulocyte colony-stimulation factor, and gastrin-releasing 
peptide, and this is the reason that these types of cancer are presented with systemic 
manifestations as well. Although small cell carcinomas frequently respond to 
radiation therapy and chemotherapy, patients with these neoplasms typically 
progress to widespread distant metastases 16.  Leiomyosarcoma is the commonest 
mesenchymal tumour affecting the oesophagus, accounting for less than 1% of all 
oesophageal malignancies 16. These occur at the lower third as bulky masses with 
the typical manifestation of significant haemorrhage and necrosis. Malignant 
lymphoma and Hodgkin’s disease rarely involve the oesophagus, and oesophageal 
involvement typically is secondary to extension from other sites in these conditions, 
although primary lymphoma of the oesophagus has been reported. Acquired 
immunodeficiency syndrome may display Kaposi’s sarcoma that would involve the 
oesophagus. Malignant melanoma involving the oesophagus is very rare and 
presents as a bulky intra-oesophageal tumour of varying polypoid appearance and 
colour depending on Melanin production. The prognosis here is very poor for these 
patients even with the adoption of aggressive treatment 16-20.   
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1.1.5 Molecular Biology and mechanisms of Oesophageal 
Cancer 
Adenocarcinoma of the oesophagus and GOJ show multiple genetic alterations, 
which indicate that the progression of cancer is a multistep complex process with 
many different changes. Consequently, it is not one molecular factor that can predict 
the biological behaviour of the cancer 21. The majority of these patients develop 
haematogenous recurrences, but also locoregional, pleural and peritoneal 
recurrences are common 22 23. The 5-year survival rates after intentionally curative 
oesophagectomy rarely exceed 30% 24 25.  
1.1.5.1 Avoidance of apoptosis 
The western world, including Europe and the United States, has witnessed in recent 
decades a profound increase in incidence rates of adenocarcinoma, whereas 
squamous cell carcinoma continues to predominate globally. These tumours are still 
managed as a single entity, although it would seem appropriate to individualize their 
treatment. Unfortunately, present-day therapeutic interventions have had little 
impact on survival, as observed through the equivalence of incidence and mortality 
rates. A more thorough understanding of the initiating events, the molecular biologic 
basis, and treatment successes and failures will hopefully generate a new era of 
therapy that can effectively target both types of cancers 16. 
Apoptosis is a form of cell death which is regulated at the gene level and plays a 
central role in cell number control during embryonic development and 
organogenesis; it determines the cellular response to various physiological situations 
in adult tissues and during pathophysiological conditions including malignant 
turnover. Also, defects in the apoptotic pathway may represent a crucial element in 
the progression of neoplastic disease and may also coincide to determine treatment 
efficiency at the cellular level. In fact, many of the effects of the chemical and 
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physical agents that are commonly used in the treatment of human malignancies are 
mediated by induction of apoptosis 26-28 and thus rely at least in part on the same 
biochemical mechanisms involved in physiological cell death control. Therefore, 
genetic alterations that prevent or delay normal cell turnover may also be 
responsible for treatment inadequacy in tumour cells. 
The ability of tumour cells to expand in number is not only determined by the rate of 
cell proliferation, but also by the rate of programmed cell death (apoptosis). The 
apoptotic apparatus comprises several signalling pathways. Once the apoptosis 
pathway is stimulated, the cell is destroyed within 3 - 120 minutes. In this manner, 
apoptosis provides a protective mechanism by removing DNA-damaged or diseased 
cells. These pathways and inter-relationships can be highlighted in the following 
figure (Figure  2) 
 
 
Figure(2). Relationship between the diverse prognostic factors in adenocarcinoma of the 
oesophagus and gastro-oesophageal junction 
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One mechanism through which cancer cells avoid apoptosis is by interfering with 
agent like p53 which normally activate apoptosis 8. The appearance of the hallmarks 
of tumourigenesis and attainment of the malignant phenotype with all of its biologic 
causes of disturbance require, as described by Hanahan and Weinberg 8, 
organisation of certain capabilities by the cell, including growth signal self-
governing, ability to ignore antigrowth signals, unlimited replicative ability, 
avoidance of apoptosis, angiogenesis, as well as invasion and metastatic potential. 
The molecular alterations and mechanisms underlying these acquired characteristics 
in many human tumours, including oesophageal and gastric cancer, have become 
evident as the understanding of molecular biology has exponentially increased in 
recent years. Table (2) shows collectively the molecular changes which are linked to 
oesophageal cancer. 
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Protein Product Alteration Mechanism Acquired Functional 
Capability 
p53  Mutation, LOH  Tumour suppressor—
causes G1 arrest of DNA-
damaged cells 
Resistance to antigrowth 
signals  
p16  Mutation, LOH, 
promoter hyper- 
methylation 
Tumour suppressor—
inhibits CD/CDK complex 
Resistance to antigrowth 
signals  
p15  Mutation, LOH, 
promoter hyper- 
methylation 
Tumour suppressor—
inhibits CD/CDK copies 
Resistance to antigrowth 
signals  
VEGF/VEGFR  Over-expression  Endothelial cell growth 
factor/receptor  
Sustained angiogenesis  
COX-2  Over-expression  Inhibition of apoptotic 
pathways  
Avoidance of apoptosis  
Cyclin D1/E  Gene amplification  
Promotes entry into S 
phase  Growth self-sufficiency  
Rb 
(retinoblastoma)  
Mutation, LOH  Tumour suppressor—
blocks passage to S phase 
Growth self-sufficiency  
EGF/EGFR  Gene 
amplification  
Growth factor/growth 
factor receptor  
Growth self-sufficiency  
TGF-α  Gene 
amplification  
Growth factor  Growth self-sufficiency  
erbB-2  Gene 
amplification  
Growth factor receptor  Growth self-sufficiency  
FAS/FAS ligand  Under-
expression, over-
expression  
Death receptor/death 
receptor ligand  
Inhibition of apoptosis 
(cancer cell)  
Promotion of apoptosis 
(lymphocyte)  
Inhibition of immune 
surveillance 
Telomerase  Up-regulation  Maintenance of telomere length  Unlimited DNA replication  
E-cadherin  Down-regulation  Cellular adhesion  Invasion and metastasis  
CD/CDK, cyclin D1/cyclin-dependent kinase; COX-2, cyclooxygenase-2; EGF, epidermal growth factor; EGFR, epidermal 
growth factor receptor; LOH, loss of heterozygosity; TGF-α, transforming growth factor-α; VEGF, vascular endothelial 
growth factor; VEGFR, vascular endothelial growth factor receptor; erbB-2, human epidermal growth factor receptor 2. 
Table (2). Molecular changes associated with the acquired oesophageal cancer 
 
Many of the genetic alterations resulting in unchecked growth and proliferation and 
avoidance of programmed cell death do so by modifying the cell cycle. Evidence for 
specific molecular events linked to the carcinogenic process has been found for both 
squamous cell carcinoma and adenocarcinoma of the oesophagus. 
In the cell cycle during transition from the G phase to the S1 phase, a crucial 
decision point (restriction point) is reached in which cells either complete the cell 
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cycle and go on to divide or withdraw from the cycle. Many of the mutations that 
lead to gain or loss of function (oncogenes or tumour suppressor genes, respectively) 
exert their effects at this critical stage. Control of the restriction point is mediated by 
retinoblastoma (Rb) protein via complex interactions with cyclins and cyclin-
dependent kinases (CDKs). Active non-phosphorylated Rb protein blocks passage 
through the restriction point to the S phase, whereas phosphorylation inactivates Rb 
protein, opposing its blocking function and facilitating completion of the cell cycle. 
Cyclins are a group of specialized proteins that bind to and activate CDK molecules, 
which leads to phosphorylation of target proteins regulating the cell cycle. Cyclin 
D1 binds with CDK-4 during G phase, and these complexes phosphorylate Rb, 
inactivating its suppressor effect and promoting the cell to go into the S phase. Both 
cyclin D1 and cyclin E have been detected in biopsy specimens from patients with 
either premalignant conditions or cancer of the oesophagus 16. 
Over-expression of cyclin D1 has been identified in approximately 30% of patients 
with Barrett’s oesophagus or oesophageal squamous dysplasia and in up to 70% of 
patients with squamous cell carcinoma of the oesophagus. In multiple studies, cyclin 
D1 over-expression is a predictor of poor outcome as measured by correlation of 
cyclin D1 over-expression with regional and distant metastases, advanced tumour 
grade and stage, poor response to chemotherapy, and decreased overall survival. 
As well, Cyclin E over-expression was identified in patients with Barrett’s 
oesophagus with dysplasia and adenocarcinoma and in patients with squamous cell 
carcinoma of the oesophagus. There is a suggestive evidence indicating altered Rb 
function in the carcinogenic process in Barrett’s oesophagus, adenocarcinoma, and 
squamous cell carcinoma have not been documented. Allelic loss of 13q where the 
locus of the Rb gene resides can render the Rb gene to be non-functional. LOH has 
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been noted in up to 50% of patients with Barrett’s adenocarcinoma and squamous 
cell carcinoma 16 . Loss of immunostaining for Rb protein has been noted in 
Barrett’s oesophagus with dysplasia, adenocarcinoma, and squamous cell carcinoma 
of the oesophagus. 
1.1.5.2 Proliferative pathways 
Growth factors and their receptors can activate proliferative pathways by inducing 
cyclin expression. Exogenous growth factors or endogenous growth ligands can bind 
to growth factor receptors, leading to uncontrolled cell division. Tyrosine kinase 
growth factor receptors as well as their ligands, epidermal growth factor (EGF), and 
transforming growth factor-α have been showing some role in the carcinogenic 
process of both squamous cell carcinoma and adenocarcinoma. Increased expression 
of transforming growth factor-α and the EGF receptor have been detected in 
Barrett’s oesophagus, oesophageal adenocarcinoma, and squamous cell carcinoma 
of the oesophagus 16. Its EGF receptor over-expression may predict a poor response 
to chemoradiotherapy and be associated with poor outcome. Itakura et al. 29 showed 
that EGF receptor immunoreactivity was associated with decreased survival in 
patients with squamous cell carcinoma. Additionally, Kitagawa et al. 30 and  
Shimada et al. 3 noted that EGF receptor over-expression was associated with 
regional and distant recurrence and diminished overall survival in patients 
undergoing oesophagectomy for squamous cell carcinoma. Like other oncogenes, 
mutated erbB2 is associated with unrestrained proliferative activity 31. Some 
researchers detected erbB2 over-expression in Barrett’s oesophagus, high-grade 
dysplasia, and adenocarcinoma 32 33, whereas others have found no evidence for 
increased expression in biopsy samples from patients with Barrett’s oesophagus, 
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either with or without dysplasia 34. The same conflicting results have been seen for 
squamous cell carcinoma of the oesophagus 35 36.  
Anti-growth signals disrupt the cell cycle at the restriction point by causing cells to 
become dormant or initiating growth arrest and differentiation. The majority of these 
events are a consequence of the effects of anti-growth signals on the Rb pathway. 
The p53 gene product prevents cells with DNA damage from replicating by causing 
arrest in the G phase and allowing repair mechanisms to act before entry into the S 
phase. The p53 can exert its effects in different routes. One mechanism to regulate 
cell-cycle progression involves inhibiting the function of the cyclin and CDK 
complex, which effectively blocks inactivation of the Rb protein by 
phosphorylation. If the tumour suppressor function of p53 is lost, Rb 
phosphorylation occurs, inactivating that tumour suppressor and allowing cell-cycle 
progression through the restriction point and replication of damaged DNA 16.   
Multiple mechanisms exist to inactivate tumour suppressor genes making their 
protein products of no purpose, including mutation, loss of heterozygosity (LOH), 
and promoter hyper-methylation preventing gene transcription. Detection of mutated 
p53 protein by immunohistochemistry has been demonstrated with increasing 
frequency during histological progression from Barrett’s oesophagus (5%) through 
dysplasia (65% to 75%) to adenocarcinoma (reaching to 90%). Loss of allele 17p, 
the site of the p53 gene locus, has been detected in 50% to 90% of Barrett’s 
adenocarcinoma 37 38. 
Identification of both mutant p53 protein and LOH of 17p in Barrett’s specialized 
intestinal metaplasia suggests that p53 inactivation occurs early in the carcinogenic 
process. Both mutant p53 protein detected by immunohistochemistry and specific 
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p53 gene mutations detected by genomic sequencing have been identified in 40% to 
75% of patients with squamous cell carcinoma of the oesophagus. The presence of a 
p53 point mutation detected by direct sequencing of p53 exons 5 to 8 significantly 
correlated with response to induction chemoradiotherapy and predicted survival after 
oesophagectomy in patients with either squamous cell carcinoma or adenocarcinoma 
of the oesophagus. Both p16 and p15, are tumour suppressor gene products that 
inhibit cyclin D1–CDK complexes, preventing Rb protein phosphorylation and 
maintaining its ability to exert control over the cell cycle at the restriction point 16. 
Inactivation of these tumour suppressor genes by any mechanism would result in 
inactivation of the Rb protein by phosphorylation and subsequently unchecked 
cellular proliferation. LOH of 9p21, the locus for both p16 and p15, has been 
demonstrated with high frequency in both dysplastic Barrett’s epithelium (90%) and 
Barrett’s adenocarcinoma (>80%). 
Promoter hypermethylation, which blocks transcription and so preventing tumour 
suppressor function, has been recognised and correlates with the degree of dysplasia 
in Barrett’s oesophagus, which eventually might lead to adenocarcinoma. It is 
present in up to three quarters of specimens with high-grade dysplasia and is found 
in more or less 50% of patients with adenocarcinoma of the oesophagus. These data 
support the role of p16 as a tumour suppressor gene in cancer progression in 
Barrett’s oesophagus. Point mutations of p16 in invasive squamous cell carcinoma 
have been found, but conflicting results have been reported concerning its 
frequency. In one study, altered expression of p16 protein documented by 
immunohistochemistry has been observed in 50% of the study patients with 
squamous cell carcinoma of the oesophagus and appears to correlate with over-
expression of cyclin D1 and poor outcome 16.  
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Also, p53 protein exerts its tumour suppressor effects by activating pro-apoptotic 
pathways in the presence of severe DNA damage. Tumour cells may avoid 
programmed cell death by increased synthesis of enzymes such as COX-2, which 
inhibits apoptotic pathways. COX-2 over-expression has been demonstrated in 
premalignant and malignant epithelium in both squamous cell carcinoma and 
adenocarcinoma of the oesophagus 39-41. The second mechanism that allows tumour 
cells to avoid apoptosis is alteration of the expression of death receptors. FAS is 
expressed by normal cells and when bound by the FAS ligand activates pro-
apoptotic pathways. Reduced expression of FAS would inhibit apoptosis of tumour 
cells, but on the other hand over-expression of FAS ligand by tumour cells would 
activate apoptotic mechanisms in lymphocytes responsible for immune surveillance. 
This over-expression has been detected in both adenocarcinoma and squamous cell 
carcinoma of the oesophagus as well as in premalignant squamous epithelium. 
Contradictory results concerning reduced expression of the FAS receptor have been 
reported in Barrett’s oesophagus and Barrett’s oesophagus-associated 
adenocarcinoma; nevertheless, decreased expression of the FAS receptor has been 
demonstrated in dysplastic squamous cell epithelium and invasive squamous cell 
carcinoma 16.   
Vascular endothelial growth factor receptors are also up-regulated in Barrett’s 
oesophagus. Loss of cell-cell adhesion can lead to both invasion and metastases. 
Alterations in expression of E-cadherin, a cell-cell adhesion molecule, or its 
associated catenins disrupt cell-cell interactions, which results in   the potential for 
tumour progression. Reduced expression of E-cadherin has been correlated with 
progression from Barrett’s oesophagus to dysplasia and finally to adenocarcinoma 
16. 
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It is very evident from the discussion above that there is a lot of work to be done to 
reach to the markers and signals that help predicting and assessing the progress of 
the oesophageal cancer, and more research is required to explore the available, as 
well as, new markers that might help to predict the pathway of the disease, and 
maybe helping to predict the exact affected areas of the cancer pathway that could 
be manipulated or suppressed. 
1.1.6 Staging of oesophageal cancer 
1.1.6.1 TNM classification of oesophageal cancer  
T stage:  
• Tx Primary tumour cannot be assessed 
• Tis carcinoma in situ  
• T1 tumour confined to the inner layer of the oesophageal wall 
(submucosa or lamina propria)  
• T2 tumour invades into the muscular layer of the wall  
• T3 tumour invades into the adventitia  
• T4 tumour invades into other structures or organs  
N stage (for any subsite):  
• Nx Regional lymph nodes cannot be assessed 
• N0 no spread to lymph nodes  
• N1 tumour spread to regional lymph nodes  
o lymph nodes outside the chest are considered "M1"  
M stage:  
• Mx Distant metastasis cannot be assessed 
• M0 no tumour spread to other organs  
• M1 tumour spread to other organs  
This is also broken down by site of the primary tumour within the oesophagus:  
Tumours of the lower oesophagus:  
• M1a cancer spread to celiac lymph nodes  
• M1b other distant metastasis 42 
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1.2 Gastric cancer 
1.2.1 Epidemiology 
1.2.1.1 Incidence and mortality 
Gastric cancer is the second most common cancer worldwide, with a frequency that 
varies greatly across different geographic locations 43, as well as accounting for 3% 
to 10% of all cancer-related deaths 44. In Europe, it ranks fifth after lung, prostate, 
colorectal and bladder cancers in men and breast, colorectal, lung and cancer of the 
uterus in women. Each year there are some 192,000 new cases, representing about 
23% of all malignant neoplasms 45 46, and displaying an annual incidence of 80 to 90 
deaths per 100,000 cases in Japan. In the Far East, most gastric cancer patients are 
diagnosed with early gastric cancers, which are limited to the gastric mucosa and 
submucosa, rarely show metastatic spread, and display 10-year survival rates 
between 80% and 95% 46. 
The substantial mortality associated with gastric cancer has predominated despite 
technical advances in surgery and the use of adjuvant therapy. Ninety percent of all 
tumours of the stomach are malignant, and gastric adenocarcinoma comprises 95% 
of the total number of malignancies 47. Curative therapy involves surgical resection, 
most commonly a total or subtotal gastrectomy, with lymphadenectomy. The overall 
5-year survival rate of patients with resectable gastric cancer ranges from 10% to 
30% 48-50 51. 
The incidence is higher in lower social classes, but has been declining in recent 
years in different parts of the world. The decline has been more rapid for women 
than for men.  The male-to-female ratio in incidence rates is about 1.6:1. In fact, in 
every region of the globe, gastric cancer has a higher incidence in males than 
females (ratio of 1.5 - 2.5:1) 45. This manifests itself, particularly in men, around the 
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age of 55 year (in the European Union, the median age at diagnosis is 62 years), and 
in lower socio-economic groups 52. The decline in mortality has occurred at a 
slightly faster rate than that for incidence. In Italy for example, there has been a 
consistent downward trend in both incidence and mortality in both sexes. Similar 
trends have been observed in many countries 53. There is a marked geographic 
variation in the incidence of gastric cancer. For example, the annual age-
standardized incidence rate is higher in eastern (34.1/100.000 in men) and southern 
Europe (19.5/100.000 in men) than in northern (6.1/100.000 in women) and western 
Europe (7/100.000 in women) 45 54. The current overall 5-year survival figures for 
gastric cancers in Western patients are in the range 5–17% 51 55, and have not 
changed significantly in 30 years. 
As for the United Kingdom, gastric cancer remains a relatively common 
malignancy. Current data indicate that there are an estimated 10.000 new diagnoses 
and 7500 deaths from gastric cancer each year but has been declining by about 5% 
every 5 years in England in a steady rate. The overall age-standardized incidence has 
shown a steady decrease over the past few decades. However, this has had relatively 
little impact on the associated workload, which has remained fairly constant, 
reflecting the ageing population 56.  Data from the Office for National Statistics 
show that the incidence for men is 20.4 and women 7.4 per 100.000 in England and 
Wales. More than 80% of the cases are being diagnosed after the age of 65, although 
a regional survey suggested that early gastric cancer (disease limited to the mucosa 
and submucosa) generally affects a population approximately 10 years younger than 
more advanced disease. In the UK, as elsewhere, the incidence of gastric cancer is 
strongly associated with poor socioeconomic status and this largely explains the 
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geographical pattern of disease, with higher rates in the north of England, Wales, 
and Scotland 2. 
1.2.1.2 Survival 
In Europe, the relative survival from gastric cancer in  2000-2004 was poor in both 
sexes: 42% at 1 year and 23% at 5 years 57 58. Five-year survival was higher in 
people under 45 years (35%); however, gastric cancers were rare in this age group. 
Survival declined slowly with increasing age up to 74 years, but fell sharply in 
patients over 74 years (17%). Five-year relative survival for stomach cancer 
increased slightly from 18% in the period 1983–1985 to 21% in 2000-2004 58 59. In 
Western countries, patients are diagnosed mostly at advanced clinical stages, 
typically showing lymphatic tumour dissemination and a poor prognosis with 5-year 
survival rates of less than 30% 60. Clinical studies demonstrated that the extent of 
lymphatic dissemination critically determines the clinical outcome of gastric cancer 
patients, and that surgical clearance of lymphatics is essential if curative treatment is 
intended 60 61. Therefore, exact determination of nodal spread is indispensable for 
optimising therapeutic strategies and correct assessment of prognosis. Current 
procedures for detection of lymph node affection in gastric cancer include computed 
tomography (CT) scan, endoluminal ultrasound (EUS), and laparascopy 60 62. 
Although clinically well established, these methods also have clear limitations 60. 
Therefore, identification of molecular markers for assessment of nodal status and 
prognosis in gastric cancer patients is highly desirable. 
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1.2.1.4 Prevalence of gastric cancer 
This is the number of people living with a diagnosis of gastric cancer. In Europe, for 
both sexes, stomach cancer accounts for 4% of the total cancer prevalence 57. In 
1992, the prevalence was 85 per 100.000. The 5-year prevalence, as is available 
from the recent EU estimate, that is the number of living people with a diagnosis of 
stomach cancer made five or less years before the index date, was 37 per 100.000 63 
64. This last figure indicates the need for clinical follow-up and treatment for 
recurrences. Less than 50% of all patients with stomach cancer were long-term 
survivors living with a diagnosis made five or more years before the index date. 
1.2.2 Changing patterns of gastric cancer 
While the incidence of ‘endemic’ gastric cancer, with intestinal pathology and being 
located in the body of the stomach, has undoubtedly fallen, there are recent reports 
that tumours of the cardia are on the increase, especially among males and notably in 
the UK, Ireland, Northern Europe, Australia and New Zealand, China, and North 
America 46 65-67. Among UK males with gastric cancer, for example, 54% of cases 
diagnosed in 1990 were tumours of the cardia 46. There also appears to be a rising 
trend in adenocarcinomas of the lower oesophagus, in which hyperacidity, reflux 
oesophagitis, Barrett’s oesophagus and obesity are possible aetiological factors. The 
rate at which the incidence of proximal stomach cancers has risen exceeds that of 
any other cancer 66 67. 
The majority of gastric cancer patients have stage III or IV disease at presentation 
and are therefore candidates for some form of chemotherapy 68. Currently, 1-year 
survival rates are less than 50% in stage IIIA and B disease, and less than 25% in 
stage IV disease. As has already been noted, a rising proportion of patients now 
present with tumours of the upper stomach, particularly of the gastro-oesophageal 
junction 67 69 70. This changing epidemiology has implications for treatment since 5-
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year survival following resection is approximately 45%. Five-year survival for 
patients with resected cardia or gastro-oesophageal junction appears to be in the 
range of 10%. 
1.2.3 Pathology and biology of gastric cancer 
1.2.3.1 Histogenesis 
Gastric carcinomas do not take place de novo from normal epithelium, but occur 
through successive changes. These are well characterised for the intestinal type of 
human gastric cancer, while lesions predisposing to the development of the diffuse 
type of gastric cancer are not yet well understood. The development of the intestinal 
type gastric cancer includes the transformation of the normal mucosa into another 
type which resembles intestinal epithelium (intestinal metaplasia). The presence of 
intestinal metaplasia increases the risk of gastric cancer, which is proportional to the 
extent of the surface area involved by that change 71. Subsequently, intestinal 
metaplasia may progress to dysplasia, and finally to carcinoma. By contrast, diffuse 
type gastric cancer presumably arises as single-cell changes in the mucus-neck 
region of the gastric glands. Then, these cells may proliferate and invade out from 
the crypt into the lamina propria. A hypothesis about gastric carcinogenesis was 
proposed in 1975 by Correa et al.72 73. According to this hypothesis, gastric 
carcinogenesis is a multi-stage and multi-factorial process which involves irritant 
environmental and other factors, acid secretion, bacterial overgrowth, and bacterial 
production of nitrites or N-nitroso compounds from dietary nitrates. The result of a 
cascade of events is the progressive spectrum of histological states ranging from 
normal gastric epithelium to gastric adenocarcinoma of intestinal type 74. 
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1.2.3.1 Dysplasia 
There is general agreement that the term dysplasia implies a neoplastic, non-
invasive, process in the gastric mucosa and is thought to be the immediate precursor 
lesion of invasive cancer. Invasion of the lamina propria by neoplastic cells is 
required before establishing a diagnosis of intra-mucosal carcinoma. Three grades of 
dysplasia may be encountered: low, moderate, and severe; this classification is based 
on nuclear features and structural complexity of the epithelial layer. However, some 
authors recommend that only two grades of dysplasia should be distinguished: high- 
and low-grade 75. For high-grade dysplasia, endoscopic resection or, sometime, 
gastrectomy is needed. 
1.2.4 Histological types of gastric cancer 
Adenocarcinoma accounts for over 95% of all malignant gastric neoplasms, and 
generally the term gastric cancer refers to adenocarcinoma of the stomach. Although 
no normal lymphoid tissue is found in the gastric mucosa, the stomach is the most 
common site for lymphomas of the gastrointestinal tract. Other malignant tumours 
include squamous cell carcinoma, adenoacanthoma, carcinoid tumours, and 
leiomyosarcoma.  
Several classifications of gastric cancer have been proposed in the past decades: e.g. 
the classifications of the WHO 76, Ming 77, Mulligan 78, and Laurén 79, and a later 
one introduced by Goseki et al 80. They can be classified based on gross 
morphological and histopathological features. Macroscopically, the most widely 
used classification system is that of Borrmann in 1926 81 82. As for the microscopic 
classification, a simple and widely used classification is used and proposed by 
Laurén et al. 79, who differentiates gastric cancers into two major types: intestinal or 
diffuse. It has been reviewed by Borchard 83 and Songun et al 84, supporting its 
feasibility and wide usage. This classification has advantages in that it distinguishes, 
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by microscopy alone, two main cancer pathogolies which appear to have clearly 
dissimilar entities from the clinical and epidemiological aspects. These are gastric 
adenocarcinomas of diffuse (DGCA) and intestinal (IGCA) subtypes 79. The division 
of gastric cancer (GC) into two main histopathological patterns (intestinal and 
diffuse) gives an impact in understanding the epidemiology, demography, 
progression and survival of GC patients 85. The commonest histological variant 
present in high-risk populations is intestinal type GC. It results from exposure to 
various environmental factors including H pylori infection and it evolves via a series 
of chronological events that include chronic gastritis, atrophy, intestinal metaplasia, 
dysplasia, early carcinoma, invasion, and metastases. In low risk populations, the 
diffuse type of GC is more common. Diffuse tumours are associated with the same 
superficial gastritis as intestinal tumours. They demonstrate high H pylori antibody 
levels as well 85. 
The differences between the subtypes are based on studies from the 1950s and 1960s 
by Járvi et al showing that IGCA-type carcinomas associate with or develop from 
intestinal-type metaplastic epithelium not only in the stomach but also in the nose, 
gallbladder, urinary tract, and many other sites 86. The main epidemiologic, clinical 
and morphological difference between IGCA and DGCA are presented in Table (3). 
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Characteristics Intestinal type Diffuse type 
Gross morphology  Exophytic  Ulcerating, diffuse  
Microscopy  Glandular  Single cells, signet-ring 
cells  
Main co-existing 
precancerous 
condition 
Atrophic gastritis, intestinal 
metaplasia  
Non-atrophic gastritis  
Precancerous lesion  Adenoma, dysplasia; ‘Correa 
sequence’  
Possible foveolar 
hyperplasia  
Age  Old age  Young age, all age groups  
Sex  Males > females  Equal  
Prevailing site  Antrum Corpus, whole stomach  
Metastasis  Lymph nodes, liver  Lymph nodes, visceral  
Biology  Oestrogen protects?  Neuroendocrine 
differentiation?  
Prior or co-existing H. 
pylori 
Common by serology (>80 - 90%)  
False-negative results frequent with  
breath test, antigen stool test, 
biopsy-based urease test, or by 
microscopy 
Common (>90%)  
All tests are reliable 
Table (3). The main differences between intestinal and diffuse gastric adenocarcinomas 
 
1.2.5 Histological grading of gastric adenocarcinoma 
Adenocarcinomas are graded based on the degree of glandular differentiation into 
well, moderately, and poorly differentiated subtypes, based on the extent of 
glandular differentiation 87. 
• Grade X: cannot be assessed. 
• Grade 1: well differentiated (greater than 95% of tumour composed of 
glands). 
• Grade 2: moderately differentiated (50–95% of tumour composed of glands). 
• Grade 3: poorly differentiated (49% or less of tumour composed of glands). 
Tubular adenocarcinomas are not typically graded but are low-grade and would 
correspond to grade 1. Signet-ring cell carcinomas are not typically graded but are 
high-grade and would correspond to grade 3. Small cell carcinomas and 
undifferentiated carcinomas are not typically graded but are high-grade tumours and 
would correspond to grade 4. 
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1.2.6 Diagnostic strategy of gastric cancer 
1.2.6.1 Diagnostic studies 
An upper gastrointestinal series is often the first examination performed to evaluate 
symptoms related to the oesophago-gastric tract. However, the diagnosis of these 
cancers should always be confirmed by endoscopy. It has been suggested that the 
investigation of dyspeptic patients aged over 40 can increase the proportion of early 
gastric cancer (EGC) detected to 26% and the proportion of operable cases to 63% 
88. The discussion here is more inclined towards the gastric investigations, due the 
histopathological nature of the work done, which is adenocarcinoma that is mostly 
located in the lower oesophagus, OGJ and stomach. 
1.2.6.2 Radiological techniques and their indication 
The development and refinement of double-contrast barium techniques over the past 
few years have improved the radiologist’s ability to detect gastric cancer and 
characterise gastric ulcers. The double-contrast upper gastrointestinal series is better 
than a single-contrast examination in detecting gastric cancer: double-contrast 
techniques allow for visualization of mucosal details, and may indicate a reduced 
ability of the stomach to distend, which may be the only sign of the presence of a 
diffuse infiltrative carcinoma. Furthermore, barium radiological studies provide a 
useful evaluation of extrinsic lesions that are causing compression and contour 
defects in the gastrointestinal tract, and the assessment of the degree of obstruction. 
Advantages of barium examination are low cost, lower percentages of side-effects 
and complications, and high sensitivity (ranging from 85% to 95%) for the diagnosis 
of gastric carcinomas 89. A crucial problem for radiologists is the differentiation of a 
benign tumour from a malignant ulcer or even a lymphoma. Early gastric carcinoma 
may have some of the signs of a benign ulcer (extension of the crater beyond the 
gastric wall, and folds radiating from its margins), and partial healing may occur in 
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an early malignant ulcer in up to 70% of such ulcers 90. Conversely, approximately 
95% of gastric ulcers are found to be benign 91.  
1.2.6.3 Endoscopy and pathological assessment 
As a rule, endoscopy is most effective in evaluating intra-luminal gastrointestinal 
disorders, focal and diffuse, benign and malignant. The procedure can be 
informative, but it is less effective in assessing abnormal motility, extrinsic 
compression, and degree of luminal obstruction. Newer upper gastrointestinal 
endoscopes are thin, highly manoeuvrable, and safe for the patient. Thus, endoscopy 
may result in a comfortable, rapid examination that requires only mild sedation for 
the patients 92 93. Although more invasive and expensive than barium upper 
gastrointestinal radiography, endoscopy is more accurate and may avoid multiple 
procedures, with their associated added costs. The specificity of barium studies 
versus primary endoscopy is similar 94. No randomised trial has shown any benefit 
of endoscopy over barium studies; however, endoscopy allows for a full 
macroscopic assessment of the gastric mucosa and for the histological confirmation 
of the type of the lesion 95. The diagnostic accuracy of endoscopy and biopsy for 
primary upper GI cancer is in the range of 95% 96-98. 
1.2.6.4 Biological markers 
A great deal of effort has been spent in search of serological markers that would 
enable the early detection and diagnosis of gastric cancer. Integrated research in 
molecular pathology has clarified the details of genetic and epigenetic abnormalities 
related to the development and progression of gastric cancer 99 100. Their 
effectiveness for diagnosis leaves a room for improvement. Tumour antigens either 
in the sera (CEA, CA19-9, CA72-4, CA50) or in the gastric juice (CEA, CA19-9, 
foetal sulfoglycoprotein) have not been found useful for diagnostic purposes. CEA 
and CA19-9, in particular, are elevated in approximately 30 - 40% of primary gastric 
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cancer patients, but significantly higher levels of such antigens were typically found 
in patients with more advanced disease, rather than in patients at early stage of 
disease101-103. 
1.2.6.4.1 Biologic prognostic factors studied in gastric cancer 
Molecular pathology may be helpful not only to understand the disease 
pathogenesis, but also to give useful prognostic molecular markers. Over-expression 
of p53 as demonstrated by immunohistochemistry, has been reported in 17 - 91% of 
invasive tumours 85, whereas the reported incidence of p53 mutations in invasive 
carcinomas range from 0% to 77% 104 105. Published studies have reported 
conflicting and even contradictory results since they have involved 
immunohistochemical detection of the protein, which has been performed with 
different antibodies, detection techniques, or methods of interpretation. Other 
suggested biological prognostic factors were p21 expression 106, VEGF expression 
107 108 or microvessel count density 108, over-expression of EGF-α 109, cyclin D2 
over-expression 110, the serum level of soluble receptor for IL-2 (SoIIL-2R) 111, or 
some proliferation-related factors, such as Ki-67 or proliferating cell nuclear antigen 
(PCNA) 112-114. Recent data on the correlation between molecular markers and 
response to chemotherapy are still controversial 115. 
 
1.2.7 Staging of gastric cancer 
1.2.7.1 Preoperative staging: standard and optional  
The standard measures for the staging of patients with potentially curable gastric 
cancer go in the form of good history taking, physical examination, laboratory data 
which include blood count, CEA, CA19-9, liver functions, and gastric evaluation in 
which endoscopy is the gold standard. Once the diagnosis is confirmed many other 
studies take place in the form of routine ECG, chest x-ray, CT scanning of the whole 
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body, as well as Endoscopic ultrasonography (EUS) which has improved the local 
accuracy in estimating the depth of tumour invasion and lymph node involvement. 
The accuracy of EUS in determining the extent of infiltration of the primary tumour 
ranges from 67% to 92% 116, and it is superior to CT for determining the overall T 
stage 117 118. MRI imaging so far has not achieved clinical importance; it is, however, 
helpful in the characterization of associated liver lesions. Preliminary data confirm 
that adenocarcinoma of the stomach is a fluorodeoxyglucose avid tumour; 
prospective comparisons will be necessary to evaluate the utility of positron 
emission tomography (PET) 119 120 before this becomes standard. At the present 
time, these procedures are still regarded as investigational, or being not considered 
as standard practice. 
1.2.7.1.1 Criteria for stage classification of gastric cancer 
The two main staging systems for gastric cancer are the TNM staging system of the 
International Union Against Cancer (UICC), and the Japanese Classification of 
Gastric Carcinoma by the Japanese Gastric Cancer Association (JGCA). Similarities 
between these two staging systems exist, as it is dependent on the extent of the 
primary tumour, the extent of lymph node involvement, and the presence or absence 
of distant metastasis. However, there still remain fundamental differences between 
the two staging systems. The most recognisable difference lies with the 
classification of regional lymph node spread. The UICC/TNM staging system 
divides N stage on the basis of the number of metastatic lymph nodes, while the 
Japanese classification stresses the location of involved nodes 121. Both the systems 
are downloadable from http://www.jgca.jp/PDFfiles/JCGC-2E.PDF. 
In addition to providing an indication of prognosis, staging should ideally be able to 
provide an outline for treatment decisions, and should allow for evaluation of 
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treatment with meaningful comparisons between different treatments or the same 
treatment modalities by different groups 121. Other systems have been proposed, 
which will be mentioned later 121. Treatment decisions are usually made in reference 
to the American Joint Committee on Cancer (AJCC) and the International Union 
Against Cancer (UICC) 122 123, which is adopted in the UK. 
1.2.7.2 TNM classification of gastric cancer 42 122 123 
The whole concept of system dates back to 1970, when the AJCC published a TNM-
based staging system, using clinical, surgical, and histological information. The 
background database was from 1241 patients with gastric cancer, which had been 
analysed by a task force from seven American institutions. The system used 
penetration of stomach wall (T), proximity to the primary cancer of metastatic 
perigastric lymph nodes (N), and presence or absence of distant metastases (M), 
including nodes not in the perigastric area, as these criteria had the greatest impact 
on outcome in the above cohort 108 109. 
 
Primary tumour (T): 
• TX:  primary tumour cannot be assessed 
• T0:  no evidence of primary tumour 
• Tis:  carcinoma in situ: intraepithelial tumour without invasion of the 
lamina propria 
• T1:  tumour invades lamina propria or submucosa 
• T2:  tumour invades muscularis propria or subserosa 
T2a:  tumour invades muscularis propria 
T2b:  tumour invades subserosa 
• T3:  tumour invades the serosa (visceral peritoneum) without invasion of 
adjacent structures 
• T4:  tumour directly invades adjacent structures 
 
Remarks: 
1. A tumour may penetrate the muscularis propria with extension into the gastrocolic or 
gastrohepatic ligaments or into the greater or lesser omentum without perforation of the 
visceral peritoneum covering these structures. In this case, the tumour would be classified as 
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T2. If there is perforation of the visceral peritoneum covering the gastric ligaments or 
omenta, the tumour is classified as T3. 
2. Intramural extension into the duodenum or oesophagus is classified by the depth of greatest 
invasion in any of these sites, including the stomach. 
 
Regional lymph nodes (N): a minimum of 15 lymph nodes# must be examined 
• NX: regional lymph node(s) cannot be assessed 
• N0: no regional lymph node metastasis 
• N1: metastasis in one to six regional lymph nodes 
• N2: metastasis in 7–15 regional lymph nodes 
• N3: metastasis in more than 15 regional lymph nodes 
# The regional lymph nodes are the perigastric nodes, found along the lesser and greater curvatures, and the 
nodes located along the left gastric, common hepatic, splenic, and coeliac arteries. A regional lymphadenectomy 
specimen will ordinarily contain at least 15 lymph nodes. Involvement of other intra-abdominal lymph nodes, 
such as hepatoduodenal, retropancreatic, mesenteric, and para-aortic, is classified as distant metastasis. 
 
Distant metastasis (M): 
• MX: presence of distant metastasis cannot be assessed 
• M0: no distant metastasis 
• M1: distant metastasis 
 
 
1.2.7.2.1 Stage grouping of gastric cancer 
The following table shows the stage groupings for gastric cancer (Table 4) 122 123 
 
 
Table (4). Classification of Stage Groupings for gastric cancer 
 
Stage Groupings  TNM Classifications  
0  Tis  N0  M0  
I  T1  N0  M0  
IIA  T2  N0  M0  
 T3  N0  M0  
IIB  T1  N1  M0  
 T2  N1  M0  
III  T3  N1  M0  
 T4  Any N  M0  
IV  Any T  Any N  M1  
IVA  Any T  Any N  M1a  
IVB  Any T  Any N  M1b  
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1.2.7.3 Japanese classification of gastric cancer 
The first edition of the General Rules for Gastric Cancer Study was published by the 
Japanese Research Society for Gastric Cancer in 1962. Stage groups were defined by 
the extent of serosal involvement (S stage), the location of involved lymph nodes 
depending on the site of the primary tumour (N stage), and the extent and sites of 
distant metastases (M, H, and P stages for distant metastasis, and hepatic and 
peritoneal disease, respectively). In its twelfth edition, the General Rules changed 
from the S-stage to a T-stage system, which was equivalent to the T-staging of the 
UICC system 124. 
The JGCA classification gives a number to all of the regional lymph nodes staging, 
which are classified into three tiers according to the location of the primary tumour. 
Radical lymphadenectomy in gastric cancer surgery has long been commonplace in 
Japan and large databases of the incidence and sites of lymph node involvement 
exist, depending on the site of the tumour and its T stage. The purpose of the 
meticulous lymph node classification was to guide surgeons to decide the extent and 
location of lymphadenectomy, so that any potentially involved nodes could be 
removed according to the site and depth of penetration of the primary gastric cancer. 
Lymph node staging was characterised on the basis that gastric cancer metastasizes 
to groups of lymph nodes arranged radially around the stomach in rows or tiers. The 
nomination of different lymph node groups to their respective tier was based upon 
the results of anatomical and physiological studies on lymph flow with different 
tumour sites 121. Various amendments to the original classification followed, and the 
most recent classification is aimed at surgeons, pathologists, oncologists, and 
endoscopists who carry out endoscopic mucosal resection (EMR). 
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According to the latest changes in the Japanese classification, lymph node groups 
were reallocated from four tiers (N1 to N4) to three tiers (N1 to N3) on the basis of a 
detailed study of the effectiveness of dissection of different lymph node stations for 
tumours in the various locations within the stomach. Some lymph node groups, even 
some perigastric nodes for specific tumour locations, are no longer regarded as 
regional nodes if involved, but are regarded as sites of distant metastasis (M). this 
follows because their involvement is rare, and if it occurs, it invariably reflects a 
very bad prognosis 121. 
 
Figure (3). Lymph nodes station number (circled) in Japanese classification of gastric carcinoma. 
These stations are further classified into N1/N2/N3 according to the location of the primary 
tumour 
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  M0  
M1 
  N0 N1 N2 N3 
 
 
M0 
T1 IA IB II   
T2 IB II IIIA   
T3 II IIIA IIIB   
T4 IIIA IIIB  IV  
H1, P1, CY1, M1      
T: Tumour; N: Lymph node; M: distant metastasis; H: hepatic disease; P: Peritoneal disease 
Table (5). Japanese classification of gastric cancer 
 
1.2.7.3.1 Difference in surgical philosophy between Japan and the West 
The basic principle of Japanese surgical practice can be quoted as Moynihan said 
“Surgery of malignant disease is not the surgery of organs; it is the anatomy of the 
lymphatic system”. The commonest site of metastasis for gastric cancer is to lymph 
nodes. Japanese surgeons believe lymph node metastasis is orderly and progresses 
through the tiers of nodes in a stepwise manner. By defining the lymph node groups 
in each tier or layer, the surgeon can remove all nodes to the level above that in 
which positive nodes are apparent or likely, on the basis of preoperative and intra-
operative staging 121. 
1.2.7.4 Other classifications 
Numerous classifications have been proposed by individual groups after sub-
analysis of their own data. Most are adaptations of either anatomical or numerical 
systems of N-staging, as in the two major classifications. 
Adachi et al.125 and Whiting et al.126 both employ anatomical nodal staging, with 
junctional nodes between conventional N1 and N2 tiers. Whiting et al. suggested 
that junctional nodes could be assessed during surgery to decide whether or not to 
proceed to D2 dissection, if these nodes were involved. The rationale is based on the 
apparently high morbidity of D2 dissection in Western series, and they suggested 
that D2 dissection should be avoided if possible.  
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Kat et al.127 address the issue of limited nodal dissection and describe the predictive 
value of the number of metastatic nodes in the Japanese (old and new classifications) 
“nl” perigastric stations. They found their system to have higher sensitivity, 
specificity, and accuracy than the TNM system or the Japanese system. 
Finally, Yu et al.128 have proposed a frequency system, based on the ratio of 
metastatic to dissected regional lymph nodes (more or less than 25% involved). 
Such a system weight against limited nodal dissection, and is a relevant approach, 
assuming extended lymphadenectomy has an independent survival impact 121. 
1.3 Treatment 
1.3.1 Changing patterns of the disease and its management 
Over the past 15 years there have been many significant changes in the management 
of oesophageal and gastric cancer. Both diseases have shown remarkable changes in 
epidemiology with a concentration of tumours adjacent to the oesophago-gastric 
junction. The increase in tumours of the cardia is taking place principally in 
countries with relatively low overall rates of gastric cancer. The histology of gastric 
cardia tumours shows frequent aneuploidy and a high S-phase fraction. Spread is 
early and haematogenous, rather than locoregional and late 52. As highlighted in the 
discussion before, advances in established investigative techniques and 
developments in new technology have radically altered the way in which the two 
diseases can be assessed without the need for surgery. Greater understanding of the 
natural history has significantly influenced the approach to diagnosis and to 
treatment options. Appreciation of the fundamental need for multidisciplinary 
treatment planning has reflected greater recognition by all interested clinicians of the 
role of the various treatment modalities 2. 
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1.3.2 Overall treatment strategy 
Surgical resection of the primary tumour and regional lymph nodes is the treatment 
of choice for gastro-oesophageal cancer. The extent of the disease, the operative 
procedure, and patient selection are crucial in optimizing outcome. Adjuvant therapy 
(mainly, chemotherapy ± radiotherapy) still warrants further evaluation for high-risk 
(T3-4, N+) gastric cancer patients. Neoadjuvant therapy may reduce tumour mass 
enabling resection with potentially curative intent. When the disease is metastatic, 
treatment of gastric cancer is exclusively palliative or symptomatic. 
1.3.3 Neoadjuvant treatment 
In Western countries, the majority of patients are diagnosed with locally advanced 
gastric cancer, namely T3-4/N0-2/M0 disease. A curative resection may be 
performed in about half of these patients, and even after an R0 resection two third of 
the patients will show recurrence within 2 - 3 years 129. For this group of high-risk 
patients, an optimal strategy which may possibly prolong disease-free survival and 
overall survival of such patients is the administration of preoperative chemotherapy. 
In this setting, neoadjuvant chemotherapy may also allow the down-staging of an 
unresectable primary tumour, thus enabling the performance of a potentially R0 
resection, and the eradication of occult micro-metastatic disease. Preoperative 
assessment of resectability of gastric cancer is critical. CT scan is useful for 
detecting both tumour invasion of adjacent organs and liver metastases. EUS is quite 
accurate for the assessment of the exact T-category, and laparoscopy may exclude 
peritoneal tumour spread and allow an assessment of the presence of tumour cells by 
peritoneal lavage. The accuracy of prediction of lymph node status may be increased 
by adding EUS to CT scan 130 131. Assessing response in patients with localized 
tumours is another important and controversial issue. It is difficult to measure the 
tumour mass accurately in locally advanced gastric cancer. Also, it is difficult to 
52 
 
gauge the degree of tumour shrinkage precisely in a locally advanced gastric cancer, 
and no method of defining an objective response is universally available. Phase II 
studies of neoadjuvant chemotherapy have demonstrated that such treatment can be 
given with acceptable toxicity and with no obvious increase in operative morbidity 
or mortality. In patients with potentially resectable gastric cancer, many phase II 
trials have shown that preoperative chemotherapy is able to increase the rate of R0 
resection, ranging from 72% to 87% 132-136. 
1.3.4 The role of surgery 
Gastro-oesophageal cancer is a highly lethal disease with a 5-year mortality > 80%. 
Even after intended curative surgery, overall survival remains poor. In 
approximately two-thirds of the patients, local recurrences and/or distant metastases 
are detected within five years of follow-up 137. In approximately 30% of patients 
undergoing surgery, who were clinically considered to have resectable disease, 
radical excision with curative intent could not completely eliminate microscopic 
remnants of the disease as noted on pathological examination of surgical specimens 
25. The shortcomings in current diagnosis and staging tools for gastric and 
oesophageal cancer indicate that the actual patient selection for multimodality 
treatment and the assessment of their outcome remains unreliable 138. Hence, the 
need for a non-invasive diagnostic test that assesses tumour type, behaviour, stage or 
even predicts histopathological response to preoperative therapy has been 
emphasized by many investigators 139. 
1.3.5 The role of chemotherapy 
Approximately one-third of gastric cancer patients have stage I or II disease at the 
time of diagnosis. One-quarter have stage III disease, and the remaining 40% or so 
stage IV disease. As with other tumours, prognosis is clearly related to stage: 
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Currently, 1-year survival rates are around 50% in stage IIIA and B disease, and 
<25% in stage IV disease,   estimated adjusted survival 5 years after surgery is 
82.9% for stage I, 62.8% for stage II, 17.8% for stage III and 3.3% for stage IV 52. 
As has already been noted, a rising proportion of patients now present with tumours 
of the upper stomach, particularly of the gastro-oesophageal junction. This changing 
epidemiology has implications for treatment according to recent statistics. Five-year 
survival for patients with resected cardia or gastro-oesophageal junction appears to 
be in the range of 10% 52.    
A recent investigation into patterns of care showed that many gastric cancer patients, 
even those with relatively early stage disease, are not receiving chemotherapy. This 
appears to reflect a perception that systemic treatment has little effect, which is not 
in fact the case 52. Most patients with gastric cancer are unresectable at diagnosis, or 
will suffer a relapse after surgery, resulting in a five-year overall survival of less 
than 20%140 141. Preoperative chemotherapy could be an approach that might 
improve surgical resectability, which is one of the main prognostic factors in 
patients with gastric carcinoma65. However, only 40 - 50% of patients benefit from 
this treatment modality, whereas approximately 30% of patients experience 
moderate to severe toxic side effects. Understanding the molecular genetic features 
that determine response or resistance to chemotherapy could permit the selection of 
the most suitable patients for preoperative treatment129 142 143. 
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1.4 Neoadjuvant therapy in oesophageal and gastric 
adenocarcinoma 
1.4.1 Introduction 
Adenocarcinoma of the oesophagus is responsive to chemotherapy. Shrinkage of the 
tumour by at least 50% may occur in 15 - 30% of patients who are treated with 
fluorouracil, taxanes (paclitaxel or docetaxel), or irnotecan 144. Similar responses 
have been reported in 35 - 55% of patients who receive Cisplatin in combination 
with these agents11 145 146. 
Gastric carcinoma, even when clinically localized, resists curative surgical removal 
despite more extensive operations, including subtotal gastrectomy, total 
gastrectomy, radical gastrectomy with splenectomy and distal pancreatectomy, as 
well as extended lymph node dissection. Current efforts are now focused on 
designing and testing multimodal, perioperative strategies with the aim of achieving 
the same encouraging effects observed with combined, multidisciplinary therapies 
employed in the treatment of other solid tumours, such as breast cancer, colon and 
rectal cancers, and anal cancer 147. 
The prognosis of gastric and oesophageal cancer remains poor, despite the recent 
advances, whether surgically or medically. As there are no formal screening upper 
gastrointestinal protocols, upper GI tumours are commonly diagnosed in advanced 
stages. Apart from that fact, lymphatic and haematogenous spread is often present 
even in early stages. Moreover, gastric cancer is only moderately sensitive to 
chemotherapy and radiation therapy. For this reason, the potential role of 
neoadjuvant and adjuvant treatment remained uncertain. Now, with the presentation 
of the survival results of MRC Adjuvant Gastric Infusional Chemotherapy 
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“MAGIC” trial, there is rising evidence that patients may benefit from neoadjuvant 
chemotherapy 148. 
1.4.2 Molecular basis of chemotherapeutic effect on cancer tissues 
Chemotherapy is an essential part of management protocols of oesophageal and 
gastric cancer. Accepted approaches include preoperative chemotherapy followed by 
surgery (oesophageal cancer), chemo-radiotherapy alone (oesophageal cancer) and 
perioperative chemotherapy (gastric and gastro-oesophageal adenocarcinomas). The 
underlying principles behind neoadjuvant therapy are to improve resectability by 
tumour shrinkage/down-staging and to treat occult metastatic disease as early as 
possible. The response rate to cytotoxic therapy is about 40% in oesophago-gastric 
cancer. Available evidence suggests that a favourable histopathological response to 
cytotoxic therapy may be a useful positive predictive marker in oesophago-gastric 
cancer. However, the ability to predict tumour response in routine clinical practice is 
difficult and is an area of intense investigation. 
Chemotherapeutics used to treat oesophageal and gastric cancer include  
5-fluorouracil (5-FU), Cisplatin, Carboplatin, Bleomycin, Mitomycin, Doxorubicin, 
Methotrexate, Paclitaxel, and Irinotecan. In chemoradiotherapy, the most frequently 
used drugs are 5-FU and Cisplatin given together 149. Many trials are currently 
underway to assess efficacy of different treatment combinations for management of 
gastroeosophageal cancer (Table 6). 
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Name Country Level of Study Design Indication 
TOGA  Korea Phase III XP or FP +/- trastuzumab  Advanced gastric 
cancer HER2-
positive  
AVAGAST  USA Phase III XP +/- bevacizumab  Metastatic gastric 
cancer  
REAL-3  United Kingdom Phase III, 
multicentre 
EOX +/- panitumumab  Advanced 
oesophago-
gastric cancer  
FFCD 03-
07  
France Phase III ECX followed by FOLFIRI 
vs. FOLFIRI followed by 
ECX  
Advanced 
oesophago-
gastric cancer  
EXPAND  25 countries Phase III XP +/- Cetuximab  Advanced/Metast
atic gastric cancer  
MAGIC-B  United Kingdom Phase III Perioperative ECX +/- bevacizumab 
Neo-adjuvant 
gastric cancer 
CLASSIC  USA Phase III XELOX vs. observation  Adjuvant gastric 
cancer 
EOX, Epirubicin, Oxaliplatin & Capecitabine; SP, Xeloda; FP, 5-FU & Cisplatin 
Table (6). Few of the trials currently assessing the efficacy of different treatment protocol of 
gastro-oesophageal cancer 
 
 
In the MAGIC trial, replacement markers of tumour response and down-staging, 
such as smaller primary tumours (3 cm vs. 5 cm), early-stage tumours (T1 and T2 vs. 
T3 and T4), and less advanced nodal status (N0 or N1 vs. N2 or N3) were 
significantly more frequently recorded in the perioperative chemotherapy group 
compared to the primary surgery group 150. Similar results have also been 
demonstrated in the MRC OEO2 trial of surgical resection with or without 
preoperative chemotherapy [consisting of two cycles of Cisplatin and 5- fluorouracil 
(5-FU) chemotherapy] in oesophageal cancer 61.  
1.4.3 Rationale for neoadjuvant and adjuvant therapy 
Multimodal approaches are based either on radiotherapy, which basically may 
increase the local tumour control, and and/or chemotherapy in order to improve the 
systemic disease control. Both may be applied pre- or postoperatively, which is 
usually called neoadjuvant and adjuvant, respectively. Three more general aspects 
about neoadjuvant therapy deserve some attention. 
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1. Practicability of Neoadjuvant therapy 
After a radical tumour resection in the gastric or oesophageal regions, the potential 
effectiveness of adjuvant treatment is often hampered by poor tolerance. This is 
mainly due to the postoperatively impaired physical condition of the patients. Body-
weight loss during the first 6 months after gastrectomy amounts to 10% in relation to 
the preoperative body weight. So, the patients may encounter an increased rate and 
intensity of side effects. Neoadjuvant treatment strategies, on the other hand, have 
proved to be feasible and well tolerated by patients in different phase II and phase III 
trials 148.  
Although surgery plays a central role in the overall management of operable disease 
151-154, it is clear that additional therapy is required to improve patient outcomes 57 
150.  The United Kingdom Medical Research Council Adjuvant Gastric Infusional 
Chemotherapy (MAGIC) trial demonstrated a 25% reduction in the risk of death and 
a significant improvement in 5 year survival in patients given perioperative 
chemotherapy compared to those treated with surgery alone 150. 
Current evidence suggests that preoperative treatment does not negatively impact on 
surgical outcomes. However, one of the arguments against preoperative therapy has 
been the risk of delaying surgery in those patients who do not respond to 
chemotherapy. Predictive markers of response would therefore be invaluable in 
individualizing patient treatment as it would enable discrimination of those patients 
likely to respond to combination therapy from those likely to be non-responsive and 
may progress during therapy. 
2. Local and systemic effects of neoadjuvant therapy 
Neoadjuvant treatment may, theoretically, be superior to postoperative therapy for 
mainly two reasons. Firstly, neoadjuvant treatment potentially leads to reduction in 
the size of the tumour and therefore may improve the complete resectability rate, 
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which is the keystone of cure in oncological surgery. Secondly, neoadjuvant 
induction chemotherapy is the earliest way of tackling the systemic spread of cancer 
cells, which in many cases is the cause of the poor long-term prognosis. Studies 
evaluating the pattern of recurrence after curative gastrectomy revealed that in only 
30%-38% of patients a sole locoregional failure was found, whereas the remainder 
of the patients encountered distant or combined local and distant failure 148.   
Neoadjuvant ECF chemotherapy has previously been associated with high response 
rates (43 - 61%) and low levels of toxicity and mortality (0-2.5%) in both operable 
and inoperable lower oesophageal and gastric cancers 155-158. But in another study 
ECF chemotherapy was associated with significant toxicity and the early curtailment 
of treatment in nearly 20% of patients either because of progressive disease or 
chemotherapy toxicity 159 but despite significant chemotherapy toxicity, surgical 
outcomes did not appear to be adversely affected. Also, in another study, it was 
shown that the use of neoadjuvant therapies has not increased the rates of surgical 
morbidity or mortality at our institution 160. 
3. Follow-up during neoadjuvant therapy 
Due to the advances in investigational techniques, the accuracy of clinical staging 
has certainly improved. On the other hand, monitoring during neoadjuvant treatment 
and accurate evaluation of response are still entirely unsatisfactory. With the 
exception of bulky lymph node involvement, assessment criteria of the clinical 
response frequently used for metastatic disease have not been validated for localized 
tumours limited to the gastric wall. Endoscopic ultrasound, although accurate in 
assessing T category in patients who have not been pre-treated, cannot be relied on 
in patients who have received neoadjuvant chemotherapy. The use of PET in order 
to assess metabolic response during neoadjuvant chemotherapy for gastric cancer is 
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a very interesting approach but certainly still in its early phases and should be 
reproduced by larger sample sizes and other research work. In summary, there is as 
yet no reliable morphological or functional substitute parameter for response and for 
the true value of neoadjuvant chemotherapy in gastric and oesophageal cancer. 
Therefore, so far the endpoint of neoadjuvant treatment would remain the rate of R0 
resections and, more importantly, overall survival 148.  
Unfortunately, resectability is one of the main prognostic factors in patients with 
gastric carcinoma, and survival is longer when tumours are completely removed 65. 
The use of neoadjuvant chemotherapy is an attractive idea for increasing curative 
resection. Although this approach determined about 50 - 60% of clinical responses 
and allowed radical surgery in 40 - 50% of patients with previously unresectable 
tumours 65 129 142 143 158 161 162, chemotherapeutic regimens currently administered to 
gastric carcinoma patients have substantial toxicities, so that identification of 
responsive patients appears worthwhile to avoid the side effects associated with 
chemotherapy in unresponsive patients. Currently, the use of clinical parameters 
cannot accurately predict which patients may be best served by preoperative 
chemotherapy. 
Results of neoadjuvant chemotherapy 
In the Western world, two-thirds of patients with gastric carcinoma already have 
locally advanced tumours (International Union Against Cancer [UICC] Stage IIIA, 
IIIB, or IV) at the time of diagnosis. The chance of achieving a complete resection 
of the tumour through surgery alone in these cases is less than 50%. During the last 
20 years, attempts have been made to use pre-operative chemotherapy with the 
hopeful goals of 1) down-staging the primary tumour to increase the likelihood of a 
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successful complete resection and 2) destroying occult lymph node and distant 
metastases to diminish the rate of tumour recurrence. In many of Phase II studies of 
neoadjuvant chemotherapy, patients with clinical responses have had an appreciably 
better prognosis than non-responding patients, particularly when a complete (UICC 
R0) resection was performed 132 135 163-165. 
Phase II studies have demonstrated that neoadjuvant chemotherapy can be given 
with acceptable toxicity and without excessive postoperative morbidity and 
mortality. However, some adverse effects associated with neoadjuvant treatment, 
such as chemotherapy-induced anaemia which would dictate preoperative allogenic 
red cell transfusion, should be carefully investigated for their prognostic impact. 
What is known from phase II trials is that patients who respond to neoadjuvant 
chemotherapy have a markedly improved prognosis compared with non-responders 
148. 
Patients with localized node negative gastric cancer have 5-year survival rates that 
approach 75% when treated with surgery alone 166. This is in contrast to patients 
with lymph node involvement, in whom survival rates range from 10% to 30% 49. 
167. Studies of adjuvant and neoadjuvant therapy in the treatment of gastric cancer 
have produced conflicting results. The inconsistency may be a indication of the 
differences between populations studied (high- vs. low-risk groups) 168, pathologic 
classification 169, extent of surgical procedure (D2 vs. D1) 170 as well as differences 
in the content and timing of adjuvant therapy (immediate vs. delayed). Several meta-
analyses 171-176 have been available in attempt to address discrepancies reported in 
the literature, the findings of which are summarised in Table (7). 
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 Patients RCT OR 95% CI P value 
Hermans et al.171 2096  11  0.88  0.78–1.08  NS  
Earle et al.172 173 1990  13  0.80  0.66–0.97  0.024  
Mari et al.173 3658  20  0.82  0.75–0.89   <0.001  
Janunger et al.174  3962  21  0.84  0.74–0.96  N/A  
Gianni et al.175 3118  17  0.72  0.62–0.84  N/A  
Hu et al.176 4543  14  0.56  0.40–0.79   <0.001  
Janunger et al.177 1928  25  0.94  0.77–1.14  NS  
Significance is noted by P value <0.05; NS, not significant; N/A, not reported. 
Patients, number of patients included in meta-analyses; RCT, randomized clinical trial and number of studies included in the 
meta-analyses; 95% CI, 95% confidence interval; OR, odds ratio 
Table (7). Some of the meta-analyses of randomized clinical trials of adjuvant chemotherapy in 
gastric cancer 
 
 
Three of 7 meta-analyses suggest a small but significant advantage of adjuvant 
chemotherapy in the treatment of completely resected gastric cancer 172 173 176. 
However, these authors have suggested the results to be interpreted cautiously, as 
they are of borderline significance 172 and may be influenced by a series of biases as 
well as poor methodological quality173. This goes hand in hand with an earlier report 
that reviewed the results of 43 randomized trials between 1967 and 1993 concerning 
all adjuvant therapies for gastric cancer, including those published in the Japanese 
literature 178. In that review, it was  concluded that the results from North American 
and European randomized trials did not support the routine use of adjuvant 
chemotherapy for gastric cancer 178. Janunger et al, 174 in a systematic overview of 
153 scientific papers (involving 12,367 patients), examined the effects of adjuvant 
chemotherapy in gastric cancer. In their meta-analysis, a significant overall survival 
benefit was demonstrated. However, separate analysis of  Western and Asian studies 
demonstrated a significant difference in outcome in Asian (OR, 0.58; 95% CI, 0.44 - 
0.76), but not in Western (OR, 0.96; 95% CI, 0.83 - 1.12) reports, a difference 
attributed to timing of diagnosis, extent of surgery, and stage migration 174. In a 
more recent meta-analysis, Jununger et al,177 applying modern drug combinations 
over the last 10 years, failed to demonstrate any significant survival benefit. Overall, 
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there is insufficient evidence at present to recommend postoperative chemotherapy 
as standard adjuvant treatment in Western centres 171-174 177. 
One of the significant studies in the effect of neoadjuvant therapy is the MAGIC 
study which was initiated by the MRC to address the question of perioperative 
chemotherapy (pre- and post-) in gastric and oesophageal cancer 150. In this study, 
503 patients with adenocarcinoma of the stomach, lower oesophagus, or gastro-
oesophageal junction were randomly assigned to receive either three cycles of 
preoperative ECF chemotherapy followed by surgery and then by another three 
cycles of postoperative ECF (CSC arm; n=250) or surgery alone (n=253). In the 
CSC treatment arm, 88% of patients completed three cycles of preoperative 
chemotherapy, 55% commenced postoperative chemotherapy, and 40% completed 
all six cycles. Preoperative chemotherapy in the CSC arm resulted in significant 
tumoural down-staging relative to the control arm, with a mean maximum diameter 
of resected tumour of 3 cm for CSC patients compared with 5 cm for surgery only 
patients (P < 0.001). The CSC arm, compared with the surgery alone arm, also had a 
higher proportion of T1-2 staging (54% vs. 36%, respectively; P =0.01) and down-
staged nodal disease with a higher number of N0-1 patients (80% vs. 71%, 
respectively; P=0.10). Resection was curative in 79% of patients in the CSC arm 
compared with 69% of surgery-alone patients (P=0.02), and postoperative 
complication rates were almost equal between the two groups. Progression-free 
survival was improved in the treatment arm (hazard ratio=0.7, P<.02), although 
overall survival was not improved at 1 year. The results of the trial are summarised 
in table (8). Follow-up for this study is still short, and thus, more mature data is 
required before drawing conclusions regarding a survival benefit. Continuing on 
from the MAGIC study, another Swiss/Italian phase III study has randomly assigned 
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patients with locally advanced operable gastric cancer to four cycles of either 
preoperative or postoperative DCF chemotherapy, with a projected accrual of 240 
patients 179. 
 
 
ECF Surgery alone 
No. Of patients having surgery 212 (85%) 232 (92%) 
Median time to surgery (days) 99 14 
Proportion of curative resection 
(%) 
79* 69 
Proportion T3/T4 tumour (%) 49** 64 
*p = 0.018, **p = 0.011 
Table (8). Gastric cancer. MAGIC trial treatment results: effects of neoadjuvant therapy on 
curative resection and down-staging of tumour180 
 
1.5 Chemotherapeutic Agents used in neoadjuvant therapy for 
gastro-oesophageal adenocarcinoma 
Various agents and their combinations were shown to be effective. 5-Fluorouracil 
(5-FU) is the earliest and yet one of the most important cytotoxic agents in the 
managements of this disease. Cisplatin, which is often used in combination with 5-
FU, has also shown activity. In fact, the combination of 5-FU and Cisplatin is 
regarded as a standard chemotherapy. Additional agents have been introduced 
recently with promising efficacy. They include the oral fluoropyrimidines, taxanes, 
irnotecan and the new platinum analogue Oxaliplatin 181.  To show the diversity of 
the usage of these agents, the following table (table 9) summarises some of phase II 
and III studies. 
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Trial Protocol Used No. of patients 
R0 (no. of 
patients) 
Median 
survival 
(months) 
2-year 
survival 
(%) 
Wilke et al.182  EAP  34 10 18 26 
Ajani et al.132  EFP  25 18 15 44 
Alexander et 
al.134  5-FU, FA and INF-α2a  22 18 18 52 
Hartgrink et 
al.183 FAMTX 27 18 (67%) 18 44% 
Kelsen et al.184 Preop. FAMTX  
Postop. i.p. CDDP 
and 5-FU; i.v. 5-FU 
56 34 15 40 
Schuhmacher et 
al.163 EAP  42 31 19 40 
Crookes et al.185 CDDP and 5-FU 
Postop. i.p. CTx 59 40 > 48 64 
Siewert et al.186 CDDP, 5-FU and FA  41 30 n.s. 56 
Ott et al.187 PLF 42 32 (76%) 25 NS 
R0, microscopically complete resection; EAP, etoposide–Adriamycin (doxorubicin)–Cisplatin; EFP, etoposide–5-fluorouracil 
(5-FU)–Cisplatin; FA, folinic acid; IFN, interferon; FAMTX, 5-FU–doxorubicin–methotrexate; CDDP, Cisplatin; CTx, 
chemotherapy; i.p., intraperitoneal; i.v., intravenous; PLF. Cisplatin-leucovorin-fluorouracil; n.s., not specified 
Table (9). Some of the trials (phase II & III) of neoadjuvant chemotherapy and the results on 
survival 
 
1.5.1 Fluoropyrimidines 
5-FU belongs to the family of drugs known as anti-metabolites and principally acts 
via inhibition of DNA and RNA synthesis 188 189. Since its introduction in 1957, 5-
FU has remained an integral member in the management of gastrointestinal 
malignancies, including gastric cancer. The pathway of 5-FU metabolism is shown 
in Figure (4). 
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Figure (4). 5-FU pathway. 
 5-FU is converted into 5-fluoro-deoxyuridine monophosphate FdUMP), an irreversible inhibitor of thymidylate 
synthase (TS), preventing the formation of thymidine 5’-monophosphate (dTMP), thus inhibiting DNA synthesis. 
Dihydropyrimidine dehydrogenase (DPD) is responsible for degradation of 5-FU into its inactive metabolite 
5,6-dihydro-5-FU (DHFU), and then α-fluoro-β-alanine (FBAL). Thymidine phosphorylase (TP) mediates the 
conversion of 5-FU into its derivative 5-fluoro-2’-deoxyuridine (FdUrd). 
 
Two biochemical mechanisms appear to be implicated in the cytotoxic effects of 5-
FU 190-192. The main mechanism for the cytotoxicity of 5-FU is via ‘‘thymine-less 
death’’. Upon entering cells, 5-FU is converted to its active form, 5-
fluorodeoxyuridine (5-FUDR) by the enzyme thymidine phosphorylase (TP). 5-
FUDR is converted to 5-fluorodeoxyuridine monophosphate (5-FdUMP) by 
thymidine kinase (TK). 5-FdUMP competes with endogenous deoxyuridine 
monophosphate (dUMP) for binding to thymidylate synthase (TS) in a complex that 
is stabilised by 5,10-methylenetetrahydrofolate (CH2THF). Binding of 5-FdUMP to 
TS depletes the thymidine nucleotide pool and hence DNA synthesis. The exact 
molecular mechanisms are not clear, but recent studies suggest that depletion of 
dTMP leads to imbalances in the deoxynucleotide pool and accumulation of dUMP 
FdUrd
 
TP 
5-FU DPD 
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and dUTP which may be incorporated into the DNA 193. The other mechanism is 
that 5-FU is converted to 5-fluorouridine monophosphate (5-FUMP), by the action 
of orotate phosphoribosyl-transferase (OPRT). 5-FUMP is eventually converted to 
5-fluorouridine triphosphate (5-FUTP), which inhibits RNA synthesis 194. 
Several enzymes are involved in the action and metabolism of fluorouracil and other 
fluoropyrimidines. Fluorouracil acts by inhibiting TS, an enzyme involved in DNA 
synthesis. Folinic acid binds to a separate binding site, stabilising the ternary 
complex and increasing TS inhibition. Dihydropyrimidine dehydrogenase (DPD) is 
the first and rate-limiting enzyme involved in the catabolism of uracil and thymine 
to β-alanine. DPD is responsible for most of the breakdown of fluorouracil. The 
enzyme is present in high concentration in some normal tissues such as the liver 195. 
5-FU-based therapy (especially combined with Cisplatin) is considered standard 
therapy in the treatment of advanced gastric cancer and a reference arm in most 
clinical trials. 5-FU - Cisplatin combinations have shown response rates ranging 
from 20 to 50%. Its main toxicities are mucositis, neutropenia, gastrointestinal 
toxicities and, if combined with Cisplatin, neuropathy and renal toxicities can also 
be observed 181.   
There are newer oral anti-metabolites related to 5-FU, like Capecitabine  which is 
converted to 5-FU by carboxyesterase (CE), cytidine deaminase (CD) and TP. The 
daily oral administration of capecitabine parallels the intravenous infusion of 5-FU 
in efficacy, helping in more patient and health care system convenience 196. Also, 
there is the oral S-1 which is composed of   Tegafur, a pro-drug of 5-FU; Gimeracil, 
which reversibly inhibits DPD (the enzyme involved in inactivation of 5-FU); and 
Potassium oxonate, which reversibly inhibits the enzyme responsible for 
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phosphorylation of 5-FU (orotate phosphoribosyl-transferase) thereby reducing the 
gastrointestinal side effects of 5-FU197. 
1.5.2 Platinums 
Cisplatin and Oxaliplatin are the main platinating agents used in the treatment of 
oesophageal and gastric cancer. Cytotoxicity is predominantly due to their ability to 
generate free radicals and bind to DNA and produce cross-links leading to DNA 
damage. Therefore, DNA repair capacity represents the major factor affecting the 
therapeutic efficacy in cancer cells (Figure 5). Both Cisplatin and its third-
generation analogue Oxaliplatin-based therapies have considerable clinical benefit. 
Their mechanism of cytotoxicity is thought to be through DNA alkylation and 
formation for DNA adducts that result in inhibition of DNA synthesis, function and 
transcription. Several mechanisms of resistance to platinum compounds have been 
identified, including decreased drug accumulation, caused by alteration in cellular 
transport, drug inactivation by sulfhydryl-containing proteins, such as glutathione, 
and enhanced DNA repair 181. 
Once Cisplatin enters a cell its chloride ligands are replaced by water molecules 
generating a positively charged hydrophilic molecules that can react with 
nucleophilic sites on intracellular macromolecules to form protein, RNA and DNA 
adducts 198-201. Cisplatin treatment results in inhibition of DNA replication 202 203, 
RNA transcription, arrest at the G2 phase of the cell cycle and/or programmed cell 
death 204 205. The molecular mechanisms that link the formation of DNA adducts 
with these downstream biological events are not well understood. 
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Figure (5). Pathways involved in the repair of platinating agents. Predictive markers within the 
pathways are shown in bold. 
AP, apurinic/apyrimidinic; ERCC, excision repair cross-complementing group; FEN-1, flap structure specific 
endonuclease 1; PCNA, proliferating cell nuclear antigen; RAD23B, RAD23 homolog B; RPA, replication 
protein A; RFC, replication factor C; XPA and XPC, xeroderma pigmentosum complementation groups A and 
C; XRCC1, x ray cross-complementation group 1. The TFIIH complex is cdk7, cyclin H, maturation associated 
protein 1 (MAT1), xeroderma pigmentosum complementation groups B and D (XPB and XPD), p34, p44, p52 
and p62 
 
1.5.3 Other chemotherapeutics used in gastric and oesophageal 
cancer treatment 
Other chemotherapeutic agents used in the treatment of oesophago-gastric cancer 
include Docetaxel which is a taxane analogue that inhibits microtubule disassembly 
206 and Irinotecan which is a topoisomerase I inhibitor 207. Proficient DNA repair in 
cancer cells may lead to enhanced repair of DNA damage induced by cytotoxic 
agents thereby contributing to therapeutic resistance. On the other hand, sub-optimal 
DNA repair in normal tissue may negatively impact on normal tissue tolerance, 
leading to the increased toxic effects of the drug.  
69 
 
1.6 Prediction of response the chemotherapy 
Currently the ability to predict response to neoadjuvant therapy does not exist, but 
would be of clinical advantage for several reasons. Firstly, neoadjuvant therapy is 
time-consuming, expensive, and increases perioperative morbidity. The ability to 
predict response either before or in the early stages of treatment may spare poorly 
responding patients from undergoing treatment from which they would derive no 
benefit. Instead, they would be candidates for alternative or more intensive treatment 
strategies. Secondly, the ability to accurately predict good response may alter the 
subsequent management of patients. 
The role of predictive biomarkers has been well established in solid tumours such as 
in breast cancer (over-expression of Her-2 predicts response to herceptin and 
oestrogen receptor positivity predicts tamoxifen response), chronic myeloid 
leukaemia (breakpoint cluster region - Abelson murine leukaemia oncogene (BCR–
ABL)) translocation predicts response to imatinib mesylate), brain tumours (EGFR 
mutations in the extracellular domain and response EGFR inhibitors), lung cancer 
(epidermal growth factor receptor (EGFR) kinase domain mutations predict 
response to erlotinib or geftinib), and colonic cancer (mutations in KRAS predict 
response to EGFR specific antibody therapy).  
Since clinical responses do not always correlate with histological responses, 
however, predictive molecular markers may further help define who may be 
considered for non-operative approaches. Moreover, a molecular understanding of 
response and resistance may be encompassed in future studies for any novel agents 
that might emerge. 
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1.6.1 Factors affecting cancer cell death and response to 
chemotherapy  
To highlight the large diversity of studies which are trying to get a better 
understanding of the nature and pathway of oesophageal and gastric cancer, below 
are some aspects of the different routes of studies and work that have been explored 
in a bid to reach to a way that might get better understanding and control of the 
disease. 
1.6.1.1 Apoptosis 
The mechanism by which cancer cells die is complex and may include necrosis, 
mitotic catastrophe and apoptosis (programmed cell death). It has been well 
documented that chemotherapy and irradiation initiate cell death mainly through 
apoptosis. There are at least two known pathways of apoptosis in cells: (1) the 
intrinsic pathway largely mediated by the mitochondria; and (2) the extrinsic 
pathway that is activated by interaction with death receptors on the cell surface. 
Chemotherapy and irradiation initiate apoptosis through the mitochondrial (intrinsic) 
pathway. However, this is tightly controlled by pro-apoptotic and anti-apoptotic 
factors. These factors have been considered potentially important predictive markers 
in oesophago-gastric cancer 149. It has been shown in recent studies that, for 
example, over-expression of inhibitors of apoptosis (such as Bcl-2 and Survivin) or 
down-regulation of pro-apoptotic factors (such as Bax) may lead to relative 
resistance to chemotherapy in cancer. 
1.6.1.2 Transcription factors 
 1.6.1.2.1 TP53 (p53) 
TP53 (p53) is considered to be an important transcription factor involved in key 
cellular activities as cell cycle regulation, apoptosis and DNA repair. Mutation of 
p53 is a hallmark of many cancers. More details about its role and involvement in 
gastro-oesophageal cancer will be discussed later. 
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1.6.1.2.2 Nuclear factor kappa B 
Nuclear factor kappa B (NF-kB) protein expression was studied in 43 patients with 
oesophageal cancer (both squamous cell and adenocarcinomas) who underwent 
neoadjuvant chemo-radiotherapy, where its positivity correlated with lack of tumour 
response and poor overall survival 208. 
1.6.1.2.3 Hypoxia-inducible transcription factor-1 (HIF-1) 
The hypoxic microenvironment is being believed to select cells that are capable of 
avoiding apoptosis and survive in the absence of normal oxygen availability. 
Tumour hypoxia is an important factor in the induction of angiogenesis within 
tumours. Therefore, it is accepted that the hypoxia-inducible transcription factor-1 
(HIF-1) mediated pathway is vital for tumour angiogenesis. HIF-1 transcription 
factors cause the over-expression of several genes that control various biological 
processes necessary for tumourigenesis such as cell proliferation, apoptosis, 
migration and angiogenesis (VEGF expression) 209. In a recent study in gastric 
cancer, patients with VEGF-negative tumours had response rates very similar to 
VEGF-positive tumours, but the median survival in VEGF negative tumours was 
significantly longer than in VEGF positive tumours. This highlights the prognostic 
significance of VEGF in gastric cancer 210. Multiple other pathways have also been 
identified as being strong effectors of the mechanism of cellular resistance to 
chemotherapy; these include Multi-drug resistance related protein-1 (MRP-1) and 
multidrug resistance related gene-1, tyrosine kinases, messenger RNA expression 
levels of c-erb-B1 and c-erb-B2, EGFR protein expression, Caldesmon and also 
polymorphisms of glutathione S-transferases 211. 
1.6.1.3 Survivin 
This is a prominent member of the inhibitor of apoptosis (IAP) family that halts the 
activation of downstream checkpoints of apoptosis such as the caspases 212. Survivin 
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expression might be the reason behind resistance to Cisplatin-induced apoptosis 
during chemotherapy. 
In a study of 42 patients with gastric cancer the mRNA expression of survivin and 
its relationship between expression and sensitivity of Cisplatin (CDDP) was 
examined. Survivin was frequently up-regulated in gastric cancer tissue and was 
negatively associated with overall survival in patients in that study 213. Another 
study of 51 patients with oesophageal squamous cell cancer receiving Cisplatin and 
5-FU neoadjuvant chemotherapy showed that Survivin expression in the cancer 
tissue in patients who achieved a partial response was significantly lower than that 
in patients with no response or those with progressive disease 214. 
1.6.1.4 Bax 
Kang et al. led a study on patients treated by definitive chemo-radiotherapy for 
locally advanced oesophageal cancer, where they examined protein expression of 
Bax, p53, Bcl-2 and galectin-3 in pre-treatment biopsy specimens. Low expression 
of Bax was significantly correlated with a lack of clinical complete response. In 
addition the low expression of Bax was associated with a poor overall median 
survival of 8 months vs. 16 months in the other group 215. 
1.6.1.5 Cyclooxygenase-2 (COX-2) 
COX-2 may be involved in the up-regulation of factors that promote cell survival, 
despite the uncertainty of its molecular action. High levels of COX-2 have been 
reported in oesophageal 41 and gastric cancers 216. Its over-expression has been found 
to be associated with resistance to apoptosis. In a study of 52 patients with 
resectable oesophageal cancer following neoadjuvant chemo-radiotherapy, high 
COX-2 protein expression levels seemed to be significantly associated with poor 
prognosis and a poor histopathological response to chemotherapy 217. 
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The studies described above have focused on a single marker or a set of markers 
targeting a specific pathway or a set of pathways that may be involved in cellular 
response to cytotoxic agents. However, the cancer phenotype is the total of 
simultaneous changes that occur leading to its occurrence and proliferation, as well 
as the way the cancer spreads and metastasize. This involves many agents, whether 
concerning apoptosis, proliferation, vascular supply, angiogenesis as well as 
lymphangiogenesis. So, it appears logical to try and pursue at least a group of these 
agents together and monitor if there is a relationship between these agents and the 
response to neoadjuvant chemotherapy. 
1.7 Multimodality management of gastro-oesophageal cancer 
The multidisciplinary management of gastric and gastro-oesophageal cancers, in 
diagnosis as well as in treatment strategies, gains now even more ground after the 
results of recent randomized studies became available. It is a well practised regimen 
at the moment to adopt the multimodal treatments to increase the chance of better 
outcome, longer survival or even cure. By using this team approach, all diagnostic 
and therapeutic disciplines, such as the gastroenterologist, surgeon, oncologist, 
radiologist and radiotherapist, have become instrumental in planning the effective 
administration of their treatment modalities. The diagnostic facilities, i.e. CT scan, 
endoscopic ultrasound (EUS), mini-laparoscopy, MRI and PET, allow improved 
pre- or postoperative staging 218. For endoscopically large tumours and tumours of 
the gastro-oesophageal junction in particular, CT scan of the abdomen/thorax and 
EUS are mandatory for an exact preoperative tumour and node metastases staging. 
EUS allows the differentiation between small and large tumours as well as staging 
or biopsies of mediastinal and coeliac lymph nodes. In addition, mini-laparoscopy is 
a valuable tool, as peritoneal carcinosis is found in about 20% to 30% of all gastric 
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cancer patients at first diagnosis 219. As PET scan has also been shown to effectively 
predict clinical response in oesophageal and gastric cancer, it might potentially 
allow better allocations and adjustments for further individualized and optimized 
treatment strategies. Staging with PET may best be used either in patients with 
locally advanced disease who may benefit from curative resection, if distant 
metastases are not found, or in patients with high-grade stenosis, where EUS is not 
applicable 218. 
These methods have been evolving as more accurate modalities for preoperative 
staging become widely available. Techniques such as spiral computed tomography 
(CT), endoscopic ultrasonography (EUS), and staging laparoscopy are becoming 
standard, and newer modalities such as thoracoscopy, magnetic resonance imaging 
(MRI), and positron emission tomography (PET) are currently being evaluated. The 
accuracy of EUS for assessing T and N status has been reported to be 85% and 75%, 
respectively, and that is against the sensitivity of CT for staging T and N disease 
which is about 50% and 60 - 87%, respectively. Thus, the combined use of all three 
modalities is often needed for initial staging of oesophageal cancer 220. Most centres 
in the UK offer endoscopic surveillance for predisposing conditions as Barrett’s 
oesophagus with the aim to detect early, curable lesions. But surveillance in its 
current form is burdensome and costly 221. 
Depending on tumour stage, current treatment options for oesophageal and gastric 
cancer range from endoscopic mucosal resection to preoperative chemoradiotherapy 
followed by oesophagectomy or gastrectomy plus radical lymphadenectomy with a 
curative intent is done to remove the tumour and all draining lymph node groups, 
thus achieving an R0 resection margin; this is further improved with post-operative 
chemotherapy and/or radiotherapy according to the number and position of lymph 
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nodes involved. Most of these therapeutic approaches are associated with substantial 
morbidity and mortality, as well as a long-term compromise in the quality of life. 
Accurate pre-therapeutic staging by imaging techniques, or any other relatively 
accurate histopathological method, is therefore crucial in order to select the 
appropriate form of therapy 139. 
1.8 Histopathological and molecular methods of assessing 
response for neoadjuvant therapy 
The introduction of new effective therapies, most notably Taxans and others, has 
created a need for a high level of reproducibility and accuracy in the evaluation of 
the tumour response. This is currently achieved by the application of several similar 
grading systems that take into account the relationship between the amount of 
fibrosis and the residual cancer cells, and the reproducibility is usually regarded as 
fair to good. 
Molecular predictive factors are still not included in prognostic models such as the 
TNM classification. The main reason for this is that molecular biological research is 
rapidly evolving and an astonishing number of biomarkers have been described, but 
sufficiently large studies about the predictive and/or prognostic value of one specific 
gene or protein are still lacking. Another drawback of many studies is that squamous 
cell- and adenocarcinoma samples are combined to draw conclusions. These results 
may be difficult to interpret because squamous cell cancers form a different 
histological subtype and have a different pathogenesis and perhaps clinical 
behaviour 21. 
1.8.1 Mandard Staging system 
The original study by Mandard et al 222 reported on the predictive/prognostic 
significance of histopathological response to cytotoxic therapy in oesophageal 
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cancer specimens following neoadjuvant chemo-radiotherapy. It is important to 
highlight that specimens used in that study were predominantly squamous cell 
carcinomas. Tumour regression grade (TRG) analysis was used as a marker of 
treatment response. It was scored from complete regression (TRG1) to absent 
regression (TRG5). In this study, cases were separated into two histological groups. 
In the first group, the tumour showed no regressive changes. The second group 
included all those cases in which regressive changes were noted. Regressive changes 
included the following: 
• Stromal changes in the form of collagenous or oedematous fibrosis, with or 
without inflammatory infiltrate, (e.g. giant cell granuloma and keratin). 
• Cancer cellular changes, including cytoplasmic vacuolization and/or 
eosinophilia, nuclear pyknosis, and necrosis. 
On the basis of these changes, primary tumour regression was classified into five 
regression grades: Grade 1 (complete regression) showed absence of histologically 
recognisable residual cancer and fibrosis extending through the different layers of 
the oesophageal wall, with or without granuloma. Grade 2 was characterised by the 
presence of residual cancer cells, scattered through the fibrosis. Grade 3 showed an 
increase in the number of residual cancer cells, but fibrosis still predominated. Grade 
4 had the residual cancer outgrowing fibrosis. Grade 5 was characterised by the 
absence of any regressive changes. The grades in accordance to changes are 
summarised in table (10). 
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Tumour 
regression 
grade  
Histological characteristics  
1 Complete regression: no histologically identifiable residual cancer, only 
fibrosis  
2 Rare residual cancer cells scattered through fibrosis 
3 Increase in the number of cancer cells, but fibrosis still predominant  
4 Residual cancer outgrowing fibrosis 
5 Absence of regressive changes  
Table (10). Grading of tumour regression after neoadjuvant radiochemotherapy according to 
Mandard 222 
 
The same grading system was used for assessing tumour regression in metastatic 
lymph nodes. In the latter, “complete regression” corresponded to the presence of 
keratin plugs or neoplastic squamous ghost cells scattered in dense fibrosis. The 
above definition enabled the investigators to confirm the nature of regressed 
metastatic lymph nodes, as these were also included in this study. 
Assessment of oesophageal wall involvement by residual cancer and/or regressive 
changes was also done. Oesophageal specimens were divided into two groups. In the 
first group residual cancer and/or regressive changes extended only in the mucosa 
and submucosa. In the second group, residual cancer and/or regressive changes 
extended within the muscularis propria or beyond, to the adventitia 222 . 
Of 93 patients, 42% were TRG1–2, 20% TRG3 and 33% were TRG4–5. Tumour 
size, pathological lymph node status, TRG and oesophageal wall involvement 
correlated highly with disease-free survival. On multivariate analysis, however, only 
TRG (TRG1–3 vs. TRG4–5) remained a significant (p=0.001) predictor of disease-
free survival 222. Similar results for gastric cancer patients receiving neoadjuvant 
chemotherapy were demonstrated in another study where survival benefit was 
shown to be significantly improved in the group of patients where histopathological 
evidence of response to cytotoxic therapy was achieved 223. 
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1.8.1.1 Trials to modify Mandard Grading system 
The ability to predict the degree of regression as guided by the histopathological 
changes which occur as a result of neoadjuvant and radiological treatment of 
oesophageal cancer has been going on for a long time, even before the currently 
widely accepted work of Mandard. The most notable of these is that of Darnton et al 
224. 
 
Figure (6). Stages of Mandard regression system 
 
However, since the publication of their work, many studies worked on trying to get 
more accurate assessment of the regression in relation to the overall disease-free 
survival. According to the work done by Cheriec et al., the outcome of patients after 
preoperative radiochemotherapy (RCT) was much better if no residual carcinoma 
(Stage 0) is found in the resected specimens, representing a pathologic complete 
response (CR). A pathologic CR occurs in > 30% of patients who undergo surgery 
after pre-operative radiochemotherapy 225. 
Then an alternative system was proposed by Rohatgi et al., where 235 patients who 
received RCT residual cancer in the resected specimen, and group C as > 50% 
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residual cancer. Although the disease-free survival was significantly longer for 
group A compared to group B (and C), the authors did not state any significant 
differences in overall survival between groups A and B 226. 
Also, in the work done by Hermann et al., five-year overall survival rate (OS) with 
TRG 1 was 90%, with TRG 2 26%, with TRG 3 25.9% and with TRG 4 4.0%. OS 
of patients with TRG 1 was significantly higher compared to patients with TRG 2,3 
and 4. There were no significant differences in OS of patients with TRG 2, TRG 3 
and TRG 4 detectable, when these stages were compared with each other. Thus, the 
latter (TRG 2, TRG 3, TRG 4) were comprised as ‘Incomplete tumour regression’, 
and had a significantly lower OS compared to patients with ‘Complete tumour 
regression’ (TRG 1). In this study, none of the 10 patients with TRG 1 developed 
disease progression. On the other hand, they could not detect significant disease-free 
survival or OS of patients with TRG 2, TRG 3, and TRG 4. So, it was suggested that 
these groups which are distinguishable only on a more or less quantitative level, 
should be comprised in one single group ‘Incomplete tumour regression’, rather than 
evaluating them separately. Also, there were few other studies which tried to prove 
that the reproducibility of a 3-point system are more accurate and easier than the 5-
point system used by Mandard, as in the studies by Wheeler et al, and Ryan et al 227-
229. 
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Mandard Five-
point TRG 
Description Three-point TRG 
1 No viable cancer cells 1 2 Single cells or small groups of cancer cells 
3 Residual cancer outgrown by fibrosis 2 
4 Significant fibrosis outgrown by cancer 3 5 No fibrosis with extensive residual cancer 
Table (11). Comparison between the 5- and 3-point Tumour regression grading (TRG) systems 
 
In another study by Becker et al, The grading of tumour regression in response to 
chemotherapy (Table 12) was based on an estimation of the percentage of vital 
tumour tissue in relation to the macroscopically identifiable tumour bed that was 
evaluated histologically. Three grades were used: Grade 1, complete (0% residual 
tumour; Grade 1a) or subtotal tumour regression (<10% residual tumour per tumour 
bed; Grade 1b); Grade 2, partial tumour regression (10–50% residual tumour per 
tumour bed), and Grade 3, minimal or no tumour regression (<50% residual tumour 
per tumour bed). In the current study, grading of regression according to 5 classes 
(complete, subtotal, partial, minimal, or no regression) did not show significant 
association with survival (P =0.08) 223. 
 
Grade Description 
1a No residual tumour/tumour bed 
1b <10% residual tumour/tumour bed 
2 10-50% residual tumour/tumour bed 
3 >50% residual tumour/tumour bed 
Table(12). Grading of Histopathological regression in the primary tumour bed according to 
Becker et al.223 
 
From the above mentioned studies performed through the years, since the first work 
done by Mandard et al. in 1994, it is clear that the pathologists have not completely 
agreed on one solid system of evaluating the degree in regression in response to 
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neoadjuvant therapy, although there is evidence that it is a clinically useful grading 
system. 
 
1.8.2 Tumour Markers 
1.8.2.1 Concept of studying tumour markers 
Predicting response to treatment has been the Holy Grail of surgical oncologists and 
gastroenterologists since the introduction of adjuvant therapy. The introduction of 
neoadjuvant therapy brought the goal a step closer, as pathological outcome could 
now be correlated with pre-treatment markers. Neoadjuvant therapy has rapidly 
gained a role in the management of oesophageal and gastric cancers, because the 
prognosis of oesophageal cancer is very poor and the results of surgery, the mainstay 
of treatment, are still weak. Surgical publications report that only about 25% of 
carefully selected patients operated upon can hope to survive long-term. Since the 
surgical group represents, at most, 20 - 30% of all oesophageal and gastric cancers 
in the community, the contribution of surgery to survival is less than 10%. And since 
many patients are unsuitable for curative surgery because of age or combined 
disease, other options are imperative. 
There are two categories of markers that can be of use in the assessment of the 
progress of patients afflicted with cancer, either predictive or prognostic. Predictive 
factors provide information about which patients will do well with a very specific 
treatment, that is, these markers will allow us to choose which chemotherapeutic 
agent is most likely to provide benefit. Therefore, predictive factors will play a 
major role in the neoadjuvant setting, allowing the selection of chemotherapy with a 
high probability to achieve complete pathological response. In contrast, prognostic 
factors are associated with overall outcome independent of treatment. Thus a 
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prognostic factor may be useful in the adjuvant setting to identify patients at high 
risk for tumour recurrence and therefore should receive adjuvant chemotherapy and 
the predictive markers would select the agents used in this setting. 
One strategy to improve the outcome of patients treated with chemoradiotherapy is 
to select treatment responders for directed therapy. Current acquaintance about the 
molecular mechanisms of cancer-related pathways is facilitating numerous studies 
that attempt to identify molecular markers of both response to preoperative therapy 
and overall survival. Markers of interest include those associated with apoptosis 
(p53, bax, and Bcl-2), cell cycle control (p16, p21, and cyclin D1), growth 
regulation [epidermal growth factor receptor (EGF-R), transforming growth factor-
α, HER-2/neu, Ki-67], and DNA repair (ERCC1), metastatic potential (tissue 
inhibitor of metalloproteinase, E-cadherin), angiogenesis (vascular endothelial 
growth factor), and sensitivity to chemotherapy (P-glycoprotein, thymidylate 
synthase, glutathione S-transferase, and metallothionine) 8. Despite extensive study, 
there remain no clear candidate markers that predict pathological response, and there 
are only equivocal data for a limited number of markers that might predict survival 
for patients treated with preoperative multimodality therapy 230-234. Although the 
study by Harpole et al. 230 contained mostly adenocarcinomas, many of the studies 
involved only squamous cell histologies, despite the marked increase in the 
incidence of adenocarcinoma 12 235. The need for additional information about these 
mechanisms is becoming more serious with the recent and ongoing development of 
drugs that target these markers and pathways. 
Unfortunately, chemoresistance is a major clinical problem and cause for failure in 
the treatment of gastrointestinal malignancies. Several mechanisms have been 
suggested to contribute to chemotherapeutic drug resistance: amplification or over-
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expression of membrane transporters; changes in cellular proteins involved in 
detoxification or in DNA repair; or activation of oncogenes 236. Recently, the search 
for molecular determinants able to predict the likelihood of response to 
chemotherapy has generated great interest. In gastrointestinal cancers, clinicians 
have directed their efforts towards the evaluation of proto-oncogenes and tumour-
suppressor genes, such as p53, ras genes, and Her2/neu, or determinants involved 
into fluoropyrimidine metabolism, such as thymidylate synthase (TS). Generic and 
specific predictors of response to chemotherapy may be discriminated. Generic 
markers are directly or indirectly related to the chemosensitivity of tumour cells to a 
large spectrum of anti-tumoural agents, without specificity for a single drug (e.g. 
p53). Specific markers should predict for response to a specific drug or a class of 
drugs, but not to other anti-tumour agents e.g. TS in relation to 5-FU. This 
distinction may have important clinical implications. The ability to identify patients 
with tumours potentially unresponsive to chemotherapy may be useful to spare 
useless toxicity and to offer alternative drugs. One distinctive example in this area is 
the use of oestrogen receptor quantification in the management of breast cancer. It is 
significant that unlike hormonal or Her2/neu directed therapies in breast cancer or 
molecular-targeted therapies against chronic myeloid leukaemia, in gastrointestinal 
cancers the use of molecular determinants has not yet found its way into clinical 
programs. 
One of the arguments against preoperative therapy has been the risk of delaying 
surgery in those patients who do not respond to chemotherapy, in spite of the fact 
that current evidence suggests that preoperative treatment does not negatively 
impact on surgical outcomes 150. Therefore, predictive markers of response would be 
of unequalled significance in individualizing patient treatment as it would pre-
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classify those patients likely to respond to combination therapy from those likely to 
be non-responsive. 
The analysis of tumour DNA can lead to the identification of specific mutations, loss 
of heterozygosity, amplification, methylation, aneuploidy, MSI, and many other 
changes on a single microscopy slide. RNA expression can be assessed by real-time 
reverse transcriptase PCR. In this technique, RNA is extracted from the tumour and 
reverse transcription to cDNA is followed by quantitative PCR with oligonucleotide 
primers and a fluorochrome-labelled probe. The expression of the gene of interest 
can be compared with that of a consistently expressed ‘housekeeping’ gene, 
allowing high or low expression of the gene of interest to be identified. This 
technique is proving useful, even with formalin-fixed specimens 237. 
The above technologies are not available routinely in most hospital pathology 
departments. However, protein expression can be assessed easily by 
immunohistochemistry. In many, but not all cases, the amount of protein expression, 
as detected by immunohistochemistry, is directly proportional to the amount of 
mRNA expression, as a response to treatment, time to progression, and overall 
survival. Tumour specimens can be analysed for predictive markers at the level of 
DNA, RNA, or protein. The use of formalin-fixed specimens has some limitations, 
particularly for assessment of RNA expression, because the fixation process leads to 
structural changes in RNA 238. 
Most patients with gastric cancer are unresectable at diagnosis, or will suffer a 
relapse after surgery, resulting in a five year overall survival of less than 20% 129 141. 
Preoperative chemotherapy could be an approach that might improve surgical 
resectability, which is one of the main prognostic factors in patients with gastric 
carcinoma 65. However, only 40–50% of patients benefit from this treatment 
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modality, whereas approximately 30% of patients experience moderate to severe 
toxic side effects 129 142 143. Understanding the molecular genetic features that 
determine response or resistance to chemotherapy could permit the selection of the 
most suitable patients for preoperative treatment. 
1.8.2.2 Studies for assessing tumour markers as an aid of predicting 
response 
There have been many studies which tried to look at the effect of neoadjuvant 
therapy on many predictive markers. Few of them tried to combine more than one 
marker to try to establish some relationship between these markers and response. 
For example, Kitamura et al.239 assayed p53 protein and Ki-67 antigen expression in 
biopsy specimens of 95 advanced oesophageal cancers immunohistochemically. All 
patients received one course of either chemoradiotherapy or hyperthermo-
chemoradiotherapy preoperatively. Forty-one per cent of specimens were positive 
for p53 protein staining and treatment as monitored by histopathological assessment 
was effective in 72%, while the efficiency rate was 59% in p53 negative patients. 
Shimada et al. 240 correlated p53 and cyclin D1 expression in pre-treatment biopsy 
samples with sensitivity to Cisplatin in 59 patients with oesophageal squamous cell 
carcinoma receiving Cisplatin chemotherapy followed by oesophagectomy. They 
found that p53 expression in the pre-treatment biopsy samples indicated resistance 
to Cisplatin, but no correlation between cyclin D1 expression and histological effect. 
Sarbia et al. 241 also examined the prognostic impact of cyclin D1 expression, as 
detected by immunohistochemistry, and concluded that expression of cyclin D1 in 
carcinomas with multimodal treatment was correlated with poor response to 
chemotherapy but not with overall survival. Moreira et al. 242 studied the predictive 
value of apoptosis immunohistochemically in 55 samples of oesophageal squamous 
cell carcinoma using the BM1 Mab. Sections from untreated patients, or 
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preoperatively treated by chemotherapy, radiation or both were compared. Their 
results suggested that in-situ assessment of apoptotic response better correlates to 
the apoptosis induced by radiation than that by chemotherapy. Sarbia et al. 243 
assayed pre-treatment tumour biopsies immunohistochemically for expression of 
p53, Bcl-2, Bax, and Bcl-X(L). No correlation was found between the expression of 
Bcl-2 and Bax and the response to chemotherapy. Patients treated by 
radiochemotherapy and surgery with p53-negative tumours had a significantly better 
outcome than patients with p53-positive tumours (mean survival, 31.1 months 
vs.11.3 months).  The aforementioned studies may provide preliminary data on the 
role of potential biomarkers in oesophago-gastric cancer. However, published 
studies are limited and patient numbers are too small to provide convincing evidence 
that this approach is feasible in routine clinical practice. Therefore, whether 
predictive markers will be routinely incorporated in clinical practice remains to be 
seen, especially that this field of research is expansive and involves complex 
procedures.  
1.8.2.3 Tumour markers included in the studies 
18.2.3.1 P53 
1.8.2.3.1.1 The Gene and protein 
P53 is a nuclear tumour suppressor protein involved in the maintenance of genomic 
integrity. In human, the gene is composed of 393 amino acids and is contained 
within 16 - 20 kb of cellular DNA, located on the short arm of human chromosome 
17 at position 17q13.1. The gene contains 11 exons, the first of which (213 bases) 
non-coding and is spaced some 6 - 10 kb from the other 10 exons. The fully 
processed and spliced mRNA is 2.2 - 2.5 kb in size and is expressed in all cells of 
the body 244 245. p53 acts by maintaining the G1/S and G2/M cell cycle checkpoint 
where it detects damaged or mutated cells which are attempting to replicate and 
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initiates a pathway which causes them to be eliminated via apoptosis. This is the 
reason why p53 is often referred to as ‘a guardian of the genome’ 246.  
The p53 is the most commonly mutated gene in human tumours. It acts as a tumour 
suppressor gene, negatively regulates the cell cycle, and requires loss of function 
mutations for tumour formation. p53 is also a genomic stabiliser and an inhibitor of 
angiogenesis. TP53 mutations are predominantly inactivating and can induce 
changes in protein conformation. Loss of p53 function may result in defective DNA 
replication and malignant conversion, increased genetic instability, changes in 
ploidy i.e. the number of chromosome sets, and survival of cells with an increased 
mutational load. Loss of p53 function could result from either mutations, bi-allelic 
gene deletions that result in the loss of the p53 protein, or potentially from genetic 
polymorphisms that may result in different encoded proteins 85. Nuclear 
accumulation of the p53 protein can result from up-regulated expression of the wild-
type p53 protein or decreased protein degradation in response to various cellular 
stresses, including DNA damage. Over-expression of the wild-type protein is a 
normal physiological response to slow down the cell cycle at the G1 phase to allow 
repair of damaged DNA. Therefore, low levels of wild-type p53 can be detected in 
the nucleus, especially if sensitive immunohistochemical detection techniques, such 
as antigen retrieval, are used. In addition, gene abnormalities other than missense 
mutations do not lead to nuclear protein accumulations and therefore escape 
detection by immunohistochemical techniques 85. p53 can also trigger apoptosis 
itself by shifting into mitochondria where it interacts with anti-apoptotic Bcl 
proteins, and eventually induces cytochrome C, which is a potent catalyst of 
apoptosis 247 248. 
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It has been demonstrated that p53-dependent apoptosis modulates the cytotoxic 
effects of common anti-tumour agents such as 5-fluorouracil, doxorubicin, and 
Cisplatin 249.  Cells lacking wild-type p53 are resistant to these agents, and p53 assay 
could be used to predict the response of cancer to chemotherapy 250 251. This 
association has been found in non-small cell lung carcinoma and ovarian carcinoma 
252 253. Nuclear over-expression of p53 protein as determined by 
immunohistochemistry (IHC) occurs in approximately 50% of gastric carcinomas 
and is an independent prognostic factor for relapse and survival 254. 
However, despite the fact that there have been many studies monitoring p53, The 
possible reasons for a lack of a confirmed relationship between 
immunohistochemical p53 status and response to treatment may be found in the 
different immunohistochemical staining used, or the small size of samples in the 
studies. However, a p53 positive staining may not simply reflect a mutant form; as 
most of the antibodies recognised both wild-type and mutant protein, p53 positivity 
may be due to reduced degradation, or to the altered cellular environment which 
may leave wild-type protein detectable without necessarily inactivating it. On the 
contrary, the absence of p53 staining may occur with gene deletion, failure of 
transcription, or a non-stabilising mutation, all of which may be associated with loss 
of p53 function. 
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Figure (7). Flow diagram of the p53/apoptosis pathway 
 
1.8.2.3.1.2 P53 in gastric and oesophageal cancers 
It appears that p53 changes occur early in the development of gastric carcinoma, 
being present even in the non-neoplastic mucosa and they increase in frequency as 
the pathway of gastric carcinoma development progresses. p53 immunoreactivity is 
seen in 17% - 90.7% of invasive gastric carcinoma. p53 nuclear staining can be seen 
in both intestinal and diffuse type gastric tumours, although it is more common in 
intestinal than in diffuse type. p53 alterations occur much more commonly in 
proximal lesions than in distal ones, suggesting that the molecular events leading to 
the development of gastric carcinoma may be very different in proximal versus 
distal tumours. And there is a tendency for p53 expression to be more common in 
poorly differentiated tumours than in well differentiated lesions p53 mutations occur 
in 0% - 77% of gastric carcinomas. The mutations are distributed widely across the 
gene from exons 4 - 11 with hot spots of mutation at codons 175, 248, 273, 282, 
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245, and 213. G:C > A:T transitions at CpG sites are the commonest type of 
mutation. At least 60% of carcinomas with mutations also exhibit p53 LOH 85. 
p53 negativity has been correlated with good tumour response in four published 
studies handling gastric cancer 255-258. In contrast, one study of 25 patients with 
metastatic gastric cancer who received high-dose chemotherapy followed by 
autologous bone marrow transplantation, over-expression of p53 and the presence of 
p53 mutations in exons 5 - 9 in pre-treatment biopsy specimens was significantly 
associated with increased overall survival. In addition, p53 protein expression and 
mutation status were the only parameters associated with objective tumour 
regression and histological response in that study 259. 
A comparison of the immunohistochemical reactivity rates in endoscopic biopsies as 
compared to the rate of positivity in the subsequent resection specimens showed that 
the positive predictive rate is only about 80%. This undoubtedly reflects the fact that 
there is often heterogeneity in the p53 staining pattern within a given tumour. In 
approximately 50% of p53 positive GC, 75% or more of the tumour cells are 
stained. In approximately 25% of p53 positive GC tumours, less than 25% of the 
tumour cells are p53 immunoreactive within individual tumours. Estimation of the 
immunohistochemical detection of p53 as a prognostic marker has yielded 
conflicting results. Two interesting studies suggest that it is the tumours with 
intermediate levels of p53 expression that have the lowest risk of metastasis, while 
tumour that are either negative or strongly positive are more likely to metastasize 85. 
In another study, p53 was positive in 68% of patients with gastric cancer, more 
frequently in advanced stage and none of the individuals with intestinal metaplasia. 
This indicated that the mutation of p53 might be a late event in gastric 
carcinogenesis. Although most of the gastric cancer tissue in this study was positive 
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for p53, the apoptotic index (AI) was higher in this group than in IM, confirming the 
hypothesis that apoptosis can be induced via a p53 gene independent pathway 260. 
Young patients (< 40) have a lower incidence of p53 mutations than older 
individuals. It has been reported that mutations are more common in metastatic than 
in primary gastric carcinomas and the proportion of mutations in GC cell lines in 
general is much higher than that seen in primary GC. In addition, GC-containing 
mutations are much more likely to metastasize than those tumours without 
mutations. The risk of metastasis is further magnified if the mutations are at hot 
spots (codons 175, 248, and 243) and at non-CpG sites.  
Similarly, in oesophageal cancer, the results have been conflicting. Whilst one study 
suggests that p53 negativity may correlate positively to tumour response 261, other 
studies did not find any correlation between p53 protein expression and response to 
cytotoxic therapy 262 263. Another study also suggests that p53 mutations may 
correlate with complete pathological response and improved survival 264. It is 
generally accepted that p53 mutations may be associated with resistance to 
chemotherapeutic drugs, as p53-dependent apoptosis modulate the cytotoxic effects 
of many anti-neoplastic agents 249. Loss of p53 activity through mutation or deletion 
could provide a genetic basis for the therapeutic resistance to DNA damaging cancer 
treatments 249 265 266. Few trials evaluated p53 expression as a determinant of 
response to chemotherapy, mostly associated with radiotherapy in patients with 
oesophageal cancer. One series 267 using immunohistochemistry for p53 
determination on archival specimens, showed that p53 positivity was strongly 
predictive for residual disease in the resected specimen. All the 42 samples had an 
adenocarcinoma of the distal oesophagus or gastro-oesophageal junction, and 
received neoadjuvant Cisplatin (CDDP), 5-fluorouracil (5FU) and radiation therapy. 
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Twenty-eight out of 33 (84%) p53-positive tumours had residual disease in the 
specimens as compared to 4 out of 9 (44%) p53-negative tumours (P=0.01). 
Similarly, in patients with squamous cell carcinoma 268, a statistically significant 
relationship was observed between p53 over-expression by immunohistochemistry 
and lower complete response rate to simultaneous CDDP/5FU and radiotherapy, 
performed prior to surgery (n=19) or as the only treatment (n=39). Other studies 
found no correlation between p53 staining and the outcome to preoperative therapy 
(CDDP/5FU/radiotherapy) in squamous cell oesophageal carcinoma 215 262. 
As mentioned earlier, gastric carcinoma is histologically classified into two major 
types: intestinal (generally well differentiated) and diffuse (generally poorly 
differentiated) types. It has been shown that the apoptotic index, as being monitored 
by p53 immunostaining, is significantly higher in intestinal than in diffuse 
carcinoma, but the cell proliferation labelling index is higher in diffuse than in 
intestinal tumours; this indicates that the high number of apoptotic cells and low 
proliferation in intestinal carcinoma may be related to the natural tendency of slow 
growth. Moreover, Ikeda et al. showed that the apoptotic index did not differ among 
very small (<5 mm in diameter), early, and advanced carcinomas of either 
histological type, whereas cell proliferation increased gradually with tumour 
progression, probably explaining the more rapid growth nature of advanced 
intestinal and diffuse carcinoma 269.  
By immunohistochemical p53 analysis on endoscopy samples before treatment, two 
studies suggested a correlation between p53 staining and response to neoadjuvant 
CDDP-based chemotherapy 256 258. In 23 gastric cancer patients 258 receiving 
5FU/CDDP, seven out of ten responding patients had p53-negative staining, while 
11 out of 13 non-responders over-expressed p53 protein (P=0.013). Cascinu et al. 256 
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evaluated 30 unresectable gastric cancer patients treated with a weekly 
administration of CDDP, epi-doxorubicin, leucovorin, and 5FU, and the response 
rate for patients with p53-negative tumours was significantly higher than that for 
those with p53 over-expression (respectively, 71 vs. 12%; P=0.004). These data may 
have implications in the treatment of locally advanced gastric carcinoma. In fact, the 
expression of some molecular markers that determine response to chemotherapy 
would allow the selection of those patients more suitable for neoadjuvant treatments. 
Interestingly, this correlation was obtained by immunohistochemical staining rather 
than genetic analysis, thus presenting a largely accessible method of p53 status 
assessment. Yet, two other series 255 270 did not confirm the correlation between p53 
status and response to chemotherapy. In the first study, Boku et al. 255 showed 
higher response rates in patients with p53-negative tumours, as well as TS-negative 
tumours, but in both cases a statistical significance was not  reached (respectively, 
P=0.72 and P=0.30). 
 
For adenocarcinoma the best evidence for a predictive marker comes from the study 
of Duhaylongsod et al. on c-erb B2 and p53 protein expression in the pre-treatment 
biopsy specimens of 42 patients 267. Both c-erb B2 negativity and p53 positivity 
significantly correlated with the presence of residual disease in the resected 
specimen after treatment. p53 negativity predicted a favourable response to 
neoadjuvant chemotherapy (Cisplatin and 5-FU) and irradiation and improved 
survival 234. 
Although nearly 200 articles concerning p53 abnormality in gastric cancer in 
relation to patients’ prognoses have been published, the prognostic impact remains 
controversial. Recent reports indicate that abnormal expression of p53 significantly 
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affects cumulative survival and that p53 status may also influence response to 
chemotherapy 271 272. Below is a table summarising many of the studies which 
involved the monitoring of p53 in relation to neoadjuvant therapy. 
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Type of 
cancer 
Number 
of 
patients 
Protocol used in 
treatment  
Markers 
assessed 
Pre- or Post 
specimen 
Aspect of 
assessment 
Result  
Oesophageal 
215  63 Definitive CRT  
TP53 
(protein) 
Pre- Survival No correlation with 
response  
Oesophageal 
262 
94 Neoadjuvant CRT (F/C)  TP53 (protein) 
Pre- Histo/survival No correlation with 
tumour regression  
Oesophageal 
261 62 
Definitive CRT and 
neoadjuvant CRT (C and F)  
TP53, TP21 
and 
TP53R2 
Post- Hsito/survival TP53 negativity 
associated with improved 
response. No correlation 
with TP21 
Oesophageal 
264  
54 Neoadjuvant CRT (F/C)  TP53 
mutation 
Pre- Survival Presence of complete 
response and TP53 
mutation correlated with 
increased survival 
Oesophageal 
208 
43 Neoadjuvant CRT 
(docetaxel, irinotecan, F)  
NF-kB 
(protein) 
Pre- & post- Histo/survival NF-kB positivity 
associated with poor 
response.  
Oesophageal 
273  52 
Neoadjuvant CRT and 
Definitive CRT (C/F)  
TP53 
(protein) 
Pre- Survival No association with 
response 
Gastric 258 20 F and C chemotherapy  TP53 
(protein) 
Post- Histo 70% resonders are p53-  
Gastric 187 53 Neoadjuvant chemotherapy (C-based)  
MSI/LOH 
TP53 
mutation 
Pre- Survival No association for TP53 
mutation or protein 
expression and response. 
No association with MSI 
and response. LOH at 
chromosome 17p13 
showed significant 
association with 
response 
Gastric 257 55 Irinotecan and C 
chemotherapy  
TP53 
(protein) 
Unresectable Survival TP53 negativity 
associated with improved 
response  
Locally 
advanced 
gastric cancer 
256 
30 Leucovorin/Glutathione/5-FU/CDDP P53 
Post- CT & 
endoscopy P53- tumours more likely to respond than p53+ 
tumours 
Locally 
advanced GC 
274 
28 Paclitaxil/Carboplatin P53 
Unresectable Histo 
No relation 
Stage II III 
patients 275 46 MMC/5-FU P53 
Post- Survival P53-ve 82% 4 year 
survival, p53+: 45% year 
survival 
Advanced 
gastric 276  
28 F, C and pirarubicin 
chemotherapy  
TP53 
(protein) 
Unresectable Survival TP53 negative expression 
associated with improved 
survival  
Advanced 
gastric 255  39 
Combination F/C 
chemotherapy  
TP53 
(protein) 
Unresectable Survival Negativity correlated 
with response rate 
Advanced 
gastric 277 11 5-FU/MMC/ADM/CDDP P53 
Pre- Survival Chemosensitivity is 
inversely correlated with 
p53 expression 
Advanced 
gastric 278 74 CHHP/MMC P53 
Post- Survival No relation 
Metastatic 
gastric 259  
25 HDCT (Eto/C/Mit C/bone 
marrow)  
TP53 
(protein) 
Pre- & post- survival Positive staining useful 
predictor of response  
C, Cisplatin; CRT, chemo-radiotherapy; dox, doxorubicin; Epi, epirubicin; Eto, etoposide; F, 5-fluorouracil; leuc, leucovorin; 
LOH, loss of heterozygosity; Mit, mitomycin C; MSI, microsatellite instability; NF-kB, nuclear factor kappa B. ? Response, 
questionable response; pre-, pre-neoadjuvant; post, post-resection or treatment; histo-, histopathology 
Table (13). Summary of some of the studies which were done to assess the ability of p53 (TP53) to 
be used as a predictive biomarker for the response to neoadjuvant therapy 
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1.8.2.3.2 Bcl-2 
The Bcl-2 oncoprotein functions as a programmed cell death (apoptosis) inhibitor, 
and therefore, prolongs the cell life span. It thus increases the risk of acquiring other 
unfavourable changes, such as chromosomal abnormalities, DNA-damaging agents 
and viral infection rendering the cells more susceptible to malignant transformation 
279-281. Bcl-2 protein is an inhibitor of apoptosis induced by different factors, 
including irradiation and anti-cancer drugs (e.g. Cisplatin, 5-Fluorouracil) 282 283, so 
the cells expressing Bcl-2 protein should be potentially drug-resistant 282. 
The Bcl-2 gene was originally discovered owing to its involvement in the 
chromosomal translocation occurring in the majority of non-Hodgkin’s B-cell 
lymphomas. This translocation places the Bcl-2 gene at chromosomal location 
18q21 in juxtaposition with the immunoglobulin heavy chain locus at 14q32, 
resulting in transcriptional deregulation of the Bcl-2 gene and abnormally high 
levels of the Bcl-2 protein 284. The product of the Bcl-2 gene is a 26 Kd protein that 
is known as an inhibitor of apoptosis and it may be considered a “generalised cell 
death suppressor gene”. Bcl-2 expression is a potential mechanism by which tumour 
cells escape p53-mediated apoptosis and their expression has been reported for a 
variety of human epithelial malignant tumours including carcinomas of the stomach 
285 and colon 286. 
The Bcl-2 family consists of about 20 homologues of important pro- and anti-
apoptotic regulators of programmed cell death. This function is based on the 
preservation or disturbing of mitochondrial integrity, thereby inducing or preventing 
release of apoptogenic factors such as cytochrome C. The family regulates caspase 
activation and caspases in turn are at the centre of the cell’s decision to live or die in 
response to an apoptotic signal, including cytotoxicity and ionising radiation 287 288. 
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Bcl-2 and Bax are pro-survival and pro-death proteins, respectively. The primary 
function of Bcl-2 is to maintain integrity of the outer membrane of the mitochondria. 
Bax, on the other hand, acts to breach this integrity and can be activated by pro-
apoptotic stimuli or p53 289 290. Bcl-2 negatively regulates this process. Once the 
membrane has been breached, pro-apoptotic proteins such as cytochrome C are 
released which cause caspase activation, culminating in cell death 291. In summary, 
Bcl-2 interacts with bax family genes to produce heterodimer which inhibit 
apoptosis. The balance of bax heterodimers and homodimers, which promote 
apoptosis, play an important role in the regulation of apoptosis 292. 
1.8.2.3.2.1 Bcl-2 in gastro-oesophageal cancer 
There have been very few studies monitoring and assessing the impact of bcl-2 in 
gastric and oesophageal cancer. In one study, Bcl-2 positive patients had a 
significantly better survival compared with Bcl-2 negative patients in 
adenocarcinoma of the oesophagus 10. However,  there have been similar studies in 
other tumours where Bcl-2 protein expression or gene activation have been 
associated with poor response to therapy and/or shorter disease-free survival in some 
groups of patients with lymphomas 293, leukaemia 294, prostate cancer 295 and breast 
cancer 296 297. In head and neck tumours on the other hand Bcl-2 positivity proved to 
be either highly indicative 298 299 or independent 300 of the response to treatment. 
A poor response to chemotherapy and short survival was observed in a subgroup of 
patients with metastatic breast cancer whose tumours showed reduced bax 
immunostaining 301. Similarly, it was shown that high bax expression in ovarian 
cancer was associated with a significant increase in the percentage of complete 
remissions after first-line chemotherapy including paclitaxel and a platinum 
analogue, and also with an improvement in survival 302, although such findings are 
not universal 303. 
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Below is a table summarising some of the studies that handled the relation between 
bcl-2 and chemotherapy. In most of them, though the numbers are small, there has 
been a correlation between improved response and/or survival in case of bcl-2 
negative patients. 
 
 
Type of 
cancer 
Number 
of 
patients 
Protocol of 
treatment 
Biomarkers 
assessed 
Pre- or Post-
specimen 
Aspect of 
assessment 
Results 
Oesophage
al 215 255 
63 Definitive 
CRT 
Bcl-2 and 
galectin 
Pre-resection Survival No correlation 
with response 
Gastric 257 55 Irinotecan 
and Cis 
chemothera
py 
Bcl-2 Unresectable Survival & 
radiological 
findings 
Bcl-2 
negativity 
associated 
with improved 
response 
Advanced 
gastric 276 
28 F, C and 
pirarubicin 
chemothera
py 
Bcl-2 and Ki-
67 
Unresected Survival Bcl-2 negative 
expression 
associated 
with improved 
survival 
Advanced 
gastric 4 
39 Combination 
F/C 
chemothera
py 
Bcl-2 Post-resection survival Negativity 
correlated 
with increased 
response rate 
Table (14). Some of the studies for assessing Bcl-2 in prediction of response to Neoadjuvant 
therapy 
 
1.8.2.3.3 Ki-67 
Ki-67 is recognised as a nuclear antigen present in proliferating cells during the 
growth and synthesis phases of the cell cycle (G, S, G2 and M) but not in the resting 
phase, G0 304. This strict correlation of cell proliferation and Ki-67 expression makes 
this protein an excellent marker for the determination of the so-called growth 
fraction of a given cell population. Thus, Ki-67 immunostaining provides a measure 
of the tumour proliferative fraction 305 333.  
1.8.2.3.3.1 Ki-67 in gastro-oesophageal cancer 
In one of the early studies in 1999, proliferative activity of gastric cancer cells was 
closely related to the invasion, metastasis and prognosis. In this study, it was shown 
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that Ki-67 could be used as a marker to measure the proliferative activity of gastric 
cancer cells and to predict the potential of metastasis to distant organs of gastric 
cancer. The detection of Ki-67 antigen could be used as a useful marker to predict 
the high risk of the metastases to distant organs and help anticipating the prognosis 
of gastric cancer 306. A correlation has been shown between Ki-67 expression and 
the ability of some gastric cancers to metastasize to lymph nodes 307 308. In other 
reports, no relationship was found between Ki-67 expression and lymph node 
metastasis 309. Concerning Ki-67 in gastric cancer, a close correlation has been 
established between Ki-67 and vascular invasion 310 311.  
The epitope recognised by Ki-67 does not survive formalin fixation and paraffin 
embedding. So, the requirement of fresh tissue for cryostat sections has been a major 
obstacle to the routine use of Ki-67 305. However, with the discovery of MIB-1, this 
problem has been managed. 
1.8.2.3.3.2 MIB-1 
MIB-1 is a relatively new and promising antibody for the determination of the 
proliferative fraction of tumour cell populations. It was developed using a 
recombinant partial structure of the Ki-67 protein as immunogen. MIB-1 exhibits an 
identical immunostaining pattern to that of Ki-67 in fresh material and, furthermore, 
reacts with the native Ki-67 protein as well as with recombinant parts of the Ki-67 
antigen 312. MIB-1 can detect the Ki-67 protein in routinely formalin-fixed paraffin-
embedded material when using an antigen retrieval method, based on either the 
pressure cooker or microwave treatment 313 314. The use of MIB-1 for the 
determination of cell proliferation has several obvious advantages. First, the neat 
and clear immunoreaction products allow a clear-cut distinction between positive 
and negative cells, even if only minute amounts of antigen are stained. Second, the 
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combination of strong immunoreactivity with an optimal preserved morphology 
allows good recognition of cellular particulars and, consequently, a better 
identification of positive cellular subsets. And thirdly, it can be applied in virtually 
every histopathological laboratory all over the world, since no sophisticated 
technical skill is required 313 314. 
 
1.8.2.3.4 VEGF 
Vascular endothelial growth factor (VEGF) is a multifunctional cytokine which 
increases microvascular permeability and directly stimulates endothelial cell growth 
and angiogenesis 107 315 316. The formation of intra-tumoural microvessel caused by 
VEGF may result in a good drug delivery of chemotherapeutic agents. It is a 
homodimeric 34-42-kDa heparin-binding glycoprotein with potent angiogenic-, 
mitogenic-, and vascular permeability-enhancing activities specific for endothelial 
cells. VEGF seems to be the angiogenic factor most closely associated with 
neovascularisation in human gastric and colonic cancers. 
The VEGF family regulates the proliferation of endothelial cells. VEGF-A is known 
to play an important role in tumour angiogenesis. Four additional members of the 
VEGF family, VEGF-B, VEGF-C, VEGF-D, and PIGF, have been discovered as 
well. VEGF-C and VEGF-D are ligands for VEGFR-3, which is expressed on the 
endothelial cells of lymphatic vessels 317. The expression of VEGF-C is associated 
with the development of lymphatic vessels. Tumour angiogenesis is a complex, 
highly regulated process depending on the balance between activator and inhibitor 
factors 271.  
1.8.2.3.4.1 VEGF in gastro-oesophageal cancer 
VEGF expression in gastric cancer has been associated with various clinico-
pathological parameters such as degree of differentiation, intestinal-type tumours, 
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lymphatic invasion, and vascular invasion. Maehara et al. demonstrated that VEGF 
expression was an independent risk factor for vascular invasion that might account 
for a large number of metastasis 271. In curatively resected patients, the biologic 
nature of the tumour determines survival since almost half will die from recurrent 
cancer 318. The poor prognosis of patients with recurrent disease is due to the lack of 
an effective rescue treatment. In fact, the number of patients with recurrent gastric 
cancer in which it is feasible to perform curative surgery is less than 4% 319. It seems 
necessary to evaluate new biological markers that may predict the natural history of 
the disease as a guide to treatment. Vascular endothelial growth factors (VEGF) and 
microvessel density (MVD) are increasingly used as a measure of new blood vessel 
growth or angiogenesis. Without blood vessels, tumours cannot grow beyond a 
critical mass nor create metastases 320. A hypoxic environment and genetic 
instability in the centre of the tumour allows the evolution of cellular clones with the 
loss of p53 function. These cells have a lower apoptotic rate and produce angiogenic 
factors like VEGF, inducing new vasculature 321. These factors might provide 
information to help predict the prognosis of patients with gastric cancer. However, 
the prognostic value of p53 expression in these patients is controversial 322, although 
it has been related to the development of higher MVD 323. The expression of VEGF 
has been associated with vascular invasion, liver metastases 324, and lymph node 
metastases 107. Inhibition of the VEGF pathway using monoclonal antibodies has 
shown potent anti-tumour effects in animal models 325, and this might be a new 
approach to treat these patients in the future. 
Lymph node status is important in the prediction of prognosis of gastric and 
oesophageal cancer. Potential molecular markers that predict lymphatic involvement 
would improve the clinical management of this disease. The role of VEGF-C in 
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predicting lymphatic invasion and lymph node metastasis in gastric cancer has been 
investigated in several studies 326. High expression of VEGF has been reported to 
predict the chemosensitivity for the unresectable gastric cancer patients treated with 
5-FU 327. Saying that, still  little has been reported about VEGF-C expression in 
gastric carcinoma, including early gastric cancer 328-330. Yonemura et al. examined 
the expression of VEGF-C in human gastric carcinomas, finding that VEGF-C 
expression was correlated to VEGFR-3 expression and that patients with high 
VEGF-C expression had a significantly poorer prognosis than those with low 
VEGF-C expression 329 330. Kabashima et al. reported that lymphatic invasion was 
significantly increased in VEGF-C positive early gastric carcinoma 331. 
Immunohistochemical analysis of tumour tissue showed that VEGF-C 
immunoreactivity is restricted to gastric cancer cells and is observed diffusely 
throughout the cytoplasm 328-333. Many studies showed that the percentage of gastric 
tumours that are positive for VEGF-C protein expression varies from 26 to 51% 328 
329 332 333 , although this may be accounted for in part by the use of varying 
techniques. It has been found that an increased expression of VEGF is associated 
with increased counts of microvessels and poor patient outcome was observed 107 334 
335. Also, over-expression of VEGF was regulated at the level of transcription in 
gastric cancer as in other human cancers336-338. 
The clinical impact of the relationship between VEGF-C expression and prognosis is 
not fully understood. Non-significant trends towards reduced survival in VEGF-C 
expressing gastric cancers have been found 332 . However, in a study involving 117 
patients with gastric cancer 329, it demonstrated that high levels of VEGF-C 
expression were associated with poorer prognosis and decreased survival. Another 
noteworthy difference in survival associated with VEGF-C status has been reported 
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by Takahashi et al 333 in a group of 65 cancer patients. A potentially important 
clinical finding of this study was the negative correlation of dendritic cell density 
with VEGF-C expression in the tumour. The effect of VEGF-C on survival may be 
due, in part, to its regulatory function on dendritic cells with potential reduced 
immuno-surveillance of the tumour 326.  
 
 
Figure (8). Schematic diagram showing how production of VEGF-C and VEGF-D in tumours can 
induce lymphangiogenesis, leading to increased lymphatic vessel density in the vicinity of the 
tumour, and subsequently to metastasis of invasive tumour cells via the lymph vessels339 
 
As for studying the connection between some of the different makers, it was found 
that cancer cells with over-expressions of p53 protein and VEGF had higher growth 
potentials, as assessed by Ki-67 index307 340 and proliferating cell nuclear antigen 
labelling. 
Following is a table summarising some of the studies which assessed the relation 
between VEGF (along with other markers) in response to neoadjuvant therapy. 
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Type of cancer No. of 
patients 
Protocol of 
treatment 
Assessed 
biomarkers 
Pre- or post-
specimen 
Aspect of 
assessment 
Result 
Oesophageal 
341 
53 Neoadjuvant CRT 
(C/F) 
HIF-1a 
(mRNA and 
protein) 
Pre- Histopathology Not predictive of 
tumour 
regression or 
prognosis 
Oesophageal 
342 
65 Neoadjuvant CRT 
(C/F) 
HIF-1a 
(protein) 
Pre- Histopathology + 
survival 
Expression of 
HIF-1a may 
predict 
resistance to 
CRT 
Oesophageal 
273 52 
Neoadjuvant CRT 
and definitive 
VEGF 
(protein) 
Post- Survival Expression 
associated with 
resistance 
Oesophageal 
343 
56 Neoadjuvant CRT 
(F/C) 
VEGF and 
MIB-1 
(protein) 
Pre- Survival VEGF/MIB-1 
ratio of 1:6 or 
less prior to CRT 
responded to 
therapy 
Oesophageal 
344 46 Neoadjuvant CRT 
VEGF and 
COX-2 
(protein) 
Pre- Survival Poor predictors 
of treatment 
response 
Gastric 345 62 
Neoadjuvant 
chemotherapy 
(F/C) 
VEGF 
(protein) 
Post- Histopathology No association 
with response 
Gastric 257 55 Irinotecan and 
Cis 
chemotherapy 
VEGF 
(protein) 
Unresectable survival VEGF positivity 
associated with 
improved 
response 
C, Cisplatin; COX-2, cyclooxygenase-2; CRT, chemo-radiotherapy; F, 5-fluorouracil; HIF-1, hypoxia-inducible 
transcription factor-1; MIB-1, mindbomb homologue 1; VEGF, vascular endothelial growth factor. 
Table (15). Some of the studies where VEGF was assessed as marker of response to neoadjuvant 
chemotherapy of OGJ and gastric cancer 
 
 
Another aspect for the further need for the study of VEGF is that tumour hypoxia 
can lead to radiation- and chemo-resistance by depriving cells of oxygen essential 
for the cytotoxic activities of these agents 346. Moreover, tumour hypoxia promotes 
up-regulation of angiogenic and tumour cell survival factors resulting in increased 
proliferation, radio-resistance and angiogenesis.  
VEGF expression in Barrett’s dysplasia and Barrett’s carcinoma seems to correlate 
with vascularisation. Angiogenic properties are acquired early, particularly in pre-
cancerous lesions and in superficial cancers, demonstrating a critical step in the 
development of Barrett’s adenocarcinoma. Angiogenesis might occur as early as the 
transition from metaplasia to neoplasia. This finding could provide one possible 
explanation for the early onset of local spread and frequent recurrence of 
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oesophageal cancer. However, VEGF expression patterns and MVD apparently fail 
to give prognostic information in invasive AC of the oesophagus 1. 
Tissue oxygen status has been demonstrated to be a very important factor in 
determining radio sensitivity both in vitro and in vivo. Only a well-oxygenated cell 
is fully radiosensitive. Furthermore, tumour microcirculation and vessel 
permeability are important factors for delivery of oxygen, drugs, and radio-
sensitizers to cancer cells. Accordingly, the level of VEGF expression in 
oesophageal cancer may be of value in predicting response to CRT. However, 
VEGF expression and subsequent microvessel sprouting are also responsible for 
tumour nutrition, growth, local invasion, and metastatic spread. 1 
The results of Imdahl et al. 343 suggest that oesophageal tumours (SCC and AC) with 
low VEGF expression respond better to CRT. Weak VEGF immunoreactivity in pre-
treatment biopsies was associated with complete tumour response after neoadjuvant 
CRT (5-FU, Cisplatin, 36 Gy) and low VEGF expression led to better long term 
survival after CRT and surgery 1.  
 
1.8.2.3.5 CD-31 
CD-31 is a glycoprotein adhesion molecule expressed on leucocytes, platelets, and 
endothelial cells and has been used as a pan-vascular marker for studying of vessel 
density in tumours 347.  
1.8.2.3.5.1 CD-31 and vascular invasion  
Invasion of tumoural vessels is an essential step in the metastatic cascade 348. The 
presence of Vascular Invasion (VI) is an important pathologic feature to assess risk 
of recurrence and metastasis; however, assessment of VI in primary tumour is 
weighed down with difficulties. Early attempts to distinguish Lymphatic Vessel 
Invasion (LVI) from Blood Vessel Invasion (BVI) used histological morphologic 
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criteria, where BVI was identified by the presence of tumour emboli with fibrin clots 
and/or erythrocytes in the endothelial-lined space, features lacking in LVI 349. Others 
have used histochemical stains such as van Gieson or IHC staining with vascular 
markers such as factor VIII-related antigen 350. Such methods are less specific and 
less sensitive in detecting VI than the approach used here. However, it appears to be 
a more sensitive marker for endothelial cells than factor VIII antigen 347. 
 
1.8.2.3.6 LYVE-1(D-240) 
LYVE-1 (lymphatic vessels endothelial hyaluronan receptor 1) is one of the first and 
best-characterised markers of lymphatic endothelial cells 351. It is strongly expressed 
on the entire luminal and abluminal surface of lymphatic endothelial cells, even on 
fine filopodia of growing vessels during lymphangiogenesis 352. 
LYVE-1 receptor is type I integral membrane polypeptide expressed on the cell 
surface as a 60 kDa protein, which is reduced to approximately 40 kDa by 
glycosidase treatment 353. LYVE-1 is abundant in spleen, lymph node, heart, lung 
and foetal liver, less abundant in appendix, bone marrow, placenta, muscle, and 
adult liver, and absent in peripheral blood lymphocytes, thymus, brain, kidney, and 
pancreas. Appearance of LYVE-1 is largely restricted to endothelial cells lining 
lymphatic vessels and splenic sinusoidal endothelial cells. LYVE-1 may be 
implicated in hyaluronan (HA) metabolism in the lymphatic system. The highest 
expression of LYVE-1 was found in submucosal lymph vessels underlying smooth 
muscle in the colon, and the lacteal vessels of intestinal villi that transport dietary 
lipid absorbed from the small intestine 354. 
1.8.2.3.6.1 Lymphangiogenesis in gastric and oesophageal cancers 
The metastasis of gastric and oesophageal carcinoma to distant organs can involve 
three major pathways, which are through seeding of body cavities, dissemination 
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through blood vessels and travel via the lymphatic. Regional lymph nodes are the 
most common site of metastasis in gastric carcinomas 355. Even in early gastric 
carcinomas in which cancer cells confined to gastric mucosa or submucosa, the risk 
of lymph node metastasis ranges from 4% to 25% 356 357. Tumour stage is important 
for the prognosis of patients with gastric carcinoma. 
Lymphangiogenesis, the growth of new lymphatic vessels, is believed to underlie 
lymph node metastasis 358. The extent of regional lymph node metastasis is an 
important indicator of tumour aggressiveness and is a prognostic factor for patients 
with gastric carcinoma 359. Although there is a large amount of data regarding 
angiogenesis, there are few reports of lymphangiogenesis as a prognostic factor for 
human neoplasms, and the correlation between lymphatic vessel density (LVD) and 
metastasis to lymph nodes is controversial. This is partly because of a lack of 
reliable immunohistological markers specific for the lymphatic endothelium. 
Recently, a number of lymphatic-specific proteins, such as podoplanin, LYVE-1 and 
prox-1, were identified 353 360 361. Lymph node metastasis has emerged as a 
significant independent indicator of poor long-term survival in early gastric cancer 
(EGC) 362 363. 
1.8.2.3.6.2 LYVE-1 in gastro-oesophageal cancer 
LYVE-1, discovered in 1999, is found only on lymph vessel wall and is completely 
absent from blood vessels 353. Normally, LYVE-1 binds HA with a high degree of 
specificity and plays a role for the receptor in sequestering HA on the luminal 
surface of lymphatic vessels 351. The deduced amino acid sequence of LYVE-1 
predicts a 322-residue integral membrane polypeptide with 41% similarity with the 
CD44 molecule 353 . As lymphatics play a vital role in HA homeostasis, LYVE-1 is 
thus specifically expressed in the lymphatic capillaries and small vessels in various 
tissues. Many studies agreed that LYVE-1 is specific to lymph vessels 364 365, some 
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studies reported that LYVE-1 is present in other blood capillaries such as in the 
sinusoidal endothelium of liver and spleen 366. However, it has not been detected in 
blood vascular endothelium 367, with the only exception being a proportion of blood 
vessels in the lung (a cell type specialised for gaseous exchange) 368. In conclusion, 
LYVE-1 is one of the most specific markers in lymphatic endothelium or 
lymphangiogenesis study 399. 
So far, very little in the literature that has highlighted or investigated the significance 
of finding LYVE-1 in gastric and oesophageal adenocarcinoma, as seen in one of 
them done by Fujimoto et al., 369  where it was observed that lymphatic invasion was 
found in early gastric cancer. Most lymphatics were found just beneath the 
muscularis mucosae, and they were generally not seen within the mucosa. It has 
been accepted that the lymphatics arise only in the mucosa below the bases of 
gastric glands. Lymphatic vessels in the mucosal layer have no endothelial lining 
and so could be termed tissue channels rather than lymphatics. Also, lymphatics 
were almost never found in the central portion of the primary cancer. However, 
lymphatics distributed at the periphery of the cancer, which remained intact, showed 
distinct LYVE-1 positivity. In another study 370, it was found that there is a strong 
relationship between the lymph vessel density (LVD), as measured using LYVE-1 
among others, and the nodal metastasis in these cancers. 
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1.9 Image analysis 
Below is a brief description of the history, background, development and the 
different aspects of the relatively new technique of image analysis as a more 
subjective method of assessing different aspect of histopathological measures, which 
for a long time have been relying on semiquantitative and/or subjective scoring 
system. 
1.9.1 Origins and background 
The term "image analysis" is reserved for a special order in pathology that aims to 
obtain diagnostically important information in an objective and reproducible 
manner, by measuring and counting. The origins of measuring microscopic images 
are almost as old as the microscope itself. Leeuwenhoek in the 17th century 
developed a system to measure microscopic objects. As a reference, he used small 
particles of sand, as well as human hair. Using this method, in 1674 he measured 
human erythrocytes as 25000 times smaller than even the smallest of the sand 
particles, corresponding to 8.5 µm 371. 
In the recent years, quantification of fibrous tissue in biopsy sections by digital 
image analysis (DIA) has been introduced. The developers of this technique aimed 
to conquer the shortcomings of the semiquantitative scoring systems and design an 
acceptable, valid system for fibrous tissue quantification which was objective rather 
than subjective. The core principle of this method, as being assessed in the liver for 
example, is to stain the section with a connective tissue-specific stain, and then a 
number of fields with portal tracts in their centres are acquired with an optical 
microscope connected to a digital camera and a computer. With the aid of specific 
software, the acquired image is converted into a binary image and, after multiple 
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processes including shading correction and automatic thresholding, extraction of the 
fibrosis area from the digitized image is performed. Finally, the net area of fibrosis 
is counted in pixels in relation to the total area of the field 372-374. 
1.9.2 Morphometry 
Morphometry is the quantitative description of geometric features of structures of 
any dimension 375. This includes planimetry, which means the measurement of 
geometric features of structures in two dimensions. Stereology denotes all 
techniques used to obtain quantitative information about geometric features of 
structures with a test system of lower dimension than the structure itself, for 
example point or line grids. 
By the beginnings of the 1970s onwards, computers became more generally 
available. Graphic tablets connected to a computer allowed for easy measurement of 
the area of cellular or tissue components, either from microphotographs or by 
extrapolating a pinpoint light from the cursor of the graphic tablet through a drawing 
tube into the microscopic image, allowing tracing of very small structure as nuclei 
for example. From these tracings, not only could nuclear areas easily be computed 
but also information could be obtained about the shape of these nuclei. As video 
cameras became available in the 1980s, these systems were further improved. With 
modern morphometry equipment, the microscopic image is recorded by a video 
camera and displayed on a computer screen. Measurements can then be performed 
by tracing the outlines of nuclei on the screen and the precision of each 
measurement can be appreciated. 
1.9.3 Counting objects 
Counting objects of interest in tissue sections is a widely applied form of image 
analysis. Most of the time, this concerns counting of proliferation markers in 
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tumours. In 1925, Greenbough found that the number of mitoses was associated with 
survival in breast cancer patients. A similar observation was made by Grinnell for 
colorectal cancer in 1939 376. Nowadays, mitotic activity in breast cancer, next to 
lymph node status, remains one of the most important prognostic factors. On top of 
that, this powerful method in image analysis requires only a microscope and a 
haematoxylin and eosin stained slide 377. 
It became possible to obtain information on proliferation from interphase nuclei with 
techniques that, after incubation, introduced labelled nucleotide analogues in the DNA 
of proliferating cells. Counting the percentage of labelled cells, the labelling index, 
delivered a reliable measure of the proliferation fraction of a cell population. At first 
radioactive labels were used, like tritium thymidine labelling. Later, non-isotopic 
labels such as bromodeoxyuridin (BrDU) became available that could be more easily 
visualised with antibodies 378. During the last few years, antibodies have been raised 
against proliferation associated antigens such as Ki-67 and proliferating cell nuclear 
antigen (PCNA) 379 380. Specifically, the possibility of immunohistochemical 
detection of Ki-67 in formaldehyde-fixed, paraffin-wax embedded material was a 
major improvement. Stereology has been implemented with the traditional counting, 
where the counting methods are still used to score the proportion of 
immunohistochemically stained nuclei to obtain a highly reliable labelling index. 
Also, this procedure is almost 10 times as fast as the traditional method of counting 
the number of stained nuclei per 2000 nuclei 381. 
1.9.4 Cytometry and pattern recognition 
Cytometry refers to measuring the amount of a given substance in tissue, cells or 
nuclei. The observation of hyperchromatism in the nuclei of neoplastic cells, 
highlighting increased DNA content, is the subjective counterpart of DNA 
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cytometry in everyday pathology. Cytometry depends on the ability to detect the 
substance of interest by a specific dye and to measure the concentration of that dye. 
The relation between the concentration of a dye and the optical density of that dye 
emerged through the work of Lambert in 1760 and Beer in 1854. The history of 
cytometry actually is the history of DNA cytometry. In the late 1890s, Kohler & 
Von Rohr at Carl Zeiss in Germany developed an ultraviolet microscope to prove 
Abbe's theory that the use of a lower wavelength would increase the resolution of 
the microscope. Kohler observed a high absorption at 280 nm by the chromatin in 
cells, but thought this resulted from the occurrence of inorganic substances. 
However, Caspersson et al in Sweden were the ones who attributed this absorption 
to DNA, or thymonucleic acid, and so they  constructed a system for photographic 
photometry in 1933 382. Later on, the photographic detection system was replaced by 
a photoelectric spectrophotometric system, followed by photomultipliers. These 
were very accurate and well suited for high resolution analysis of intracellular 
structures, but slow nonetheless. However, as the cancer research progressed, 
systems were sought that could easily measure the total amount of DNA per cell in a 
large number of cells. 
Meanwhile, DNA cytometry using visible light came to existence. By 1933, 
Mainland had estimated the amount of haematoxylin in normal and cancerous 
cervical cells. However, haematoxylin is not a stoichiometric stain for DNA, 
contrary to the Feulgen reaction discovered by Feulgen and Rossenbeck in 1924 383. 
This staining succeeded to be specific for DNA, and the amount of stain was 
proportional to the amount of DNA present. Pollister and Ris, in 1948, built the first 
simple microphotometer using a microscope equipped with a photomultiplier and a 
galvanometer to measure the output current. In the same year, Ris and Mirsky 
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measured the total amount of DNA in a nucleus and Swift, in 1950, demonstrated 
the doubling of DNA prior to mitosis 384 385. During the following years, scanning 
microscopes saw great advance in assessing staining intensities within nuclei, and 
these gradually paved the way to systems that were able to measure large numbers 
of cells. One of the first of such systems was the cyto-analyser of Tolles et al based 
on a scanning microscope 441, who reported a study on 700 cervical and vaginal 
smears in which they measured the DNA content of 200 cells each 386 387.  
Along with enhanced measuring performance, the use of computers and advanced 
softwares have stimulated the development of systems for automatic cell 
classification based on pattern recognition. At present, systems for automatic 
classification of cells have been developed that are used, for example, for pre-
screening of Pap smears, and quality control 388. Furthermore, systems have been 
developed capable of automatic recognition of mitoses in tissue sections 389. 
Image cytometry is also used to measure the amount of immunohistochemically 
stained proteins in cells such as oestrogen receptors in breast cancer 390. It should be 
noted that this method is quite different from DNA image cytometry. While Feulgen 
staining of DNA is stoichiometric, immunohistochemical staining of antigens is not; 
the amount of staining is not proportional to the amount of antigen present and is 
influenced by many factors. Therefore, immunoquantitation by image analysis in 
any case requires calibration of the staining result by using a specimen with a known 
amount of antigen, and tissue processing is critical. For the many cases in which one 
wants to assess the proportion of cells positive for an immunohistochemical staining, 
rather than the exact distribution of staining intensities over the cells, a point 
counting procedure could be much more powerful. 
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1.9.5 Concept for using image analysis in the studies 
An alternative to the currently used semiquantitative systems similar to Mandard 
scoring systems, which relies heavily on the assessment of the amount of fibrosis in 
the examined tissue, is direct measurement of the amount of fibrosis in the biopsy 
specimen by computer-assisted morphometric image analysis. Although the 
methodology is not standardized, a number of publications and studies have 
described methods for quantifying fibrosis by image analysis, especially in liver, and 
all appear to yield similar results 391-396. In recent years, quantitative evaluations 
through image analysis have been explored. It provides objective quantitative results 
similar to, but more precise than those determined by semi-quantitative scoring 
methods, without requiring the presence of an experienced pathologist 395. In 
addition, variables are scalar rather than ordinal and provide a continuous method 
for fibrosis estimation and therefore more flexible statistical analysis. This concept 
has been explored extensively to measure fibrosis in comparison to the traditionally 
used numerical systems, as in the grading systems used in liver fibrosis of 
Scheuer397, the Metavir group395 , or Ishak et al398 , using stages that range from 0 to 
4 for Scheuer397 and Metavir395 or 0 to 6 for Ishak398. The numbers, while intended 
to be semiquantitative, actually represent categories of increasing severity based on 
a combination of location and quantity of scarring, and whether the fibrous tissue 
forms septa, bridges or nodules. Thus, it is possible for a biopsy with a small amount 
of fibrous tissue in a particular location to have a higher stage than a biopsy with a 
greater amount of fibrous tissue but not in that location. An alternative to numerical 
fibrosis scoring systems is direct measurement of the amount of fibrosis in the 
biopsy specimen by computer-assisted morphometric image analysis 399 400. 
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To provide more standardized data for the quantification of immunocytochemical 
studies, diverse computerized image analysis systems have been used and were 
found to correlate well with semiquantitative histological scoring methods and with 
biochemical data, most notably in the studies conducted in breast carcinoma 401-404. 
However, the high cost and the complexity of these image analysis systems, 
requiring major hardware and software instalments, severely limit their practicability 
in the routine diagnostic laboratory. Saying that, the techniques have improved 
tremendously over the last few years, and the cost has dropped dramatically when 
using this technique. 
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2. CHAPTER 2: METHODOLOGY  
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2.1 Background  
 There are few noticeable problems encountered in similar studies performed 
previously. The limitations of reported studies include: (i) small number of the 
samples available, (ii) lack of enough available tissue for cutting and staining, (iii) 
the mixing of different pathologies in the same study i.e. squamous and 
adenocarcinoma, as well as (iv) the choice of patients who were exposed to different 
modalities in the same study i.e. patients who had neoadjuvant therapy alone, 
together with the ones who added radiation, or others who used differing protocols 
of neoadjuvant therapy. After addressing these problems, a plan was established to 
try to overcome these shortcomings. 
2.2 Study population 
This study included 114 selected cases with adenocarcinoma of the stomach and 
lower oesophagus, as well as oesophago-gastric junction (OGJ), who were treated 
with neoadjuvant therapy in the form of at least 2 complete cycles of 5-FU and 
Cisplatin followed by oesophagectomy and/or gastrectomy from 5 institutes in the 
duration from 2000 - 2009. This study was approved  by the Ethical committee, 
Imperial College London,  that it was legal, under the Human Tissue act to use 
tissue blocks as there was no communications with human beings.  A summary of 
the study group is listed in table (17). 
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Age (years)  31-70 
Mean  50.5 
Sex   
Male  88 
Female  26 
Site of tumour   
Oesophagus 44 
Oesophago-gastric junction (OGJ) 47 
Stomach 23 
Differentiation  
Well 7 
Moderate 38 
Poorly 69 
Tumour regression grade   
TGR1 6 
TGR2 12 
TGR3 22 
TGR4 41 
TGR5 33 
 
Table (16). Patients Demographics 
2.3 Sample collection 
The first stage was to choose the eligible patients. The pool of the patients included 
in these studies was those who had operable gastric and oesophageal 
adenocarcinoma, and received neoadjuvant chemotherapy between the years 2000 - 
2009. They were traced back to their original hospitals, where their records were 
reviewed, and it was confirmed that each one of them complied with the criteria of 
selection (mentioned later). For collecting the data, a good cooperation was 
established between the institutions which participated in this research. These 
included St. Mary’s hospital, Harley Street London Clinic, Hammersmith & Charing 
Cross hospitals, Watford hospital, Ealing Hospital, and Mount Vernon Hospital and 
cancer centre. The information were collected by obtaining the medical records of 
the possible eligible patients, liaising with the surgeons and oncologists involved 
with the patients, the specialist nurses who have kept excellent records of the 
patients. 
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The second stage was to collect the archived slides which represented the endoscopy 
samples taken at the first diagnosis or prior to starting the neoadjuvant therapy, as 
well as the post-resection slides. These were all examined and verified by a lead 
pathologist who has a large experience in the area of upper GI tumours, after being 
collected from their hospitals of origin. The post-resection slides were examined, 
and a slide from each case was chosen on the basis where there is a good interface of 
tumour and/or fibrotic reaction and normal tissue. 
The third stage was to collect the paraffin blocks which corresponded to the codes of 
the slides chosen. Some difficulty arose during this stage owing to the fact that some 
of these blocks were either exhausted, or few of the cases had the original blocks 
and material out of the United Kingdom, and these were consequently excluded. 
The fourth stage was to establish the Mandard grading of the collected specimens. 
This was done by having the slides reviewed by 2 pathologists independently, and 
any disagreement that occurred was resolved by consensus. 
The fifth  stage was to cut and stain the slides. This was done with the much 
appreciated help of the histopathology and cellular pathology laboratories in both St. 
Mary’s hospital and Hammersmith hospitals. All care was taken to stick to the same 
protocols and techniques during the processing of these slides in both hospitals. 
By the end of these stages, hundred and fourteen patients were eligible for this study 
out a potential number of 245 patients. The patients who were eliminated were 
because of  (i) the pathology was not clear enough to be graded e.g. mucoid, (ii) the 
endoscopy and pre-neoadjuvant blocks were not obtainable, (iii) there was not 
enough tissue to carry on the cutting and staining the blocks, (iv)  the clinical 
records were not available to confirm their completion of at least two cycles of 
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neoadjuvant therapy, or (v) if the patients failed to continue the course of 
neoadjuvant therapy due to side effect or toxicity. 
2.4 Selection criteria of the specimens 
To evaluate the characteristics of pre-treatment tumour and resected oesophagus and 
stomach, we selected cases based on the following criteria: (1) Patients with 
resectable adenocarcinoma of the oesophagus and stomach; (2) Those who received 
neoadjuvant Cisplatin & 5-FU treatment of equal to or more than two cycles; and (3) 
Patients for which there were adequate, as well as, obtainable tumour tissues of both 
the pre- and post-resection samples. One hundread and fourteen patients met the 
inclusion criteria out of 245 patients.  
2.5 Tissue sampling and pathology evaluation 
The corresponding blocks were gathered from the different institutions which 
participated in the studies, and were all cut from formalin-fixed, paraffin-embedded 
tissue, deparaffinised and rehydrated in St. Mary’s hospital pathology laboratory. 
Tumour regression of the primary tumour was semi-quantitatively determined by the 
amount of viable tumour versus the amount of change which showed suggestive 
response to treatment according to the commonly used Mandard grading system 
setup, which focuses mainly on fibrotic changes occurring in the tumour bed. The 
slides were reviewed by 2 pathologists independently and both of them were blinded 
to the originally determined degree. Among these observations, there were 12 slides 
where disagreement was present between the pathologists, and this was resolved 
during another session, where these slides were re-examined using a double-headed 
microscope and agreement on the stage was reached by consensus. 
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2.6 Histological preparation, staining and techniques 
The following sections are dedicated to describe the methods and agents which were 
used in the studies. 
2.6.1 Methodology for Mandard regression grading study 
2.6.1.1 Haematoxylin and Eosin 
This is the basic stain which was used during the study of assessing magnitude of 
regression using Mandard regression system. Description of its staining technique is 
described in Appendix A. 
2.6.1.2 Inter-observer and intra-observer method for assessment of 
Mandard regression technique 
Ninety-five patients were available for this study. The patients were chosen 
according to the criteria mentioned before. The slides were all stained using H&E 
using the same technique in St. Mary’s cellular pathology laboratory. 
Four pathologists with an interest in upper gastrointestinal cancers and an 
experience in this field ranging between 7 - 15 years, kindly participated in the 
study. Two of the pathologists are from St. Mary’s hospital, London; one from 
Mount Vernon hospital, Hillingdon; and one from Royal Brompton & Harefield 
hospitals, Harefield. 
The 95 slides were blinded for each one of the four assessors. Each pathologist 
examined the slides without prior knowledge of the patients or their management, or 
their original Mandard scoring. Each pathologist examined the slides independently, 
and each one repeated the examination of the slides twice, with an interval of 2 - 4 
weeks between assessments. The results were recorded on a prepared spreadsheet 
template. 
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2.6.2 Methodology for the Image analysis studies 
2.6.2.1 Picro Sirius Red (PSR) staining 
This staining method was used in the slides for the Image analysis study. Picro 
Sirius Red (PSR) staining is used to demonstrate collagen and non-collagenous 
proteins in tissue sections. Collagen stains red and non-collagenous proteins stain a 
light green. It is used to demonstrate conditions such as hepatic fibrosis 400. 
Description of the character and staining of SR is shown in Appendix A. 
2.6.2.2 Tissue staining 
Ninety-five biopsy sections were selected from the available 114 specimens and 
were stained with Picro Sirius red. These were the same group of specimens used in 
the Mandard study. Each biopsy was already graded according to the Mandard 
system. Sections of each biopsy stained with Sirius red were used for measurement 
of fibrosis using digital image analysis technique. This stain binds to all connective 
tissue, but primarily to collagen, and the quantity of bound stain has been shown to 
correlate well with chemically determined collagen content and morphometrically 
determined fibrosis, as was shown in several studies in other tissue 400 405. 
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Figure (9). Layout of the Image analysis processing sequence 
 
2.6.2.3 Image capture and processing 
Image acquisition was done by a digital grabber and camera attached to a light 
microscope (Olympus BX50). This microscope offers superior performance 
covering applications from routine investigation to sophisticated research, and 
would suit a wide range of observation requirements. The Universal Infinity System 
(UIS) provides an extended field of view, higher contrast and the sharpest images, as 
well as outstanding flatness throughout the entire field of view. 
Extra-bright 100W halogen illumination was used, to deliver optimum performance. 
An analogue camera was used (Nikon, Japan). The output from the camera was 
converted to digital imaging by a CMS790 PAL frame grabber device (Scion Corp., 
MD 21701, USA). This gave a digital image, which was processed using a HP 
desktop computer with Intel DuoCore processor, that is equipped by a dedicated 
software for image analysis (NIS elements Basic Research [BR], Nikon, USA). 
The camera first had to be warmed to minimize background ‘noise’ due to changes 
in temperature. Microscopy was done using high level of illumination, with a green 
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optical filter to reduce the influence of the other non-specific objects which were 
stained by the Picrosirius red, but without reducing the staining of the fibrotic 
regions. Also, the different components of the microscope e.g. the lens, the reflective 
mirror, etc, as well as the slides had to be checked for their cleanliness to ensure 
minimum of impurities during the examinations. 
 
 
Figure (10). Steps of the techniques used in analysing each hotspot in Image analysis 
 
2.6.2.4 Thresholding 
In terms of practicality, image analysis at lower magnification gives superior 
reproducibility, correlates well with its high magnification counterpart and is 10 - 20 
times faster. Using the low (whole biopsy in one frame) magnification has several 
potential advantages: random loss of tissue caused by gaps between frames and 
double counting due to overlap does not occur. Other dark staining tissues which are 
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not collagen such as nuclei are below the level of resolution at low magnification 
and therefore do not falsely elevate the measured fibrosis area. This concept has 
been investigated and validated before in other studies 396. However, it was not 
possible at the time of the study to obtain lenses that can accommodate the whole 
slide in one frame to be assessed, so it was decided to choose 5 random sections 
from each slide at a 20x magnification, where there is apparent fibrosis in the 
interface between the apparently normal or fibrotic tissue and the tumour, and then 
taking the mean of the 5 chosen areas. 
Images were digitized following interactive light intensity equilibration, and 
analysed as RGB 24-bit images. The stained section captured represented fibrosis as 
red and the parenchyma as blue or green for illustration purposes using the available 
software. Sirius red was used in order to allow accurate location of the fibrous 
regions. The problem with counterstaining slides for image analysis is that there 
must be sufficient contrast between the counterstained tissue and the stained 
deposits for the computer to be able to differentiate between the two quantities. To 
overcome this problem, an additional colour filter (green filter) was used when 
capturing images in order to enhance the stain/counterstain contrast. A stabilised 
light source was used to ensure consistency in the data acquisition. In order to 
remove any other spurious lighting variations background subtraction was 
performed on all images. This process involved “training” the software to recognise 
the background spaces in the form of empty areas, or completely different 
colouration on the image, and subtract them from the calculation of the final 
average. After interactive thresholding, the image was converted into a binary 
image. The 2-dimensional patterns were measured by direct pixel counting on the 
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binary images. The total area of the section was the sum of all microscopic field 
including parenchyma and fibrosis. 
In terms of image intensity, the fibrous areas present with a slide should appear 
acquiring a red colour than the surrounding tissue and counterstained cells bodies. 
The computer requires an intensity threshold in order to be able to differentiate 
between these red areas and the surrounding areas. It is possible to use automatic 
methods of setting this threshold in a completely objective way; however, the 
irregular distribution of the stained deposits visible here meant that a semi-automatic 
system of intensity thresholding had to be adopted. The setting of the intensity 
threshold was performed by presenting a number of randomly selected microscope 
fields (around 75) to the software after the agreement between two pathologists as to 
the intensity of the stain that would properly represent the fibrosis area, and then 
training the software to pick up only these intensities. The values for the different 
fields were then averaged to obtain an intensity threshold for that section, which is 
an automatic process included in the software used. In an attempt to overcome any 
potential operator bias in the thresholding process, all the thresholds used in this 
study were set by one operator.  
With this image analysis system it was possible to use a low magnification view of 
the tissue sample to manually define an area to be scanned in detail. Using the image 
intensity threshold selected earlier the computer then scanned the defined area by 
each assessor at the same magnification and identified 5 of the areas which 
represented the high degree of fibrotic changes within that slide. The total areas of 
tissue scanned were automatically averaged by the software, and recorded on a 
spreadsheet template. 
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2.6.2.5 Inter-observer and intra-observer method for assessment of 
fibrosis using image analysis technique 
Inter-observer reproducibility of fibrosis percentage measurement with digital image 
analysis was assessed among three pathologists with an interest and experience in 
the use and concept of image analysis. Each one was blinded to the Mandard staging 
results of the slides in test, and each performed the complete protocol for fresh 
digitization of slides and thresholded images to obtain fibrosis percentage in a sub-
cohort of biopsies consisting of the 95 biopsies. 
The technique was reviewed and checked with the researcher, and it was confirmed 
that the same apparatus i.e. the microscope, the camera, the grabber, and the 
software, and the settings were kept in the same operating condition for every 
assessor, as well as stabilising the parameters used for each. The assessments took 
place in St. Mary’s cellular pathology laboratories. 
Each assessor was given the slides to assess independently, without a prior 
knowledge of the clinical data or the corresponding Mandard grading. Each assessor 
repeated the same test twice independently, with an interval of 2 - 4 weeks between 
examinations. 
2.6.3 Methodology of immunohistochemical staining and 
identification of the markers used in the studies 
The following is the description of the general preparation in all the slides to be used 
for the immunohistochemical studies. 
The principle of immunohistochemical staining relies on the principle that, using 
specific antigen-antibody reactions, specific cellular or tissue components may be 
identified. The aim of immunohistochemistry is to detect the desired target with very 
little unspecific staining. The staining method is mainly an advanced polymer 
technique which involves attaching the primary antibody to the target antigen 
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followed by a dextran polymer conjugated with a secondary antibody and 
peroxidase. The label which is horseradish peroxidase enzyme in combination with 
the diaminobenzamine (DAB) chromogen yields a crisp, stable, insoluble, 
distinctive colour reaction and product at the antibody binding sites, and is 
complemented by a nuclear haematoxylin counterstain. 
Tumour specimens collected at biopsy or surgery are routinely fixed in formalin and 
embedded in paraffin before histological examination and long-term storage. These 
tissues were available for analysis for potential predictive markers in patients 
undergoing systemic therapy. The marker status can then be correlated with 
outcomes for each patient, such as response to treatment, time to progression, and 
overall survival. 
Paraffin-embedded tissue blocks of formalin-fixed surgically resected samples, as 
well as the corresponding pre-neoadjuvant therapy endoscopic samples, were 
processed for conventional histological study and for immunohistochemical 
analysis.  
The markers used in the immunohistochemistry study included: p53, Bcl-2, Ki-67 
(MIB-1), VEGF, CD-31, and D-240 (LYVE-1). In the table (17) below, a list of 
these agents, their dilutions used for these experiments, their positive control, as 
well as their mother companies, is shown. 
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Antibody Control Dilution (1 in) Company 
p53 Positive control 25 Dako 
Bcl-2 Tonsil 100 Dako 
MIB-1 (Ki-67) Tonsil 100 Dako 
VEGF placenta 50 Abcam 
CD-31 Appendix 1000 Abcam 
D-240 (LYVE-1) Appendix 40 Abcam 
Table (17). The markers used in the immunohistochemistry study 
 
Paraffin-embedded tissue blocks of formalin-fixed surgically resected samples, as 
well as the endoscopy pre-neoadjuvant blocks were processed for conventional 
histological study and for immunohistochemical analysis. Immunohistochemical 
studies were performed using the automated immunohistochemical system 
TechMate 500 (Dako, Carpinteria, Ca, USA), using the EnVision system (Dako). 
Briefly, 3 µm-thick sections were processed first as for all tissues used for 
immunohistochemical staining i.e. endogenous peroxidase blocking and unmasking 
the antigen by pressure cooking. Then the slides were incubated with the primary 
antibodies as per instructed for each one, and washed in ChemMate buffer solution 
(Dako). The peroxidase-labelled polymer was then applied for 30 minutes. After 
washing in ChemMate buffer solution, the slides were incubated with the 
diaminobenzamine substrate chromogen solution, washed in water, counterstained 
with haematoxylin, washed, dehydrated, and mounted. Antigen retrieval was 
performed in citrate buffer, pH 6.0, in a pressure cooker 271. Description of the 
techniques of pressure cooking and peroxidase blocking are mentioned in appendix 
A. 
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2.6.3.1 p53 protein staining and analysis 
 
 
Figure (11). P53 staining (a) x10 (b) x25 
 
This monoclonal rabbit antibody is useful for the identification of p53 protein in 
normal and neoplastic tissue. The p53 tumour suppressor gene is activated by DNA 
damage, abnormal growth signals, and other intrinsic and extrinsic stresses. In 
normal cells, the expression level of p53 protein is generally below the detection 
level of immunohistochemical methods. Mutations of the p53 gene are among the 
most common molecular changes identified in human cancers. These mutations can 
result in accumulation and over-expression of mutant p53 protein. Mutations of the 
p53 gene have been found in a range of human tumour types from organs such as 
bladder, colorectum, oesophagus, lung, head and neck, ovary, pancreas, prostate, 
skin, stomach, and many others. Technique of its resource and processing is 
mentioned in appendix A. 
A minimum of 250 cells was counted using 250-fold magnification and picking 5 
hot spots. Positive-staining tumour cells with the morphological characteristics of 
apoptosis were identified using standard criteria including chromatin condensation, 
(b) (a) 
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nuclear disintegration, and formation of crescentic caps of condensed chromatin at 
the nuclear periphery. 
2.6.3.1.1 Calculation of the Apoptotic index (AI) for p53 
Five high-power fields (250x) per slide from each tumour specimen were analysed 
by light microscopy using a morphometric software. On average 200 - 230 tumour 
cells per slide were counted.  Apoptotic cells were determined based upon nuclear 
staining in combination with the typical morphology of programmed cell death, e.g., 
nuclear shrinkage, chromosomal condensation, and presence of apoptotic bodies 406. 
Five high-power fields per section were evaluated, and apoptotic tumour cells were 
reported as fraction of all tumour cells [index = positive tumour cells / (positive + 
negative tumour cells)]. All results were reported as mean +/- standard deviation 
(SD). 
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2.6.3.2 Bcl-2 protein staining and analysis 
 
 
Figure (12). Bcl-2 staining (a) x10 (b) x25 
 
As mentioned earlier, bcl-2 oncoprotein is a 26-KDa protein, associated with 
intracellular membranes and encoded by the gene located on the long arm of 
chromosome 18q21. It is known as an inhibitor to apoptosis 282 283. Positive 
immunoreactivity for Bcl-2 was localized in the cytoplasm of tumour cells, and most 
tumours that were scored as positive showed homogenous intensity of 
immunostaining. This was done as described in the protocols of St. Mary’s 
histopathology and labs, as well as liaising with other studies 407. A description of its 
measurement is mentioned later. 
  
(a) (b) 
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2.6.3.3 Ki-67 staining and analysis 
 
 
Figure (13). Ki-67 (MIB-1) staining (a) x10 (b) x25 
 
The Ki-67 antigen is a nuclear protein, which is defined by its reactivity with 
monoclonal antibody from the Ki-67 clone 305. The Ki-67 antigen is preferentially 
expressed during all active phases of the cell cycle (G1, S, G2 and M-phases), but it 
is absent in resting cells (G0-phase) 305. During interphase, the antigen can be 
exclusively detected within the nucleus, whereas in mitosis most of the protein is 
relocated to the surface of the chromosomes. The antigen is rapidly degraded as the 
cell enters the non-proliferative state 408, and there appears to be no expression of 
Ki-67 during DNA repair processes 312. One major drawback of the original Ki-67 
antibody was the fact that it could not be used in formalin-fixed paraffin sections, 
which are routinely used in histopathology. This disadvantage could be overcome by 
the preparation of the Ki-67 equivalent monoclonal antibody MIB-1, which can be 
used on paraffin sections after antigen reassessment by microwave-processing or 
pressure cooking 313. The technique of processing MIB-1 is detailed in appendix A. 
The labelling index was determined by observing at least 250 nuclei in areas of the 
(b) (a) 
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section with the highest labelling rates, and the percentage of Ki-67-labeled nuclei 
was used for analyses; this method was used as described in another study 311. 
2.6.3.3.1 Ki-67 measurements 
Immunohistochemical staining was performed by the standard avidin-biotin-
peroxidase complex technique using as described in previous studies 409-411, as well 
as according to St. Mary’s labs protocol and the manufactures’ instructions. The 
labelling index (LI) of Ki-67 was determined in those tumour areas with positive 
stained nuclei 411. The calculation method is explained in more details later. 
In comparison to the counting of mitotic figures, the Ki-67 labelling index is more 
sensitive, because cells in all active phases of the cell cycle are recognised. 
Furthermore, the reliable assessment of mitotic figures needs more experience and is 
more time-consuming than the counting of immunohistologically stained nuclei.  
2.6.3.3.2 Calculation of apoptotic (AI) and proliferative indices (PI) for Bcl-2 
and MIB-1 
Five high-power fields (250x) per slide from each tumour specimen were analysed 
by counting technique. On average 200 - 230 tumour cells per slide were counted. 
Proliferating cells were detected by positive staining for MIB-1. Positive and 
negative stained tumours cells were counted out of 5 high-power fields per sample. 
Calculation of the Proliferation index was done by finding the proliferating cells 
which were detected by positive staining for MIB1. Then positive and negative 
stained tumour cells were counted out of these fields per sample. The index was 
reported as fraction of all tumour cells (index = positive tumour cells/positive + 
negative tumour cells). The localization of Bcl-2, and Ki-67 antigen was recorded 
and used to identify cells positive for the proteins. Protein expression was assessed 
as percentage positive cells per total cells counted per field. This method was 
adopted in few studies previously 343 406 412 413. 
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2.6.3.4 VEGF staining and analysis 
 
 
Figure (14). VEGF staining (a) x10 (b) x25  (c) x25, Classified 
 
VEGF (Vascular Endothelial Growth Factor) is a homodimeric, disulfide-linked 
glycoprotein involved in angiogenesis which promotes tumour progression and 
metastasis. It exhibits potent mitogenic- and permeability-inducing properties 
specific for the vascular endothelium.  Human recombinant VEGF protein (Abcam) 
was used in this study.  
Vascular endothelial growth factor immunostaining was considered to be positive 
when unequivocal cytoplasmic staining was seen in the tumour cells, regardless of 
the number of cells stained. Vascular endothelial growth factor expression was 
analysed in the invasive front of the tumour away from the tumour centre where 
necrosis and hypoxia may induce VEGF expression. The technique of processing 
VEGF is mentioned in appendix A 
(a) 
(c) 
(b) 
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VEGF staining was evaluated quantitatively by measuring optical density with 
computer-based morphometric analysis software (NIS element, [BR], Nikon) and 
expressed as a percentage of the stained areas in the 5 “hotspots” of each slide. 
 
2.6.3.5 CD-31 staining and analysis 
 
 
Figure (15). CD-31 staining (a) x10 (b) x25  (c) x25, Classified 
 
CD-31, also known as platelet endothelial cell adhesion molecule 1 (PECAM1), is a 
type I integral membrane glycoprotein and a member of the immunoglobulin super-
family of cell surface receptors. It is constitutively expressed on the surface of 
endothelial cells, and concentrated at the junction between them. It is also weakly 
expressed on many peripheral lymphoid cells and platelets. CD-31 has been used to 
measure angiogenesis in relation to tumour recurrence. Technique of its staining 
process is mentioned in appendix A. 
(c) 
(a) 
(b) 
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2.6.3.5.1 Evaluation of microvascular density (MVD) using CD-31 
Evaluation of microvessel density (as a continuous variable) was determined by 
using a modified technique of Weidner et al. 414, where the capillary vessels (CD-31 
positive) were counted at the invasive edge of the tumour, in five areas selected after 
the vascular “hot spots” were identified after scanning the entire tumour section 
systemically at low magnification (100x). The vessels were highlighted by setting a 
threshold that marked only the endothelial cells, using the morphometric computer 
analysis software. The computer counted each point that was set interactively by the 
researcher and calculating these areas at higher magnification (250x). Any brown-
staining endothelial cell or endothelial cell cluster that was clearly separate from 
adjacent microvessels, tumour cells, and other connective tissue elements was 
considered a single, countable microvessel. Vessel lumens were not necessary for 
the structure to be counted as a microvessel, and red blood cells were not used to 
define a vessel lumen 415.  
2.6.3.5.2 Background of microvessel counting ”the Hotspot technique” 
In 1991, Weidner et al. 414 developed a new method to perform microvascular 
density (MVD) counting studies within tumours. The first step in Weidner’s 
approach is the identification by light microscopy of the area of highest neovessel 
density, the so-called hot spot, by scanning the whole tumoural section at low power 
(40x), then, individual microvessels are counted at a higher power (250x) in an 
adequate exposure 415. This quantitative vessel count method was also assessed by 
international consensus 416. These were identified as having the highest density of 
staining, CD-31-positive cells, or cell clusters. For each slide, the most vascular 
areas within the tumour mass were chosen. A 250x field in these areas was counted, 
and the average counts of the fields were recorded with the aid of morphometric 
computer analysis software. If multiple vascular hot spots were present, counts were 
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performed in each hot spot. Microvessels were defined as a discrete CD-31 positive 
endothelial cell aggregate, with or without definable lumina. The same technique 
was used in the calculation for VEGF. 
Higher magnification was used in the processing, as vascularisation quantification 
on randomly chosen microscopic fields is dependent on the arbitrary selection of a 
limited number of fields in a restricted area of a tumour section and does not take 
into consideration the heterogeneous distribution of microvessels in tumour tissue 
417. A higher magnification gives an increased resolution, which enables more 
microvessels to be identified. Conversely, low magnification, with its lower 
resolution, will identify a smaller number of vessels, and will dilute out the hot spot 
418. 
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2.6.3.6 D-240 (LYVE-1) staining and analysis 
 
 
Figure (16). D-240 (LYVE-1) staining (a) x10 (b) x25  (c) x25, Classified 
 
Monoclonal mouse anti-D-240 identifies a 40 kD O-linked sialoglycoprotein present 
on a variety of tissues. The cellular staining pattern is cytoplasmic and sometimes 
membranous.  
Clone D-240 reacts with an O-linked sialoglycoprotein (MW 40K) found on 
lymphatic endothelium, foetal testis and on the surface of testicular germ cell 
tumours. In recent studies, clone D-240 have shown staining in lymphatic channel 
endothelium but not in the adjacent capillary. The method of its staining for this 
study is mentioned in appendix A. 
2.6.3.6.1 Calculation of Lymphatic Vascular density (LVD) using LYVE-1 
Any endothelial cell highlighted by LYVE-1 reactivity and clearly separated from 
connective tissue elements was regarded as a countable vessel. Lymphatic vessel 
density was assessed as described previously for Microvascular density (MVD) 415.  
(a) 
(c) 
(b) 
140 
 
In the present study, the LVD was calculated by counting the numbers of lymphatic 
vessels in ‘‘hot spots.” The ‘‘hot spot” is an area with a particularly high density of 
vessels and has been widely used in the study of blood vessel density 415. This 
concept was also used in many quantitative studies of LVD 419-422. 
Briefly, 5 areas of maximal LVD and MVD were identified by screening at low 
power (40x).The number of vessels was counted at 250x magnification 370 414. For 
the lymphatic vessels count, any stained endothelial cell or cell cluster separated 
from another microvessel structure was considered a countable microvessel. Notably 
a lumen was not necessary for a structure to be counted as a microvessel. Any 
endothelial cell highlighted by LYVE-1 reactivity and clearly separated from 
connective tissue elements was regarded as a countable vessel. LVD was assessed as 
described in other studies 415 for microvessel density (MVD).  
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3. CHAPTER 3: THE STUDIES  
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3.1 Study aims and objectives 
3.1.1 Overall aim 
(i) Assessment of the currently used grading system of evaluating the regression of 
oesophageal and gastric adenocarcinoma in response to neoadjuvant therapy, and 
comparing this technique to a novel technology of image analysis as a potential and 
more objective method of assessing regression.  
(II)  Assessing the feasibility of using a panel of  markers to predict the response to 
neoadjuvant chemotherapy.  
3.1.2 Detailed objectives 
1- Assessing the inter- and intra-observer variation among pathologists in estimating 
tumour regression using Mandard regression system. 
2- Investigating some of the markers that play a crucial role in the progress of 
oesophageal and gastric adenocarcinoma in the form of p53, Bcl-2, Ki-67, VEGF, 
CD-31 and LYVE-1, by comparing the pre- and post-neoadjuvant levels in the 
appropriately immunohistochemically stained slides. 
3- Examining the potential use of Image analysis as a more objective way of 
assessing regression in these tumours, compared with the currently subjective 
method of Mandard regression grading. 
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3.2 Study I: Assessment of histopathological response to 
neoadjuvant therapy in operable adenocarcinoma of the 
oesophagus and stomach 
3.2.1 Background 
Mandard regression system is a semiquantitative method of assessing regression in 
response to treatment, which might affect the accuracy of judgement concerning the 
degree of response to neoadjuvant therapy. This evaluation is crucial in determining 
whether the patient will further receive adjuvant chemotherapy.  
3.2.2 Objectives of the study 
• Assessment of the inter-observer variability among pathologists using 
Mandard scoring system. 
• Assessment of the intra-observer reproducibility in Mandard scoring 
3.2.3 Patients and summary of the technique 
Ninety-five specimens were available for this study. The patients were chosen 
according to the criteria mentioned in the methodology chapter. Four pathologists 
with an interest in upper gastrointestinal cancers and an experience in this field 
ranging between 7 - 15 years participated in the study. Each pathologist examined 
the slides without prior knowledge of the patients, their management or previous 
Mandard scoring. Each pathologist examined the slides independently, and each one 
repeated the examination of the slides twice, with an interval of 2 - 4 weeks between 
assessments. All the slides were stained in the same pathology lab with H&E using 
the same technique. 
3.2.4 Statistical methods 
Kappa statistics were used to assess the intra-observer variation with every 
pathologist, as well as assessing the inter-observer variation. 
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The simplest use of kappa is for the situation in which 2 clinicians each provides a 
single rating of the same patient on the basis of a nominal system, or where a 
clinician provides 2 ratings of the same patient, representing inter-rater and intra-
rater reliability, respectively. Kappa also can be adapted for more than one rating per 
patient from each of 2 clinicians 423, or for situations where more than 2 clinicians 
rate each patient or where each clinician may not rate every patient 424. More 
detailed explanation of this statistical method is mentioned in appendix B. 
It is customary among statisticians and researchers currently to adopt the 
interpretation of Kappa statistics as proposed by Landis and Koch 425, as shown in 
the following table (Table 18) 
κ Interpretation 
< 0 No agreement 
0.0 – 0.20 Slight agreement 
0.21 – 0.40 Fair agreement 
0.41 – 0.60 Moderate agreement 
0.61 – 0.80 Substantial agreement 
0.81 – 1.0 Almost perfect agreement 
Table (18). Interpretation of the results of κ statistics 
 
3.2.5 Results 
The results from the 4 pathologists were collected and then processed statistically 
using SPSS statistics, Version 17, where Kappa statistics was employed to assess 
two elements: the magnitude of agreement and reproducibility among the 4 
pathologists, as well as the intra-assessor variation which might occur from the same 
pathologist. 
The results are shown in the following tables (Table 19 and 20). 
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Pathologist 
Kappa 
measure of 
agreement 
Standard 
error 
Approximate 
significance 
 
No. of 
valid cases 
Frequency 
of 
Agreement 
Proportion 
of 
Agreement 
Pathologist 1 0.29 0.073 0.000 95 50 46% 
Pathologist 2 0.29 0.072 0.0001 95 45 46.4% 
Pathologist 3 0.42 0.069 0.000 95 45 49% 
Pathologist 4 0.35 0.072 0.0001 95 45 51% 
Table (19). The results of the intra-observer variation of the 4 pathologists 
 
As observed from the results in the intra-observer variation study, in which each 
pathologist repeated the assessment of the same slides with the an interval of 2 - 4 
weeks, The Kappa measure of agreement shows a result that swings between 0.29 
and 0.42, with an average significance of p < 0.0005 which gives the degree of 
agreement according to the levelling in the Kappa interpretation as “fair”. The 
frequency of agreement in the 95 slides ranged between 45 - 50, and the proportion 
of agreement, where he or she gives that same results in both tests ranged between 
46% - 51%. 
As for the results of the inter-observer variation, the results are shown below. 
rePath
ologists 
Kappa 
measure of 
agreement 
Standard 
error 
Approximate 
significance 
 
No. of valid 
cases 
Frequency 
of 
Agreement 
Proportion 
of 
Agreement 
1 vs. 2 0.47 0.068 0.0000 95 49 51% 
1 vs. 3 0.40 0.068 0.0001 95 45 49.5% 
1 vs. 4 0.44 0.069 0.000 95 45 49% 
2 vs. 3 0.48 0.068 0.0001 95 45 50% 
2 vs. 4 0.39 0.072 0.0001 95 46 48% 
3 vs. 4 0.52 0.066 0.0000 95 48 54% 
Table (20). The result of the inter-observer variation among the four pathologists 
 
The results in table (20) show the agreement among the 4 pathologists, where each 
result from each one of them is plotted against the other. Here the measure of 
agreement ranges between 0.39 and 0.48, with an approximate significance of 
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p<0.0005, and this translates according to Kappa definition as “moderate” 
agreement. The frequency of agreement in this comparison ranged between 45 - 49, 
while the proportion of agreement was between 48% and 54%. 
5.2.6 Discussion 
Mandard scoring system 222 uses mainly the measurement of fibrosis to assess the 
response to neoadjuvant therapy, and graded in stages from 1 to 5. The numbers, 
while intended to be semiquantitative, actually represent categories of increasing 
severity based on a combination of location and quantity of scarring. Thus, it is 
possible for a biopsy with a small amount of fibrous tissue in a particular location to 
have a higher stage than biopsy with a greater amount of fibrous tissue but not in 
that location. 
Despite advances in radiological imaging,  Mandard regression grading system 
remains the “gold standard” for assessing that regression. 
The introduction of new effective therapeutic agents has created a need for a high 
level of reproducibility and accuracy in the evaluation of  tumour response. This 
currently is achieved by the application of several similar grading systems that take 
account of the extent, and the relationship between the amount of fibrosis and the 
residual cancer cells. 
There have been many studies since the introduction of Mandard scoring system 
trying to make the degree of prediction more accurate and reproducible, as 
mentioned early in the review of literature. However, all of these studies were 
concentrating on the reproducibility of a mainly subjective system, which relies 
heavily on the personal experience and impression of the pathologist, which can be 
widely varied. In this study, it was shown the reproducibility among the 
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participating pathologists were only fair, surmounting only to moderate in some 
occasions. The pathologists in this study agreed almost completely when they 
examined the slides which had Mandard scoring of 1 and 5, indicating complete or 
no response respectively. However, there was a wide range of variation in the results 
in stages 2, 3, and 4, which correspond to mild, moderate and poor response. 
An important point to mention is that the pathologists in this study were not exposed 
to the whole sets of slides for each patient, and they were only restricted in the 
judgement to one slide. However, the conditions were the same for all of them, so 
this factor might be considered as not causing a bias of the experiment, as they all 
had the same condition. 
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3.3 Study II: Assessment of the tumour markers as predictors 
for the degree of response to neoadjuvant therapy 
3.3.1 Hypothesis 
Tumour markers may be a feasible method of predicting the degree of response to 
neoadjuvant therapy.  The usage of a combination of markers rather a single one 
might give a better estimate of the prediction power. 
3.3.2 Objectives of the study 
• Assessment of the difference of the levels of some of the markers involved in 
apoptosis, proliferation, angiogenesis and lymphangiogenesis in the pre- and 
post-neoadjuvant samples. 
• Proposing a panel of markers that can be used on the endoscopic biopsies to 
predict the degree of response to neoadjuvant chemotherpy prior to starting 
any treatment. 
3.3.3 Patients and summary of the techniques 
Hundred and fourteen samples were available for this study. The samples were 
chosen according to the criteria mentioned in the methodology chapter. The blocks 
were chosen after reviewing the archived H&E slides of the eligible patients, where 
a slide was chosen from each tumour where there was a close interface between the 
cancer and the nearby normal or fibrotic tissue for the resected tumours, while the 
pre-neoadjuvant blocks were collected after examining and picking the 
corresponding H&E slides. The blocks were collected from the participating 
hospitals, where they were de-waxed, dehydrated and cut onto Envision slides for 
immunohistopathological staining in the same cellular pathology of St. Mary’s 
hospital. The slides were then stained under the same technique in both labs of St. 
Mary’s and Hammersmith hospital. All the stained slides were examined using the 
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same instruments and adjusted as explained in the methodology chapter. The 
markers used in this study were p53, Bcl-2, Ki-67 (MIB-1), VEGF, CD-31, and D-
240 (LYVE-1). The concept behind choosing these particular markers, is that they 
check the areas of apoptosis (p53 and Bcl-2), proliferation (Ki-67), angiogenesis 
(VEGF and CD-31), and lymphangiogenesis (VEGF and LYVE-1), and that would 
help to scrutinize the main two reasons of the poor prognosis of gastric and 
oesophageal cancers which are mainly due to local recurrence, as well as distant 
haematogenous and lymphatic metastases. 
The calculation of the p53, Bcl-2 and Ki-67 was based on estimating apoptotic and 
proliferative indexes in the examined slides, while the estimation of VEGF, CD-31 
and LYVE-1 was based on the idea of “hotspots” technique which was established 
by Weinder et al.415, and validated in previous studies414 416 417, and the average of 
these spots was assessed and calculated with morphometric computerized analysis 
software (Nikon NIS Elements [BR]). 
The Mandard scoring used in correlation with markers was the consensus score 
reached between 2 pathologists as described before in section 2.5.  
3.3.4 Statistical methods 
Canonical discriminant analysis was used for the statistics of this study. This is one 
of the discriminant analysis tools used in statistics among the related Linear 
discriminant analysis (LDA) and the related Fisher's linear discriminant which are 
methods used in statistics and machine learning to find the linear combination of 
features which best separate two or more classes of objects or events. The resulting 
combination may be used as a linear classifier or, more commonly, for 
dimensionality reduction before later classification. More description of this 
statistical method is mentioned in appendix B. 
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3.3.5 Results 
 
Figure (17). Graphic representation for the mean in the pre-neoadjuvant level and post-resection 
level of each marker 
 
The figure above shows the mean results of the levels in the markers used in this 
study (p53, Bcl-2, Ki-67, VEGF, CD-31 and LYVE-1). As noticed from the graphs, 
there is a relation between the changes in the level of each marker, although it is a 
151 
 
minimal change with each stage of Mandard staging. For Bcl-2, there is almost no 
change in stage 3 and 4, while the earlier stages of Mandard 1 and 2, which 
correspond to good response to therapy, levels of Bcl-2 increase during these 2 
stages. p53 level is noticed to be increasing along with the progressive stages of 
Mandard, where actually it even appears higher in the post-resection specimens 
despite the neoadjuvant therapy, which indicate that higher levels of p53 would have 
a negative effect on the response on treatment. By looking at the changing level of 
VEGF through the stages, it gives some conflicting result, as in the Mandard stage 1 
and 2 (which indicates good response to treatment), its level is high, while it starts to 
rise again at the advanced stage of Mandard (which indicate no response to 
treatment). However, observing the means of CD-31 and LYVE-1, it is apparent that 
there is a steady increase of their levels as the Mandard stages go from level 1 to 5, 
which reflects that these two markers might be playing a significant role in the 
unresponsiveness to treatment. 
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Figure (18). Graphic representation of the canonical discriminant functions of the 6 markers on 
pre treatment endoscopic biopsies 
 
  
Mandard 
Predicted Group outcome 
Total   1 2 3 4 5 
Original Count 1 6 0 0 0 0 6 
2 2 10 0 0 0 12 
3 0 0 21 0 1 22 
4 0 0 11 26 4 41 
5 0 0 1 3 29 33 
% 1 100.0 0.0 0.0 0.0 0.0 100.0 
2 16.7 83.3 0.0 0.0 0.0 100.0 
3 0.0 0.0 95.5 0.0 4.5 100.0 
4 0.0 0.0 26.8 63.4 9.8 100.0 
5 0.0 0.0 3.0 9.1 87.9 100.0 
 80.7% of original grouped cases correctly classified. 
Table (21). The results of the Canonical Discriminant functions of the total of the 6 markers on pre 
treatment endoscopic biopsies 
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By running  the levels of the 6 markers collectively prior to neoadjuvant therapy 
using the canonical discriminant functions analysis, the end result was that if the 6 
markers are used together, they will run a result of predicting the degree of response 
to neoadjuvant therapy of 80.7%, where the lowest level of degree of their prediction 
went as low as 63.4% in stage 4, while the prediction power was 100% for Mandard 
stage 1. However, this result might not reflect the real power of prediction, when the 
available specimens with Mandard grade 1 were only 6 patients, while those for 
stage 4 were 41 patients, highlighting the fact that more samples are needed within 
each group of Mandard staging to get a more realistic picture of the results. 
When running the canonical discriminant functions analysis for each marker on its 
own, the results came back as shown in the following tables 
  
Mandard 
Predicted group outcome 
Total   1 2 3 4 5 
Original Count 1 5 1 0 0 0 6 
2 4 8 0 0 0 12 
3 0 7 10 0 5 22 
4 0 1 17 12 11 41 
5 0 3 9 5 16 33 
% 1 83.3 16.7 0.0 0.0 0.0 100.0 
2 33.3 66.7 0.0 0.0 0.0 100.0 
3 0.0 31.8 45.5 0.0 22.7 100.0 
4 0.0 2.4 41.5 29.3 26.8 100.0 
5 0.0 9.1 27.3 15.2 48.5 100.0 
 44.7% of original grouped cases correctly classified. 
Table (22). Results of canonical discriminant functions analysis for p53 on pre treatment 
endoscopic biopsies 
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For p53, as seen from Table (23), only 44.7% of the cases were correctly classified, 
where the lowest level was found in Mandard stage 4, while the highest level of 
correlation was in Mandard stage 1. 
  
Mandard 
Predicted group outcome 
Total   1 2 3 4 5 
Original Count 1 3 2 0 0 1 6 
2 5 4 0 0 3 12 
3 2 6 5 3 6 22 
4 4 1 13 8 15 41 
5 0 3 5 1 24 33 
% 1 50.0 33.3 0.0 0.0 16.7 100.0 
2 41.7 33.3 0.0 0.0 25.0 100.0 
3 9.1 27.3 22.7 13.6 27.3 100.0 
4 9.8 2.4 31.7 19.5 36.6 100.0 
5 0.0 9.1 15.2 3.0 72.7 100.0 
 38.6% of original grouped cases correctly classified. 
Table (23). Results of canonical discriminant functions analysis for Bcl-2 on pre treatment 
endoscopic biopsies 
 
In the case of Bcl-2, the pre-neoadjuvant marker level was able to correlate with the 
Mandard stages only in 38.6% of the samples, with the highest level in Mandard 5, 
and lowest level of agreement in Mandard 4. 
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Mandard 
Predicted group outcome 
Total   1 2 3 4 5 
Original Count 1 6 0 0 0 0 6 
2 2 10 0 0 0 12 
3 0 5 8 5 4 22 
4 1 2 11 24 3 41 
5 0 0 1 11 21 33 
% 1 100.0 0.0 0.0 0.0 0.0 100.0 
2 16.7 83.3 0.0 0.0 0.0 100.0 
3 .0 22.7 36.4 22.7 18.2 100.0 
4 2.4 4.9 26.8 58.5 7.3 100.0 
5 0.0 0.0 3.0 33.3 63.6 100.0 
 60.5% of original grouped cases correctly classified. 
Table (24). Results of canonical discriminant functions analysis for Ki-67 on pre treatment 
endoscopic biopsies 
 
With Ki-67, the pre-neoadjuvant level of this marker was able to correlate correctly 
with the Mandard grading in 60.5% of cases, with the lowest level of prediction in 
Mandard 3 reaching 36.4%, while yielding 100% in Mandard 1. 
  
Mandard 
Predicted group outcome 
Total   1 2 3 4 5 
Original Count 1 4 2 0 0 0 6 
2 6 2 2 0 2 12 
3 0 2 12 5 3 22 
4 2 11 23 4 1 41 
5 8 12 7 0 6 33 
% 1 66.7 33.3 0.0 0.0 0.0 100.0 
2 50.0 16.7 16.7 0.0 16.7 100.0 
3 0.0 9.1 54.5 22.7 13.6 100.0 
4 4.9 26.8 56.1 9.8 2.4 100.0 
5 24.2 36.4 21.2 0.0 18.2 100.0 
 24.6% of original grouped cases correctly classified. 
Table (25). Results of canonical discriminant functions analysis for VEGF on pre treatment 
endoscopic biopsies 
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However, in the case of VEGF, it was able to correlate correctly with Mandard 
staging in only 24.6% of the total cases, where the lowest level of prediction was in 
Mandard stage 4 at 9.8%, and the highest level of prediction of 66.7% in Mandard 
stage 1. 
  
Mandard 
Predicted group outcome 
Total   1 2 3 4 5 
Original Count 1 4 2 0 0 0 6 
2 4 7 1 0 0 12 
3 1 5 7 9 0 22 
4 1 5 7 12 16 41 
5 0 0 6 1 26 33 
% 1 66.7 33.3 0.0 0.0 0.0 100.0 
2 33.3 58.3 8.3 0.0 0.0 100.0 
3 4.5 22.7 31.8 40.9 0.0 100.0 
4 2.4 12.2 17.1 29.3 39.0 100.0 
5 0.0 0.0 18.2 3.0 78.8 100.0 
49.1% of original grouped cases correctly classified. 
Table (26). Results of canonical discriminant functions analysis for CD-31 on pre treatment 
endoscopic biopsies 
 
The level of correct level of predicting Mandard level was raised with CD-31, where 
collectively it was able to predict the stage in 49.1% of the whole cases, with lowest 
level of predicting with Mandard stage 4, where the ratio was only 29.3%, and the 
highest level with Mandard stage 5 at 78.8%. 
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Mandard 
Predicted group outcome 
Total   1 2 3 4 5 
Original Count 1 2 3 1 0 0 6 
2 6 2 5 1 0 12 
3 4 5 4 9 0 22 
4 1 0 14 16 10 41 
5 0 0 3 2 28 33 
% 1 33.3 50.0 16.7 0.0 0.0 100.0 
2 50.0 11.4 41.7 8.3 0.0 100.0 
3 18.2 22.7 18.2 40.9 0.0 100.0 
4 2.4 0.0 34.1 39.0 24.4 100.0 
5 0.0 0.0 9.1 6.1 84.8 100.0 
 43.9% of original grouped cases correctly classified. 
Table (27). Results of canonical discriminant functions analysis for LYVE-1 on pre treatment 
endoscopic biopsies 
 
Finally, LYVE-1 was able to correlate with the stage of Mandard in 43.9% of the 
whole specimens, where the highest correlation was in Mandard stage 5, and the 
lowest  level with Mandard stage 2, amounting to only 11.4%. 
3.3.6 Discussion 
This study shows that the response to neoadjuvant chemotherapy can be predicted 
from the endoscopic biopsies prior to any treatment. It was found that if the six 
markers were used together for predicting the degree of response, the accuracy 
reached about 80%, while the value of accuracy for individual markers ranged from 
the very weak predictive power of VEGF (24.6%), to the moderately sensitive 
prediction of Ki-67 (60.5%).  The ability to predict the response to neoadjuvant 
chemotherpy using histological markers has huge implication in clinical practice. A 
positive prediction indicates that the drug regimen is appropriate and, in addition, 
may be useful postoperatively. Lack of significant measurable response indicates the 
need to choose another regimen or to proceed to surgery 426. Rapid progression of 
the disease in the face of neoadjuvant therapy may identify a tumour so aggressive 
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that a patient can be spared non-therapeutic surgery and its concomitant morbidity 
147. 
Histological grading of oesophageal tumours has been used as a prognostic indicator 
in patients treated with combined neoadjuvant therapy and surgery. It is important to 
identify non-responders so that unnecessary, potentially harmful treatment is not 
given to those who will not benefit from such therapy 427 428. The problem with 
neoadjuvant therapy is that it is costly, time consuming and toxic. The ability to 
predict response and survival after that would be invaluable in patient management. 
For these reasons the need for outcome markers in the management of oesophageal, 
as well as, gastric cancers are most pressing. Published data clearly indicate that 
those with upper gastrointestinal cancer who respond to neoadjuvant therapy have a 
markedly higher chance of cure after surgery than non-responders 163 164 184. 
PET scan, as a complementary investigation to cross-sectional imaging studies has 
been shown, in two studies, to differentiate responding from non-responding 
tumours early in the course of neoadjuvant systemic chemotherapy 163 186. This is 
based on the fact that it is considered as a “metabolic” imaging study that relies on 
the differences between tumour cell glucose metabolism and that of normal cells. In 
follow-up of patients, the changes in tumour metabolic activity may be employed to 
individualise the use of chemotherapy in patients with oesophageal and gastric 
cancer 429 430. 
After complete response to preoperative chemoradiation in oesophageal cancer, the 
general prognosis is poor despite aggressive therapy, with the 5-year survival rates 
of up to 60% have been reported 267 431-433. A complete tumour response, defined as 
the absence of vital tumours cells within the surgical specimen, can be achieved in 
20% to 30% 267 432-435. However, perioperative morbidity and mortality are clearly 
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increased after chemotherapy, either alone or combined with radiotherapy, and 
apparently related to the intensity of the applied protocol 436 437.  This increase of 
perioperative mortality relates to all patients including those who show no response 
to chemoradiation. Therefore, it is of utmost importance to identify factors pre-
therapeutically that indicate a response to these modalities of treatment. 
Unfortunately, such factors are currently to the best of our knowledge unknown. 
Whilst prognostic biomarkers are measurements available at the time of diagnosis or 
surgery which are associated with recurrence, death or other clinical outcomes and 
determine how patients will fare irrespective of treatment, predictive biomarkers are 
measures that help to determine which patients do well with particular types of 
treatment.  
An ideal cell marker for microscopic or imaging studies has several desirable 
features: it should be expressed only on the cell type of interest, should be absent in 
other cells, and should have a good signal-to-noise ratio with surrounding tissues. A 
good lymphatic marker for example should preferably be expressed uniformally on 
all vessel segments during all stages of development and disease, in all species 
studied, and to be resistant to a wide range of fixation conditions. 
The present study is the first in the literature that precdicts the response to 
neoadjuvant chemotherpy prior to starting any treatment with an accuracy of 80%.  
There are only ambiguous data in the liteature for a limited number of markers that 
might predict survival for patients treated with preoperative multimodality therapy 
230-234. Although the study by Harpole et al 230 contained mostly adenocarcinomas, 
many of the studies involved only squamous cell histologies, despite the marked 
increase in the incidence of adenocarcinoma 12 235.  
160 
 
The purpose of the present study was to assess the biologic significance of 
histopathological tumour regression and to correlate the response with the apoptotic 
rate, Ki-67 labelling index, and p53 and Bcl-2 protein expression in pre-treatment 
biopsies in a group of patients with oesophageal and gastric adenocarcinoma treated 
with a similar protocol of neoadjuvant therapy, as well as studying the other crucial 
factor of poor outcome of these cancer and this is metastasis, where angiogenesis 
and lymphangiogenesis play a major rule, and these were monitored here using 
VEGF, CD-31 and LYVE-1. Unlike other studies, where response was assessed 
either by clinical-to-pathological “down-staging” or by differences in local control 
or survival, our approach used a more direct histological assessment of neoadjuvant-
induced regression of the primary cancer.  The ability to predict the response of 
neoadjuvant chemotherpy from endoscopic biopsies in standard histopathological 
laboratory using the panel of histological markers is of great advantage as it does not 
need special equipment related to genetic or proteomic analysis.  This will render the 
present study a practical one that would influence day-to-day clinical practice.  
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3.4 Study III: Image analysis as a subjective method of assessing 
regression in response to neoadjuvant chemotherapy in 
operable gastric and oesophageal adenocarcinoma 
3.4.1 Hypothesis 
Image analysis technique might be a more robust and objective method of assessing 
the degree of regression in comparison to the current standard subjective method of 
Mandard regression. 
3.4.2 Objectives of the study 
• To compare the reproducibility of the image analysis technique in estimating 
regression to the currently used Mandard scoring. 
• To examine the reproducibility in using this technique among pathologists. 
3.4.3 Patients and summary of the technique 
Ninety-five post-resection samples were available for this study, corresponding to 
the same pool of samples which were chosen in Study I. The same sections were 
stained with SR stain, as being considered one of the best stains to highlight 
collagens, which are abundant in fibrotic tissue. All the slides were cut, mounted and 
stained using the same technique and protocol in St. Mary’s cellular pathology 
laboratory. The first stage was to evaluate the reproducibility of the image analysis 
technique in relation to the currently gold standard used method of Mandard 
regression system. The application of consensus in Mandard grading between 2 
pathologists was used to correlate with imaging analysis. The second stage was to 
involve three assessors with a degree of skill and interest in the field of image 
analysis, to assess the degree of agreement on using the technique. Each assessor 
was blinded to the outcome of the corresponding Mandard grading of each sample. 
162 
 
Also, each assessor examined the slides twice, with an interval of 2-4 weeks 
between examinations, to evaluate the intra-assessor variation. 
3.4.4 Statistical methods 
Cronbach’s alpha test and Intraclass correlation coefficient statistical analyses were 
used to assess inter-rater reliability and agreement or concordance, was assessed. 
These tests assess the degree of agreement among raters. They give a score of how 
much homogeneity, or consensus, there is in the ratings given by the assessors. It is 
useful in refining the tools given to the researchers, for example by determining if a 
particular scale is appropriate for measuring a particular variable. If various raters do 
not agree, either the scale is defective or the raters need to be re-trained 438. More 
description of the statistical methods used in this study is explained in appendix B. 
3.4.5 Results 
 
Figure (19). Box-plot showing the relationship between the average fibrosis as measured by Image 
analysis and Mandard stage 
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Descriptive Statistics 
Mandard N Minimum Maximum Mean Std. Deviation 
1 Average Fibrosis 6 38.98 67.20 51.06 14.75 
2 Average Fibrosis 13 34.49 46.85 41.72 4.41 
3 Average Fibrosis 26 26.83 44.78 37.83 3.63 
4 Average Fibrosis 28 25.27 39.38 31.35 4.21 
5 Average Fibrosis 21 19.51 36.17 23.33 3.89 
Table (28). Descriptive statics showing the relation between the levels of fibrosis found in image 
analysis in relation to Mandard stages 
 
It was found that average fibrosis measured by image analysis can be related to each 
stage of Mandard staging system.   
 P1/T1 P1/T2 P2/T1 P2/T2 P3/T1 P3/T2 
P1/T1 1.00 0.89 0.87 0.79 0.83 0.81 
P1/T2 0.89 1.00 0.83 0.81 0.78 0.78 
P2/T1 0.87 0.83 1.00 0.90 0.94 0.90 
P2/T2 0.79 0.81 0.90 1.00 0.89 0.89 
P3/T1 0.83 0.77 0.94 0.89 1.00 0.93 
P3/T2 0.81 0.77 0.90 0.89 0.93 1.00 
P = Pathologist; T = Test 
Table (29). Inter-item correlation matrix of the consistency of the 3 pathologists in image analysis 
study 
 
By running the Cronbach’s alpha to assess the reliability of the consistency of the 3 
pathologists who participated in this study, where they examined the 95 slides for 
image analysis twice, it was found that Cronbach’s alpha coefficient was reported as 
being with the value of 0.97, which suggests very good internal consistency. Also, 
as noted from the table above (table 29), which summarises the inter-item 
correlation between all the tests done, it was found that the Cronbach’s alpha 
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coefficient ranged between 0.77 - 1.00, which again denotes very good internal 
consistency. 
 
 
Intraclass 
Correlationa 
95% Confidence Interval F Test with True Value 0 
 Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
0.85 0.81 0.89 35.97 95 470 .000 
Average 
Measures 
0.97 0.961 0.98 35.97 95 470 .000 
a. Type A intraclass correlation coefficients using an absolute agreement definition 
Table (30). Intraclass correlation coefficient of the 3 pathologists for agreement 
 
Intraclass correlation coefficient testing was done for the results of the 3 
pathologists, where a Two-way random model of the type ‘Absolute agreement’ was 
used to see how much the degree of agreement was found among the 3 pathologists 
when testing irrelevant of the Mandard grading of the slide. It was found that on 
average the measure was 0.97 with a narrow range of 0.96 - 0.98, indicating 
considerable level of agreement upon assessment of the slides, irrespective of the 
Mandard staging. 
 
Intraclass 
Correlationa 
95% Confidence Interval F Test with True Value 0 
 Lower Bound Upper Bound Value df1 df2 Sig 
Single 
Measures 
0.85 0.81 0.89 35.97 95 470 .000 
Average 
Measures 
0.97 0.96 0.98 35.97 95 470 .000 
a. Type C intraclass correlation coefficients using a consistency definition-the between-measure variance is excluded 
from the denominator variance. 
Table (31). Intraclass correlation coefficient for the 3 pathologists for consistency 
 
When the same statistical test was done to assess consistency of estimation of the 
degree of fibrosis, again irrespective of the Mandard grading, it was found that the 
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average degree of correlation was 0.97, with a range between 0.96 and 0.98, again 
showing impressive degree of consistency when using this method of assessment. 
3.4.6 Discussion 
Currently, physicians use semiquantitative scoring systems to assess the degree of 
tumour regression, depending mainly on the estimation between the level of fibrosis 
and residual cancer cells in a specimen. These scoring systems are subjective, 
requiring an experienced pathologist, and have a high degree of intra-observer and 
inter-observer variability, and this has been highlighted in other studies which 
monitored similar numerical scoring systems in other pathologies, such as in liver 
fibrosis and lung, assessing their degree of accuracy 392 397 398 439-441. Also, there have 
been several studies which showed a good correlation between computer-assisted 
morphometric analysis and semiquantitative staging score, especially in the field of 
liver fibrosis 394 395 442. In addition, these subjective systems lack the precision of a 
purely quantitative technique in evaluating fine morphological details. To overcome 
this problem recent studies have used computerised image analysis to assess fibrosis, 
with many studies done in liver fibrosis, as well as in skin conditions 395 396 443. 
These use colour segmentation to define areas of fibrosis. Colour segmentation is a 
process by which particular structures can be identified and isolated from the image 
according to colour. Colour segmentation eliminates the subjective component of 
semiquantitative scoring systems. Digital image analysis (DIA) allows quantitative 
assessment of fibrosis in a biopsy by using two-dimensional counting of an array of 
pixels to enable calculation of an area of fibrosis 396. In recent years, quantitative 
evaluations through image analysis have been utilized. It provides objective 
quantitative results similar to, but more precise than those determined by semi-
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quantitative scoring methods, without requiring the presence of an experienced 
pathologist 395.  
Besides its greater diagnostic accuracy and reproducibility in assessing degree of 
fibrosis, as shown in this study, image analysis has the advantage of (i) Saving time 
as the examination of one specimen is faster than other quantitative methods; (ii) 
Simplicity as the examination is easy and it can be performed by a technician and 
(iii) More descriptive as it provides the percentage of the surface occupied by 
fibrosis in the entire section. 
However, this method has few limitations:  
1) Limited information: image analysis provides a quantitative approach to 
fibrosis and cannot replace qualitative determination. 
2) Cost: image analysis is expensive. However, as laboratories become better 
equipped, the samples could be analysed in reference laboratories by 
electronic network transmission, especially as this technique requires images 
to be digitized. 
3) Unrefined method: image analysis provides a partial reflection of fibrosis 
which is a dynamic process involving numerous extracellular matrix 
components. 
Potential advantages over semiquantitative scores are that the digital image analysis 
method is truly quantitative, and that, smaller changes between biopsies may be 
detected than is possible with the relatively blunt semiquantitative scores, allowing 
differences pre and post treatment to be measured more precisely 396. In addition, 
variables are scalar rather than ordinal and provide a continuous method for fibrosis 
estimation and therefore more flexible statistical analysis. 
167 
 
The Picrosirius stain appears to be optimal for the selective colouring of collagens 
444. Collagens I, II and III are stained but not proteoglycans 445. Images of stained 
slides may then be obtained using a digital camera attached to a conventional light 
microscope and captured in digital format into a computer. 
When adopting image analysis in the area of telepathological diagnosis, as in this 
study, two different methodological approaches have been advocated for this. In 
dynamic systems, images are viewed live and in real time as the receiving viewer 
directly controls specimen orientation, field selection, and fine focus of the 
microscope via available controls. In static systems, images are captured in a digital 
format on an image frame grabber board and can be transmitted as still images to the 
receiving viewer. The receiving viewer usually has little or no direct control over 
microscope function. Although dynamic imaging is unquestionably the more 
powerful technologic approach, the substantially lower cost favours the use of static 
imaging methods for review of the specimens involved 446. For the sake of this 
study, as well as the small number of the cases here, the involved participants in this 
experiment adopted the dynamic technique. 
The best way to confirm the validity of a possible scoring system or image analysis 
is to correlate its results with another well-established technique. For example, 
Image analysis of liver fibrosis has been shown to correlate well with the chemical 
determination of liver hydroxyproline and a histological semi-quantitative scoring 
system 395. In this study, we compared a well established method of grading the 
response to neoadjuvant therapy, which is Mandard grading system, to the changes 
in the degree of fibrosis as measured and estimated by image analysis, trying to 
establish if a range of fibrosis, as measured by this technique, can correspond to the 
grades adopted by Mandard. It was found that indeed there is some element of 
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descending percentage of fibrosis corresponding to each progressive grade of 
Mandard. However, more specimens need to be available for evaluation, till 
reaching an established range that can correspond, and may replace, Mandard 
scoring system, considering that it would be much more robust, and more objective 
than the currently used semi-quantitative method. 
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The three studies in this thesis monitored one of the most common systems used to 
assess the response to neoadjuvant therapy, which is Mandard regression system. 
This scoring system uses a subjective numerical method of scoring regression of 
oesophageal and gastric cancer, depending mainly on the individual perception and 
experience of the pathologist. Mandard system has been assessed, and was 
compared from the reproducibility point to a more novel system of digital image 
analysis that is currently increasingly being used with promising results in assessing 
changes in comparison to similar numerical systems, especially in liver, prostate and 
skin cancer pathologies. Also, a panel of tumour markers was chosen to assess their 
levels of changes along with the Mandard regression system, focusing mainly on the 
ones covering apoptosis, proliferation, angiogenesis and lymphangiogenesis, 
considering the poor outcome of gastric and oesophageal cancer is mainly due to 
local recurrence as well as distant haematogenous and lymphatic spread. 
The present study has shown that Mandard regression system delivered a weak level 
of agreement among the pathologists. This was evident in the inter-observer 
variation study, where the level of agreement was weak to fair, when analysed using 
Kappa statistics. Also, the level of agreement when assessing each pathologist 
repeating the test twice showed only fair to moderate agreement.  
There was almost complete agreement at the extreme ends of the Mandard scale at 
level 1 that indicates complete regression, as well as at level 5 which reflects no 
response. The large variation in the results was in stages 2, 3, and 4. All these results 
show that this semiquantitative system might not give accurate reflection of how 
well the patient is reacting to the chemotherapy regime given to him. 
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However, there were a small number of patients who showed complete response to 
neoadjuvant therapy, in comparison to the less responsive ones. This small sample 
size may influence the degree of accuracy in the assessment of Mandard  1. Also, 
each pathologist examined only one slide of the whole set of each patient, and this 
might have given different estimation of the overall degree of response if enough 
slides for each case were available. 
In the markers study, when these markers were used collectively to predict the 
degree of response to treatment, as when the whole panel being statistically analyzed 
using the canonical discrimination analysis in relation to each grade of Mandard 
regression, it was shown that they scored an average of 80% power of prediction 
when used together, compared to much weaker results when each one of them was 
analyzed individually, ranging from 24.6% for VEGF to 60.5% for Ki-67. These 
results encourage the implementation of more markers, with the hope of reaching to 
a more accurate panel that would give a sensitive and reliable prediction power, 
sparing many of the patients who are not responsive to chemotherapy the cost, as 
well as the side effects associated with these modalities of treatment. Although the 
assessment of these markers is time-consuming and the cost of hitological 
assessment increase, it is likely to be cost-effectiveness and beneficial for patients 
and healthcare resourses as it would avoid unnecessaary chemotherpy.  
The ability to predict the response of neoadjuvant chemotherpy from endoscopic 
biopsies in standard histopathological laboratory using the panel of histological 
markers is of great advantage as it does not need special equipment related to 
genetic or proteomic analysis.  This will render the present study a practical one that 
would influence day-to-day clinical practice.  
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The image analysis study showed that there is a trend between the assessment of 
fibrosis in the slides stained specifically for that purpose using SR, and their 
corresponding degree of Mandard regression. Image analysis uses scalar rather than 
nominal measures, making it more objective. Besides, it was shown that there is a 
possibility to grade the range of fibrosis with every stage of Mandard regression, 
though there was some overlap between stages 2, 3 and 4. Also, the potential of 
using this system in the future from the point of consistency and reproducibility 
among pathologists was apparent from running the intraclass coefficient statistical 
tools for the results of the 3 assessors involved, where the average measure was 0.97 
indicating very good agreement. This might open the door for the adoption of this 
technique in the future to use this system in the evaluation of the degree of 
regression. 
Again, there were only a limited number of specimens which corresponded to 
Mandard regression grade 1, which might have given higher degree of agreement. 
There is still the problem of the cost that this technique imposes, considering for 
example the software used. This might slow down the implementation of this 
method for routine and widespread work.  
Until now, in gastric and oesophageal cancer, the only prognostic factors commonly 
accepted were the clinico-pathological features, such as performance status, age,  
and macroscopic type 447 448. The examination of biological markers on biopsy 
samples could be of particular interest in selecting potentially responding patients 
from non-responders. In the neoadjuvant setting, the finding of possible 
chemosensitive tumours might be used to identify patients who may receive 
preoperative chemotherapy in an attempt to allow the resectability of the tumour, the 
main prognostic factor for survival in gastric cancer. Nevertheless, prospective 
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studies need to address this issue definitely and other biological markers need 
further investigation and/or confirmation. 
Little attention has been paid to the relationship between tumour proliferation and 
response to treatment. The hypothesis that assessment of cellular proliferation 
during and after treatment may give clinically useful information about response 
should be considered, especially in patients treated with cytostatic drugs. In this 
respect, it should be examined whether there are differences between fast and slow 
proliferating tumours, and whether cytostatic drugs can induce changes in the 
proliferative activity. A main area of future research is to investigate the value of 
cellular proliferation in premalignant conditions. 
As an extension of the studies in this thesis, the next step is to collect more samples 
to study the validity and reproducibility of the findings. More cancers that meet the 
criteria of the studies in this thesis are currently being collected, adding to the 
already existing collection of slides. 
A validation study is currently underway to emphasize the degree of agreement in 
the usage of markers as predictors to neoadjuvant therapy in this type of cancer. 
It could be feasible to assess the relation between the levels of markers in the 
original tumour and lymph nodes metastasis, to help shed more light on the 
possibility of designing targeted therapies against these agents. 
  
174 
 
 
 
 
 
 
 
REFERENCES 
  
175 
 
1. Kleespies A, Guba M, Jauch KW, Bruns CJ. Vascular endothelial growth factor in 
oesophageal cancer. J Surg Oncol 2004;87(2):95-104. 
2. Allum WH, Griffin SM, Watson A, Colin-Jones D. Guidelines for the 
management of oesophageal and gastric cancer. Gut 2002;50 Suppl 5:v1-23. 
3. Shimada Y, Imamura M, Watanabe G, Uchida S, Harada H, Makino T, et al. 
Prognostic factors of oesophageal squamous cell carcinoma from the perspective 
of molecular biology. Br J Cancer 1999;80(8):1281-8. 
4. Bottger T, Dutkowski P, Kirkpatrick CJ, Junginger T. Prognostic significance of 
tumor ploidy and histomorphological parameters in adenocarcinoma of Barrett's 
esophagus. Dig Surg 1999;16(3):180-5. 
5. Cascinu S, Staccioli MP, Gasparini G, Giordani P, Catalano V, Ghiselli R, et al. 
Expression of vascular endothelial growth factor can predict event-free survival 
in stage II colon cancer. Clin Cancer Res 2000;6(7):2803-7. 
6. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 
2000;407(6801):249-57. 
7. Vallbohmer D, Lenz HJ. Predictive and prognostic molecular markers in outcome 
of oesophageal cancer. Dis Esophagus 2006;19(6):425-32. 
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70. 
9. Wallace-Brodeur RR, Lowe SW. Clinical implications of p53 mutations. Cell Mol 
Life Sci 1999;55(1):64-75. 
10. Raouf AA, Evoy DA, Carton E, Mulligan E, Griffin MM, Reynolds JV. Loss of 
Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with 
tumor progression and worse survival but not with response to neoadjuvant 
chemoradiation. Dis Esophagus 2003;16(1):17-23. 
11. Enzinger PC, Mayer RJ. Oesophageal cancer. N Engl J Med 2003;349(23):2241-
52. 
12. Devesa SS, Blot WJ, Fraumeni JF, Jr. Changing patterns in the incidence of 
oesophageal and gastric carcinoma in the United States. Cancer 
1998;83(10):2049-53. 
176 
 
13. Stein HJ, Feith M, Siewert JR. Malignant degeneration of Barrett's esophagus: 
clinical point of view. Recent Results Cancer Res 2000;155:42-53. 
14. Wallace MB, Perelman LT, Backman V, Crawford JM, Fitzmaurice M, Seiler 
M, et al. Endoscopic detection of dysplasia in patients with Barrett's esophagus 
using light-scattering spectroscopy. Gastroenterology 2000;119(3):677-82. 
15. Harrison RF, Perry I, Jankowski JA. Barrett's mucosa: remodelling by the 
microenvironment. J Pathol 2000;192(1):1-3. 
16. Posner MC, Gooding WE, Landreneau RJ, Rosenstein MM, Clarke MR, 
Peterson MS, et al. Preoperative chemoradiotherapy for carcinoma of the 
esophagus and gastroesophageal junction. Cancer J Sci Am 1998;4(4):237-46. 
17. Adad SJ, Etchebehere RM, Hayashi EM, Asai RK, de Souza Fernandes P, 
Macedo CF, et al. Leiomyosarcoma of the esophagus in a patient with chagasic 
megaesophagus: case report and literature review. Am J Trop Med Hyg 
1999;60(5):879-81. 
18. Caldwell CB, Bains MS, Burt M. Unusual malignant neoplasms of the 
esophagus. Oat cell carcinoma, melanoma, and sarcoma. J Thorac Cardiovasc 
Surg 1991;101(1):100-7. 
19. Haller JO, Cohen HL. Gastrointestinal manifestations of AIDS in children. AJR 
Am J Roentgenol 1994;162(2):387-93. 
20. Lim SG, Lipman MC, Squire S, Pillay D, Gillespie S, Sankey EA, et al. Audit of 
endoscopic surveillance biopsy specimens in HIV positive patients with 
gastrointestinal symptoms. Gut 1993;34(10):1429-32. 
21. Lagarde SM, ten Kate FJ, Richel DJ, Offerhaus GJ, van Lanschot JJ. Molecular 
prognostic factors in adenocarcinoma of the esophagus and gastro-oesophageal 
junction. Ann Surg Oncol 2007;14(2):977-91. 
22. de Manzoni G, Pedrazzani C, Pasini F, Durante E, Gabbani M, Grandinetti A, et 
al. Pattern of recurrence after surgery in adenocarcinoma of the gastro-
oesophageal junction. Eur J Surg Oncol 2003;29(6):506-10. 
23. Mariette C, Balon JM, Piessen G, Fabre S, Van Seuningen I, Triboulet JP. 
Pattern of recurrence following complete resection of oesophageal carcinoma and 
factors predictive of recurrent disease. Cancer 2003;97(7):1616-23. 
177 
 
24. Wu PC, Posner MC. The role of surgery in the management of oesophageal 
cancer. Lancet Oncol 2003;4(8):481-8. 
25. Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens 
P, et al. Extended transthoracic resection compared with limited transhiatal 
resection for adenocarcinoma of the esophagus. N Engl J Med 
2002;347(21):1662-9. 
26. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin 
as a model system. Cancer Cells 1990;2(8-9):275-80. 
27. Dive C, Hickman JA. Drug-target interactions: only the first step in the 
commitment to a programmed cell death? Br J Cancer 1991;64(1):192-6. 
28. Schmitt CA, Lowe SW. Apoptosis and therapy. J Pathol 1999;187(1):127-37. 
29. Itakura Y, Sasano H, Shiga C, Furukawa Y, Shiga K, Mori S, et al. Epidermal 
growth factor receptor overexpression in oesophageal carcinoma. An 
immunohistochemical study correlated with clinicopathologic findings and DNA 
amplification. Cancer 1994;74(3):795-804. 
30. Kitagawa Y, Ueda M, Ando N, Ozawa S, Shimizu N, Kitajima M. Further 
evidence for prognostic significance of epidermal growth factor receptor gene 
amplification in patients with oesophageal squamous cell carcinoma. Clin Cancer 
Res 1996;2(5):909-14. 
31. Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and 
oncogenesis: signal diversification through combinatorial ligand-receptor 
interactions. FEBS Lett 1997;410(1):83-6. 
32. Jankowski J, Coghill G, Hopwood D, Wormsley KG. Oncogenes and onco-
suppressor gene in adenocarcinoma of the oesophagus. Gut 1992;33(8):1033-8. 
33. Kim R, Clarke MR, Melhem MF, Young MA, Vanbibber MM, Safatle-Ribeiro 
AV, et al. Expression of p53, PCNA, and C-erbB-2 in Barrett's metaplasia and 
adenocarcinoma. Dig Dis Sci 1997;42(12):2453-62. 
34. Flejou JF, Paraf F, Muzeau F, Fekete F, Henin D, Jothy S, et al. Expression of c-
erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and 
prognostic correlations. J Clin Pathol 1994;47(1):23-6. 
178 
 
35. Shiga K, Shiga C, Sasano H, Miyazaki S, Yamamoto T, Yamamoto M, et al. 
Expression of c-erbB-2 in human oesophageal carcinoma cells: overexpression 
correlated with gene amplification or with GATA-3 transcription factor 
expression. Anticancer Res 1993;13(5A):1293-301. 
36. Suwanagool P, Parichatikanond P, Maeda S. Expression of c-erbB-2 oncoprotein 
in primary human tumors: an immunohistochemistry study. Asian Pac J Allergy 
Immunol 1993;11(2):119-22. 
37. Blount PL, Ramel S, Raskind WH, Haggitt RC, Sanchez CA, Dean PJ, et al. 17p 
allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma. 
Cancer Res 1991;51(20):5482-6. 
38. Meltzer SJ, Yin J, Huang Y, McDaniel TK, Newkirk C, Iseri O, et al. Reduction 
to homozygosity involving p53 in oesophageal cancers demonstrated by the 
polymerase chain reaction. Proc Natl Acad Sci U S A 1991;88(11):4976-80. 
39. Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G. 
Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex 
vivo induction by bile salts and acid exposure. Gastroenterology 
2000;118(3):487-96. 
40. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible 
nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated 
adenocarcinomas. Cancer Res 1998;58(14):2929-34. 
41. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K. 
Cyclooxygenase-2 expression in human oesophageal carcinoma. Cancer Res 
1999;59(1):198-204. 
42. Wittekind C. TNM atlas : illustrated guide to the TNM classification of 
malignant tumours. 5th ed. ed. Hoboken, N.J.: Wiley-Liss, 2008, 2005. 
43. Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L. Subtotal 
versus total gastrectomy for gastric cancer: five-year survival rates in a 
multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. 
Ann Surg 1999;230(2):170-8. 
44. Cotran RS, Kumar V, Robbins SL. Robbins pathologic basis of disease. 5th ed. 
Philadelphia: Saunders, 1994. 
179 
 
45. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: 
Globocan 2000. Int J Cancer 2001;94(2):153-6. 
46. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 
2001;2(9):533-43. 
47. Schwartz GK. Invasion and metastases in gastric cancer: in vitro and in vivo 
models with clinical correlations. Semin Oncol 1996;23(3):316-24. 
48. Green D, Ponce de Leon S, Leon-Rodriguez E, Sosa-Sanchez R. 
Adenocarcinoma of the stomach: univariate and multivariate analysis of factors 
associated with survival. Am J Clin Oncol 2002;25(1):84-9. 
49. Msika S, Benhamiche AM, Jouve JL, Rat P, Faivre J. Prognostic factors after 
curative resection for gastric cancer. A population-based study. Eur J Cancer 
2000;36(3):390-6. 
50. Harrison LE, Karpeh MS, Brennan MF. Extended lymphadenectomy is 
associated with a survival benefit for node-negative gastric cancer. J Gastrointest 
Surg 1998;2(2):126-31. 
51. Keighley MR. Gastrointestinal cancers in Europe. Aliment Pharmacol Ther 
2003;18 Suppl 3:7-30. 
52. Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, 
pathology and treatment. Ann Oncol 2003;14 Suppl 2:ii31-6. 
53. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin 
Epidemiol 2003;56(1):1-9. 
54. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. 
Gastric cancer. Crit Rev Oncol Hematol 2005;54(3):209-41. 
55. Gillison EW, Powell J, McConkey CC, Spychal RT. Surgical workload and 
outcome after resection for carcinoma of the oesophagus and cardia. Br J Surg 
2002;89(3):344-8. 
56. Fielding JW, Ellis DJ, Jones BG, Paterson J, Powell DJ, Waterhouse JA, et al. 
Natural history of "early" gastric cancer: results of a 10-year regional survey. Br 
Med J 1980;281(6246):965-7. 
180 
 
57. Micheli A, Mugno E, Krogh V, Quinn MJ, Coleman M, Hakulinen T, et al. 
Cancer prevalence in European registry areas. Ann Oncol 2002;13(6):840-65. 
58. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the 
cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18(3):581-92. 
59. Roazzi P, Capocaccia R, Santaquilani M, Carrani E. Electronic availability of 
EUROCARE-3 data: a tool for further analysis. Ann Oncol 2003;14 Suppl 
5:v150-5. 
60. Hohenberger P, Gretschel S. Gastric cancer. Lancet 2003;362(9380):305-15. 
61. Maehara Y, Kakeji Y, Koga T, Emi Y, Baba H, Akazawa K, et al. Therapeutic 
value of lymph node dissection and the clinical outcome for patients with gastric 
cancer. Surgery 2002;131(1 Suppl):S85-91. 
62. Tunaci M. Carcinoma of stomach and duodenum: radiologic diagnosis and 
staging. Eur J Radiol 2002;42(3):181-92. 
63. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 
2005;16(3):481-8. 
64. Ferlay J, International Agency for Research on Cancer., International 
Association of Cancer Registries. CI5VII electronic database of Cancer incidence 
in five continents, vol. VII. IARC cancerBase no. 2. Lyon, France: International 
Agency for Research on Cancer, 1997:2 computer disks. 
65. Roder JD, Bottcher K, Siewert JR, Busch R, Hermanek P, Meyer HJ. Prognostic 
factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 
1992. Cancer 1993;72(7):2089-97. 
66. Westblom TU. Gastroduodenal disease and helicobacter pylori: 
pathophysiology, diagnosis and treatment. Berlin ; New York: Springer, 1999. 
67. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF, Jr. Rising incidence of 
adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265(10):1287-
9. 
68. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on 
poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth 
181 
 
Edition American Joint Committee on Cancer staging, proximal disease, and the 
"different disease" hypothesis. Cancer 2000;88(4):921-32. 
69. Yang L, Parkin DM, Whelan S, Zhang S, Chen Y, Lu F, et al. Statistics on 
cancer in China: cancer registration in 2002. Eur J Cancer Prev 2005;14(4):329-
35. 
70. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer 
J Clin 2005;55(2):74-108. 
71. Stemmermann GN. Intestinal metaplasia of the stomach. A status report. Cancer 
1994;74(2):556-64. 
72. Correa P. Clinical implications of recent developments in gastric cancer 
pathology and epidemiology. Semin Oncol 1985;12(1):2-10. 
73. Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric 
cancer epidemiology. Lancet 1975;2(7924):58-60. 
74. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--
First American Cancer Society Award Lecture on Cancer Epidemiology and 
Prevention. Cancer Res 1992;52(24):6735-40. 
75. Goldstein NS, Lewin KJ. Gastric epithelial dysplasia and adenoma: historical 
review and histological criteria for grading. Hum Pathol 1997;28(2):127-33. 
76. Jass JR, Sobin LH, Watanabe H. The World Health Organization's histologic 
classification of gastrointestinal tumors. A commentary on the second edition. 
Cancer 1990;66(10):2162-7. 
77. Ming SC. Gastric carcinoma. A pathobiological classification. Cancer 
1977;39(6):2475-85. 
78. Mulligan RM. Histogenesis and biologic behavior of gastric carcinoma. Pathol 
Annu 1972;7:349-415. 
79. Lauren P. The Two Histological Main Types of Gastric Carcinoma: Diffuse and 
So-Called Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical 
Classification. Acta Pathol Microbiol Scand 1965;64:31-49. 
182 
 
80. Goseki N, Takizawa T, Koike M. Differences in the mode of the extension of 
gastric cancer classified by histological type: new histological classification of 
gastric carcinoma. Gut 1992;33(5):606-12. 
81. An JY, Kang TH, Choi MG, Noh JH, Sohn TS, Kim S. Borrmann type IV: an 
independent prognostic factor for survival in gastric cancer. J Gastrointest Surg 
2008;12(8):1364-9. 
82. Luebke T, Baldus SE, Grass G, Bollschweiler E, Thiele J, Dienes HP, et al. 
Histological grading in gastric cancer by Ming classification: correlation with 
histopathological subtypes, metastasis, and prognosis. World J Surg 
2005;29(11):1422-7; discussion 1428. 
83. Borchard F. Classification of gastric carcinoma. Hepatogastroenterology 
1990;37(2):223-32. 
84. Songun I, van de Velde CJ, Arends JW, Blok P, Grond AJ, Offerhaus GJ, et al. 
Classification of gastric carcinoma using the Goseki system provides prognostic 
information additional to TNM staging. Cancer 1999;85(10):2114-8. 
85. Fenoglio-Preiser CM, Wang J, Stemmermann GN, Noffsinger A. TP53 and 
gastric carcinoma: a review. Hum Mutat 2003;21(3):258-70. 
86. Vauhkonen M, Vauhkonen H, Sipponen P. Pathology and molecular biology of 
gastric cancer. Best Pract Res Clin Gastroenterol 2006;20(4):651-74. 
87. Siriwardena BS, Tilakaratne A, Amaratunga EA, Udagama MN, Ogawa I, Kudo 
Y, et al. Analysis of histopathological and immunohistochemical differences of 
oral squamous cell carcinoma in young and old patients in Sri Lanka. J Oral 
Pathol Med 2007;36(6):357-62. 
88. Hallissey MT, Allum WH, Jewkes AJ, Ellis DJ, Fielding JW. Early detection of 
gastric cancer. BMJ 1990;301(6751):513-5. 
89. Low VH, Levine MS, Rubesin SE, Laufer I, Herlinger H. Diagnosis of gastric 
carcinoma: sensitivity of double-contrast barium studies. AJR Am J Roentgenol 
1994;162(2):329-34. 
90. Sakita T, Oguro Y, Takasu S, Fukutomi H, Miwa T. Observations on the healing 
of ulcerations in early gastric cancer. The life cycle of the malignant ulcer. 
Gastroenterology 1971;60(5):835-9 passim. 
183 
 
91. Levine TS, Price AB. Helicobacter pylori: enough to give anyone an ulcer! Br J 
Clin Pract 1993;47(6):328-32. 
92. Winawer SJ, Posner G, Lightdale CJ, Sherlock P, Melamed M, Fortner JG. 
Endoscopic diagnosis of advanced gastric cancer. Factors influencing yield. 
Gastroenterology 1975;69(6):1183-7. 
93. Silvis SE, Nebel O, Rogers G, Sugawa C, Mandelstam P. Endoscopic 
complications. Results of the 1974 American Society for Gastrointestinal 
Endoscopy Survey. JAMA 1976;235(9):928-30. 
94. Dooley CP, Larson AW, Stace NH, Renner IG, Valenzuela JE, Eliasoph J, et al. 
Double-contrast barium meal and upper gastrointestinal endoscopy. A 
comparative study. Ann Intern Med 1984;101(4):538-45. 
95. Boyce GA. Endoscopic evaluation of the patient with oesophageal carcinoma. 
Chest Surg Clin N Am 1994;4(2):257-68. 
96. Kurihara M, Shirakabe H, Yarita T, Izumi T, Miyasaka K, Maruyama T, et al. 
Diagnosis of small early gastric cancer by X-ray, endoscopy, and biopsy. Cancer 
Detect Prev 1981;4(1-4):377-83. 
97. Kurtz RC, Sherlock P. The diagnosis of gastric cancer. Semin Oncol 
1985;12(1):11-8. 
98. Graham DY, Schwartz JT, Cain GD, Gyorkey F. Prospective evaluation of 
biopsy number in the diagnosis of oesophageal and gastric carcinoma. 
Gastroenterology 1982;82(2):228-31. 
99. Stadtlander CT, Waterbor JW. Molecular epidemiology, pathogenesis and 
prevention of gastric cancer. Carcinogenesis 1999;20(12):2195-208. 
100. Yasui W, Oue N, Kuniyasu H, Ito R, Tahara E, Yokozaki H. Molecular 
diagnosis of gastric cancer: present and future. Gastric Cancer 2001;4(3):113-21. 
101. Hakama M, Stenman UH, Knekt P, Jarvisalo J, Leino A, Hakulinen T, et al. 
Tumour markers and screening for gastrointestinal cancer: a follow up study in 
Finland. J Med Screen 1994;1(1):60-4. 
102. Posner MR, Mayer RJ. The use of serologic tumor markers in gastrointestinal 
malignancies. Hematol Oncol Clin North Am 1994;8(3):533-53. 
184 
 
103. Pectasides D, Mylonakis A, Kostopoulou M, Papadopoulou M, Triantafillis D, 
Varthalitis J, et al. CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma. 
Am J Clin Oncol 1997;20(4):348-53. 
104. Yamada Y, Yoshida T, Hayashi K, Sekiya T, Yokota J, Hirohashi S, et al. p53 
gene mutations in gastric cancer metastases and in gastric cancer cell lines 
derived from metastases. Cancer Res 1991;51(21):5800-5. 
105. Correa P, Shiao YH. Phenotypic and genotypic events in gastric 
carcinogenesis. Cancer Res 1994;54(7 Suppl):1941s-1943s. 
106. Xiangming C, Hokita S, Natsugoe S, Tanabe G, Baba M, Takao S, et al. p21 
expression is a prognostic factor in patients with p53-negative gastric cancer. 
Cancer Lett 2000;148(2):181-8. 
107. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, et al. 
Prognostic value of vascular endothelial growth factor expression in gastric 
carcinoma. Cancer 1996;77(5):858-63. 
108. Araya M, Terashima M, Takagane A, Abe K, Nishizuka S, Yonezawa H, et al. 
Microvessel count predicts metastasis and prognosis in patients with gastric 
cancer. J Surg Oncol 1997;65(4):232-6. 
109. Jonjic N, Kovac K, Krasevic M, Valkovic T, Ernjak N, Sasso F, et al. 
Epidermal growth factor-receptor expression correlates with tumor cell 
proliferation and prognosis in gastric cancer. Anticancer Res 1997;17(5B):3883-
8. 
110. Takano Y, Kato Y, van Diest PJ, Masuda M, Mitomi H, Okayasu I. Cyclin D2 
overexpression and lack of p27 correlate positively and cyclin E inversely with a 
poor prognosis in gastric cancer cases. Am J Pathol 2000;156(2):585-94. 
111. Tsujitani S, Oka A, Kondo A, Katano K, Oka S, Saito H, et al. Administration 
in a hypotonic solution is preferable to dose escalation in intraperitoneal cisplatin 
chemotherapy for peritoneal carcinomatosis in rats. Oncology 1999;57(1):77-82. 
112. Kikuyama S, Kubota T, Shimizu K, Miyakita M. Ki-67 antigen expression in 
relation to clinicopathological variables and prognosis in gastric cancer. Oncol 
Rep 1998;5(4):867-70. 
185 
 
113. Rugge M, Sonego F, Panozzo M, Baffa R, Rubio J, Jr., Farinati F, et al. 
Pathology and ploidy in the prognosis of gastric cancer with no extranodal 
metastasis. Cancer 1994;73(4):1127-33. 
114. Yonemura Y, Fonseca L, Tsugawa K, Ninomiya I, Matsumoto H, Sugiyama K, 
et al. Prediction of lymph node metastasis and prognosis from the assay of the 
expression of proliferating cell nuclear antigen and DNA ploidy in gastric cancer. 
Oncology 1994;51(3):251-7. 
115. Catalano V, Baldelli AM, Giordani P, Cascinu S. Molecular markers predictive 
of response to chemotherapy in gastrointestinal tumors. Crit Rev Oncol Hematol 
2001;38(2):93-104. 
116. Pollack BJ, Chak A, Sivak MV, Jr. Endoscopic ultrasonography. Semin Oncol 
1996;23(3):336-46. 
117. Dittler HJ, Siewert JR. Role of endoscopic ultrasonography in gastric 
carcinoma. Endoscopy 1993;25(2):162-6. 
118. Botet JF, Lightdale CJ, Zauber AG, Gerdes H, Winawer SJ, Urmacher C, et al. 
Preoperative staging of gastric cancer: comparison of endoscopic US and 
dynamic CT. Radiology 1991;181(2):426-32. 
119. Gupta N, Bradfield H. Role of positron emission tomography scanning in 
evaluating gastrointestinal neoplasms. Semin Nucl Med 1996;26(1):65-73. 
120. Tschmelitsch J, Weiser MR, Karpeh MS. Modern staging in gastric cancer. 
Surg Oncol 2000;9(1):23-30. 
121. Sayegh ME, Sano T, Dexter S, Katai H, Fukagawa T, Sasako M. TNM and 
Japanese staging systems for gastric cancer: how do they coexist? Gastric Cancer 
2004;7(3):140-8. 
122. Sobin LH, Wittekind C, International Union against Cancer. TNM : 
classification of malignant tumours. 6th ed. New York: Wiley-Liss, 2002. 
123. Greene FL. AJCC cancer staging handbook from the AJCC cancer staging 
manual. 6th ed. New York: Springer, 2002:xv, 469 p. 
124. Japanese Gastric Cancer A. Japanese Classification of Gastric Carcinoma - 2nd 
English Edition. Gastric Cancer 1998;1(1):10-24. 
186 
 
125. Adachi Y, Oshiro T, Okuyama T, Kamakura T, Mori M, Maehara Y, et al. A 
simple classification of lymph node level in gastric carcinoma. Am J Surg 
1995;169(4):382-5. 
126. Whiting JL, Hallissey MT, Rowlands DC, Fielding JW. Redefining surgery for 
gastric cancer. Gastric Cancer 1999;2(4):226-229. 
127. Kato M, Saji S, Kawaguchi Y, Kunieda K, Sugiyama Y, Takagi Y, et al. A 
comparison of the prognostic significance between the number of metastatic 
lymph nodes and nodal stage in gastric carcinoma. Hepatogastroenterology 
1999;46(30):3281-6. 
128. Ukrisana P, Wangwinyuvirat M. Evaluation of the sensitivity of the double-
contrast upper gastrointestinal series in the diagnosis of gastric cancer. J Med 
Assoc Thai 2004;87(1):80-6. 
129. Rougier P, Lasser P, Ducreux M, Mahjoubi M, Bognel C, Elias D. Preoperative 
chemotherapy of locally advanced gastric cancer. Ann Oncol 1994;5 Suppl 3:59-
68. 
130. Role of endoscopic ultrasonography. American Society for Gastrointestinal 
Endoscopy. Gastrointest Endosc 2000;52(6):852-9. 
131. Savides TJ, Fisher AH, Jr., Gress FG, Hawes RH, Lightdale CJ. 1999 ASGE 
endoscopic ultrasound survey. ASGE Ad Hoc Endoscopic Ultrasound 
Committee. Gastrointest Endosc 2000;52(6):745-50. 
132. Ajani JA, Mayer RJ, Ota DM, Steele GD, Evans D, Roh M, et al. Preoperative 
and postoperative combination chemotherapy for potentially resectable gastric 
carcinoma. J Natl Cancer Inst 1993;85(22):1839-44. 
133. Ajani JA, Ota DM, Jessup JM, Ames FC, McBride C, Boddie A, et al. 
Resectable gastric carcinoma. An evaluation of preoperative and postoperative 
chemotherapy. Cancer 1991;68(7):1501-6. 
134. Alexander HR, Grem JL, Pass HI, Hamilton M, McAtee N, Fraker DL, et al. 
Neoadjuvant chemotherapy for locally advanced gastric adenocarcinoma. 
Oncology (Williston Park) 1993;7(5):37-42; discussion 42-4, 49-50, 53. 
135. Leichman L, Silberman H, Leichman CG, Spears CP, Ray M, Muggia FM, et 
al. Preoperative systemic chemotherapy followed by adjuvant postoperative 
187 
 
intraperitoneal therapy for gastric cancer: a University of Southern California 
pilot program. J Clin Oncol 1992;10(12):1933-42. 
136. Songun I, Keizer HJ, Hermans J, Klementschitsch P, de Vries JE, Wils JA, et 
al. Chemotherapy for operable gastric cancer: results of the Dutch randomised 
FAMTX trial. The Dutch Gastric Cancer Group (DGCG). Eur J Cancer 
1999;35(4):558-62. 
137. Millikan KW, Silverstein J, Hart V, Blair K, Bines S, Roberts J, et al. A 15-
year review of esophagectomy for carcinoma of the esophagus and cardia. Arch 
Surg 1995;130(6):617-24. 
138. Lerut T, Coosemans W, Decker G, De Leyn P, Moons J, Nafteux P, et al. 
Extended surgery for cancer of the esophagus and gastro-oesophageal junction. J 
Surg Res 2004;117(1):58-63. 
139. Weber WA, Ott K. Imaging of oesophageal and gastric cancer. Semin Oncol 
2004;31(4):530-41. 
140. Boring CC, Squires TS, Tong T. Cancer statistics, 1993. CA Cancer J Clin 
1993;43(1):7-26. 
141. Moriguchi S, Maehara Y, Korenaga D, Sugimachi K, Hayashi Y, Nose Y. 
Prediction of survival time after curative surgery for advanced gastric cancer. Eur 
J Surg Oncol 1992;18(3):287-92. 
142. Kelsen D, Karpeh M, Schwartz G, Gerdes H, Lightdale C, Botet J, et al. 
Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative 
FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous 
fluorouracil. J Clin Oncol 1996;14(6):1818-28. 
143. Kelsen DP. Adjuvant and neoadjuvant therapy for gastric cancer. Semin Oncol 
1996;23(3):379-89. 
144. Enzinger PC, Ilson DH, Kelsen DP. Chemotherapy in oesophageal cancer. 
Semin Oncol 1999;26(5 Suppl 15):12-20. 
145. De Besi P, Sileni VC, Salvagno L, Tremolada C, Cartei G, Fosser V, et al. 
Phase II study of cisplatin, 5-FU, and allopurinol in advanced oesophageal 
cancer. Cancer Treat Rep 1986;70(7):909-10. 
188 
 
146. Ilson DH, Forastiere A, Arquette M, Costa F, Heelan R, Huang Y, et al. A 
phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of 
the esophagus. Cancer J 2000;6(5):316-23. 
147. Silberman H. Perioperative adjunctive treatment in the management of operable 
gastric cancer. J Surg Oncol 2005;90(3):174-86; discussion 186-7. 
148. Lordick F, Siewert JR. Recent advances in multimodal treatment for gastric 
cancer: a review. Gastric Cancer 2005;8(2):78-85. 
149. Fareed KR, Kaye P, Soomro IN, Ilyas M, Martin S, Parsons SL, et al. 
Biomarkers of response to therapy in oesophago-gastric cancer. Gut 
2009;58(1):127-43. 
150. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, 
Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable 
gastro-oesophageal cancer. N Engl J Med 2006;355(1):11-20. 
151. Law SY, Fok M, Cheng SW, Wong J. A comparison of outcome after resection 
for squamous cell carcinomas and adenocarcinomas of the esophagus and cardia. 
Surg Gynecol Obstet 1992;175(2):107-12. 
152. Lerut T, De Leyn P, Coosemans W, Van Raemdonck D, Scheys I, LeSaffre E. 
Surgical strategies in oesophageal carcinoma with emphasis on radical 
lymphadenectomy. Ann Surg 1992;216(5):583-90. 
153. Lieberman MD, Shriver CD, Bleckner S, Burt M. Carcinoma of the esophagus. 
Prognostic significance of histologic type. J Thorac Cardiovasc Surg 
1995;109(1):130-8; discussion 139. 
154. Orringer MB. Multimodality therapy for oesophageal carcinoma--update. Chest 
1993;103(4 Suppl):406S-409S. 
155. Andreyev HJ, Norman AR, Cunningham D, Padhani AR, Hill AS, Ross PJ, et 
al. Squamous oesophageal cancer can be downstaged using protracted venous 
infusion of 5-fluorouracil with epirubicin and cisplatin (ECF). Eur J Cancer 
1995;31A(13-14):2209-14. 
156. Bamias A, Hill ME, Cunningham D, Norman AR, Ahmed FY, Webb A, et al. 
Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for 
189 
 
esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival. 
Cancer 1996;77(10):1978-85. 
157. Geh JI, Glynne-Jones R, Kwok QS, Banerji U, Livingstone JI, Townsend ER, 
et al. Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma. 
Clin Oncol (R Coll Radiol) 2000;12(3):182-7. 
158. Melcher AA, Mort D, Maughan TS. Epirubicin, cisplatin and continuous 
infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-
oesophageal cancer. Br J Cancer 1996;74(10):1651-4. 
159. Forshaw MJ, Gossage JA, Chrystal K, Cheong K, Atkinson S, Botha A, et al. 
Neoadjuvant chemotherapy for locally advanced carcinoma of the lower 
oesophagus and oesophago-gastric junction. Eur J Surg Oncol 2006;32(10):1114-
8. 
160. Forshaw MJ, Gossage JA, Stephens J, Strauss D, Botha AJ, Atkinson S, et al. 
Centralisation of oesophagogastric cancer services: can specialist units deliver? 
Ann R Coll Surg Engl 2006;88(6):566-70. 
161. Wilke H, Preusser P, Fink U, Achterrath W, Meyer HJ, Stahl M, et al. New 
developments in the treatment of gastric carcinoma. Semin Oncol 1990;17(1 
Suppl 2):61-70. 
162. Ajani JA, Roth JA, Ryan MB, Putnam JB, Pazdur R, Levin B, et al. Intensive 
preoperative chemotherapy with colony-stimulating factor for resectable 
adenocarcinoma of the esophagus or gastro-oesophageal junction. J Clin Oncol 
1993;11(1):22-8. 
163. Schuhmacher CP, Fink U, Becker K, Busch R, Dittler HJ, Mueller J, et al. 
Neoadjuvant therapy for patients with locally advanced gastric carcinoma with 
etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-
up. Cancer 2001;91(5):918-27. 
164. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response 
to neoadjuvant chemotherapy best predicts survival after curative resection of 
gastric cancer. Ann Surg 1999;229(3):303-8. 
190 
 
165. Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, et al. 
Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: 
results of a randomized trial. Br J Cancer 1999;80(1-2):269-72. 
166. Middleton G, Cunningham D. Current options in the management of 
gastrointestinal cancer. Ann Oncol 1995;6 Suppl 1:17-25; discussion 25-6. 
167. Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in 
Japan and its limits of radicality. World J Surg 1987;11(4):418-25. 
168. Theuer CP, Kurosaki T, Ziogas A, Butler J, Anton-Culver H. Asian patients 
with gastric carcinoma in the United States exhibit unique clinical features and 
superior overall and cancer specific survival rates. Cancer 2000;89(9):1883-92. 
169. Schlemper RJ, Itabashi M, Kato Y, Lewin KJ, Riddell RH, Shimoda T, et al. 
Differences in diagnostic criteria for gastric carcinoma between Japanese and 
western pathologists. Lancet 1997;349(9067):1725-9. 
170. Volpe CM, Driscoll DL, Douglass HO, Jr. Outcome of patients with proximal 
gastric cancer depends on extent of resection and number of resected lymph 
nodes. Ann Surg Oncol 2000;7(2):139-44. 
171. Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, et al. 
Adjuvant therapy after curative resection for gastric cancer: meta-analysis of 
randomized trials. J Clin Oncol 1993;11(8):1441-7. 
172. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for 
gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised 
trials. Eur J Cancer 1999;35(7):1059-64. 
173. Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, et al. Efficacy 
of adjuvant chemotherapy after curative resection for gastric cancer: a meta-
analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano 
per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 
2000;11(7):837-43. 
174. Janunger KG, Hafstrom L, Nygren P, Glimelius B. A systematic overview of 
chemotherapy effects in gastric cancer. Acta Oncol 2001;40(2-3):309-26. 
191 
 
175. Gianni L, Panzini I, Tassinari D, Mianulli AM, Desiderio F, Ravaioli A. Meta-
analyses of randomized trials of adjuvant chemotherapy in gastric cancer. Ann 
Oncol 2001;12(8):1178-80. 
176. Hu JK, Chen ZX, Zhou ZG, Zhang B, Tian J, Chen JP, et al. Intravenous 
chemotherapy for resected gastric cancer: meta-analysis of randomized controlled 
trials. World J Gastroenterol 2002;8(6):1023-8. 
177. Janunger KG, Hafstrom L, Glimelius B. Chemotherapy in gastric cancer: a 
review and updated meta-analysis. Eur J Surg 2002;168(11):597-608. 
178. Agboola O. Adjuvant treatment in gastric cancer. Cancer Treat Rev 
1994;20(3):217-40. 
179. Lim L, Michael M, Mann GB, Leong T. Adjuvant therapy in gastric cancer. J 
Clin Oncol 2005;23(25):6220-32. 
180. Chua YJ, Cunningham D. The UK NCRI MAGIC trial of perioperative 
chemotherapy in resectable gastric cancer: implications for clinical practice. Ann 
Surg Oncol 2007;14(10):2687-90. 
181. Park DJ, Lenz HJ. Determinants of chemosensitivity in gastric cancer. Curr 
Opin Pharmacol 2006;6(4):337-44. 
182. Wilke H, Preusser P, Fink U, Gunzer U, Meyer HJ, Meyer J, et al. Preoperative 
chemotherapy in locally advanced and nonresectable gastric cancer: a phase II 
study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 1989;7(9):1318-
26. 
183. Hartgrink HH, van de Velde CJ, Putter H, Songun I, Tesselaar ME, Kranenbarg 
EK, et al. Neo-adjuvant chemotherapy for operable gastric cancer: long term 
results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 2004;30(6):643-
9. 
184. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, et 
al. Chemotherapy followed by surgery compared with surgery alone for localized 
oesophageal cancer. N Engl J Med 1998;339(27):1979-84. 
185. Crookes P, Leichman CG, Leichman L, Tan M, Laine L, Stain S, et al. 
Systemic chemotherapy for gastric carcinoma followed by postoperative 
intraperitoneal therapy: a final report. Cancer 1997;79(9):1767-75. 
192 
 
186. Siewert JR, Fink U, Sendler A, Becker K, Bottcher K, Feldmann HJ, et al. 
Gastric Cancer. Curr Probl Surg 1997;34(11):835-939. 
187. Ott K, Vogelsang H, Mueller J, Becker K, Muller M, Fink U, et al. 
Chromosomal instability rather than p53 mutation is associated with response to 
neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. Clin Cancer Res 
2003;9(6):2307-15. 
188. Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin 
Oncol 1988;6(10):1653-64. 
189. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action 
and clinical strategies. Nat Rev Cancer 2003;3(5):330-8. 
190. Spears CP, Gustavsson BG, Mitchell MS, Spicer D, Berne M, Bernstein L, et 
al. Thymidylate synthetase inhibition in malignant tumors and normal liver of 
patients given intravenous 5-fluorouracil. Cancer Res 1984;44(9):4144-50. 
191. Nakamura H, Yu-Qin W, Miyauchi S, Nishioka N, Tanaka H, Harada N, et al. 
[Studies on the mechanism of antitumor activity of 5-FU and its derivatives--
relationship between the inhibition of tumor growth and the inhibition of 
thymidylate synthetase in vivo]. Gan To Kagaku Ryoho 1984;11(5):1049-55. 
192. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg 
PV, et al. Thymidylate synthase gene and protein expression correlate and are 
associated with response to 5-fluorouracil in human colorectal and gastric tumors. 
Cancer Res 1995;55(7):1407-12. 
193. An Q, Robins P, Lindahl T, Barnes DE. 5-Fluorouracil incorporated into DNA 
is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity. Cancer 
Res 2007;67(3):940-5. 
194. Inada T, Ichikawa A, Igarashi S, Kubota T, Ogata Y. Effect of preoperative 5-
fluorouracil on apoptosis of advanced gastric cancer. J Surg Oncol 
1997;65(2):106-10. 
195. van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De 
Abreu RA, et al. Clinical implications of dihydropyrimidine dehydrogenase 
(DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: 
193 
 
identification of new mutations in the DPD gene. Clin Cancer Res 
2000;6(12):4705-12. 
196. Venturini M. Rational development of capecitabine. Eur J Cancer 2002;38 
Suppl 2:3-9. 
197. Schoffski P. The modulated oral fluoropyrimidine prodrug S-1, and its use in 
gastrointestinal cancer and other solid tumors. Anticancer Drugs 2004;15(2):85-
106. 
198. Beck DJ, Brubaker RR. Effect of cis-platinum(II)diamminodichloride on wild 
type and deoxyribonucleic acid repair deficient mutants of Escherichia coli. J 
Bacteriol 1973;116(3):1247-52. 
199. Konishi H, Usui T, Sawada H, Uchino H, Kidani Y. Effects of anticancer 
platinum compounds on Escherichia coli strains with normal and defective DNA 
repair capacity. Gann 1981;72(4):627-30. 
200. Fram RJ, Cusick PS, Marinus MG. Studies on mutagenesis and repair induced 
by platinum analogs. Mutat Res 1986;173(1):13-8. 
201. Popoff SC, Beck DJ, Rupp WD. Repair of plasmid DNA damaged in vitro with 
cis- or trans-diamminedichloroplatinum(II) in Escherichia coli. Mutat Res 
1987;183(2):129-37. 
202. Salles B, Butour JL, Lesca C, Macquet JP. cis-Pt(NH3)2Cl2 and trans-
Pt(NH3)2Cl2 inhibit DNA synthesis in cultured L1210 leukemia cells. Biochem 
Biophys Res Commun 1983;112(2):555-63. 
203. Ciccarelli RB, Solomon MJ, Varshavsky A, Lippard SJ. In vivo effects of cis- 
and trans-diamminedichloroplatinum(II) on SV40 chromosomes: differential 
repair, DNA-protein cross-linking, and inhibition of replication. Biochemistry 
1985;24(26):7533-40. 
204. Sorenson CM, Barry MA, Eastman A. Analysis of events associated with cell 
cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 
1990;82(9):749-55. 
205. Sorenson CM, Eastman A. Mechanism of cis-diamminedichloroplatinum(II)-
induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer 
Res 1988;48(16):4484-8. 
194 
 
206. Deeks ED, Scott LJ. Docetaxel: in gastric cancer. Drugs 2007;67(13):1893-
901. 
207. Farhat FS. A general review of the role of irinotecan (CPT11) in the treatment 
of gastric cancer. Med Oncol 2007;24(2):137-46. 
208. Izzo JG, Malhotra U, Wu TT, Ensor J, Luthra R, Lee JH, et al. Association of 
activated transcription factor nuclear factor kappab with chemoradiation 
resistance and poor outcome in oesophageal carcinoma. J Clin Oncol 
2006;24(5):748-54. 
209. Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 
2002;2(1):38-47. 
210. Boku N, Ohtsu A, Nagashima F, Shirao K, Koizumi W. Relationship between 
expression of vascular endothelial growth factor in tumor tissue from gastric 
cancers and chemotherapy effects: comparison between S-1 alone and the 
combination of S-1 plus CDDP. Jpn J Clin Oncol 2007;37(7):509-14. 
211. Chin L, Gray JW. Translating insights from the cancer genome into clinical 
practice. Nature 2008;452(7187):553-63. 
212. Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, et al. An anti-apoptotic 
protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 
2001;40(4):1117-23. 
213. Nakamura M, Tsuji N, Asanuma K, Kobayashi D, Yagihashi A, Hirata K, et al. 
Survivin as a predictor of cis-diamminedichloroplatinum sensitivity in gastric 
cancer patients. Cancer Sci 2004;95(1):44-51. 
214. Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, et al. 
Expression of survivin in oesophageal cancer: correlation with the prognosis and 
response to chemotherapy. Int J Cancer 2001;95(2):92-5. 
215. Kang SY, Han JH, Lee KJ, Choi JH, Park JI, Kim HI, et al. Low expression of 
Bax predicts poor prognosis in patients with locally advanced oesophageal cancer 
treated with definitive chemoradiotherapy. Clin Cancer Res 2007;13(14):4146-
53. 
195 
 
216. Mao XY, Wang XG, Lv XJ, Xu L, Han CB. COX-2 expression in gastric 
cancer and its relationship with angiogenesis using tissue microarray. World J 
Gastroenterol 2007;13(25):3466-71. 
217. Xi H, Baldus SE, Warnecke-Eberz U, Brabender J, Neiss S, Metzger R, et al. 
High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is 
associated with minor histopathologic response and poor prognosis in 
oesophageal cancer. Clin Cancer Res 2005;11(23):8341-7. 
218. Moehler M, Lyros O, Gockel I, Galle PR, Lang H. Multidisciplinary 
management of gastric and gastro-oesophageal cancers. World J Gastroenterol 
2008;14(24):3773-80. 
219. Denzer U, Hoffmann S, Helmreich-Becker I, Kauczor HU, Thelen M, Kanzler 
S, et al. Minilaparoscopy in the diagnosis of peritoneal tumor spread: prospective 
controlled comparison with computed tomography. Surg Endosc 
2004;18(7):1067-70. 
220. Dehdashti F, Siegel BA. Neoplasms of the esophagus and stomach. Semin Nucl 
Med 2004;34(3):198-208. 
221. Fitzgerald RC. Review article: Barrett's oesophagus and associated 
adenocarcinoma--a UK perspective. Aliment Pharmacol Ther 2004;20 Suppl 
8:45-9. 
222. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et 
al. Pathologic assessment of tumor regression after preoperative 
chemoradiotherapy of oesophageal carcinoma. Clinicopathologic correlations. 
Cancer 1994;73(11):2680-6. 
223. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et al. 
Histomorphology and grading of regression in gastric carcinoma treated with 
neoadjuvant chemotherapy. Cancer 2003;98(7):1521-30. 
224. Darnton SJ, Allen SM, Edwards CW, Matthews HR. Histopathological findings 
in oesophageal carcinoma with and without preoperative chemotherapy. J Clin 
Pathol 1993;46(1):51-5. 
196 
 
225. Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, et al. 
Posttherapy pathologic stage predicts survival in patients with oesophageal 
carcinoma receiving preoperative chemoradiation. Cancer 2005;103(7):1347-55. 
226. Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, et al. Failure 
patterns correlate with the proportion of residual carcinoma after preoperative 
chemoradiotherapy for carcinoma of the esophagus. Cancer 2005;104(7):1349-
55. 
227. Wheeler JM, Warren BF, Mortensen NJ, Ekanyaka N, Kulacoglu H, Jones AC, 
et al. Quantification of histologic regression of rectal cancer after irradiation: a 
proposal for a modified staging system. Dis Colon Rectum 2002;45(8):1051-6. 
228. Ryan R, Gibbons D, Hyland JM, Treanor D, White A, Mulcahy HE, et al. 
Pathological response following long-course neoadjuvant chemoradiotherapy for 
locally advanced rectal cancer. Histopathology 2005;47(2):141-6. 
229. Hermann RM, Horstmann O, Haller F, Perske C, Christiansen H, Hille A, et al. 
Histomorphological tumor regression grading of oesophageal carcinoma after 
neoadjuvant radiochemotherapy: which score to use? Dis Esophagus 
2006;19(5):329-34. 
230. Harpole DH, Jr., Moore MB, Herndon JE, 2nd, Aloia T, D'Amico TA, Sporn T, 
et al. The prognostic value of molecular marker analysis in patients treated with 
trimodality therapy for oesophageal cancer. Clin Cancer Res 2001;7(3):562-9. 
231. Hickey K, Grehan D, Reid IM, O'Briain S, Walsh TN, Hennessy TP. 
Expression of epidermal growth factor receptor and proliferating cell nuclear 
antigen predicts response of oesophageal squamous cell carcinoma to 
chemoradiotherapy. Cancer 1994;74(6):1693-8. 
232. Muro K, Ohtsu A, Boku N, Chin K, Oda Y, Fujii T, et al. Association of p53 
protein expression with responses and survival of patients with locally advanced 
oesophageal carcinoma treated with chemoradiotherapy. Jpn J Clin Oncol 
1996;26(2):65-9. 
233. Ribeiro U, Jr., Finkelstein SD, Safatle-Ribeiro AV, Landreneau RJ, Clarke MR, 
Bakker A, et al. p53 sequence analysis predicts treatment response and outcome 
of patients with oesophageal carcinoma. Cancer 1998;83(1):7-18. 
197 
 
234. Walsh TN, Grannell M, Mansoor S. Predictive factors for success of neo-
adjuvant therapy in upper gastrointestinal cancer. J Gastroenterol Hepatol 
2002;17 Suppl:S172-5. 
235. Brown LM, Devesa SS. Epidemiologic trends in oesophageal and gastric 
cancer in the United States. Surg Oncol Clin N Am 2002;11(2):235-56. 
236. el-Deiry WS. Role of oncogenes in resistance and killing by cancer therapeutic 
agents. Curr Opin Oncol 1997;9(1):79-87. 
237. Aitman TJ. DNA microarrays in medical practice. BMJ 2001;323(7313):611-5. 
238. Masuda N, Ohnishi T, Kawamoto S, Monden M, Okubo K. Analysis of 
chemical modification of RNA from formalin-fixed samples and optimization of 
molecular biology applications for such samples. Nucleic Acids Res 
1999;27(22):4436-43. 
239. Kitamura K, Saeki H, Kawaguchi H, Araki K, Ohno S, Kuwano H, et al. 
Immunohistochemical status of the p53 protein and Ki-67 antigen using biopsied 
specimens can predict a sensitivity to neoadjuvant therapy in patients with 
oesophageal cancer. Hepatogastroenterology 2000;47(32):419-23. 
240. Shimada Y, Watanabe G, Yamasaki S, Maeda M, Kawabe A, Kaganoi JI, et al. 
Histological response of cisplatin predicts patients' survival in oesophageal 
cancer and p53 protein accumulation in pretreatment biopsy is associated with 
cisplatin sensitivity. Eur J Cancer 2000;36(8):987-93. 
241. Sarbia M, Stahl M, Fink U, Heep H, Dutkowski P, Willers R, et al. Prognostic 
significance of cyclin D1 in oesophageal squamous cell carcinoma patients 
treated with surgery alone or combined therapy modalities. Int J Cancer 
1999;84(1):86-91. 
242. Moreira LF, Naomoto Y, Hamada M, Kamikawa Y, Orita K. Assessment of 
apoptosis in oesophageal carcinoma preoperatively treated by chemotherapy and 
radiotherapy. Anticancer Res 1995;15(2):639-44. 
243. Sarbia M, Stahl M, Fink U, Willers R, Seeber S, Gabbert HE. Expression of 
apoptosis-regulating proteins and outcome of oesophageal cancer patients treated 
by combined therapy modalities. Clin Cancer Res 1998;4(12):2991-7. 
198 
 
244. Benchimol S, Lamb P, Crawford LV, Sheer D, Shows TB, Bruns GA, et al. 
Transformation associated p53 protein is encoded by a gene on human 
chromosome 17. Somat Cell Mol Genet 1985;11(5):505-10. 
245. Oren M, Bienz B, Givol D, Rechavi G, Zakut R. Analysis of recombinant DNA 
clones specific for the murine p53 cellular tumor antigen. EMBO J 
1983;2(10):1633-9. 
246. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the 
demons of the guardian of the genome. Cancer Res 2000;60(24):6788-93. 
247. Kyrgidis A, Kountouras J, Zavos C, Chatzopoulos D. New molecular concepts 
of Barrett's esophagus: clinical implications and biomarkers. J Surg Res 
2005;125(2):189-212. 
248. McKee PH, Hobbs C, Hall PA. Antigen retrieval by microwave irradiation 
lowers immunohistological detection thresholds. Histopathology 1993;23(4):377-
9. 
249. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis 
modulates the cytotoxicity of anticancer agents. Cell 1993;74(6):957-67. 
250. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for 
rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88(20):1442-55. 
251. Chang F, Syrjanen S, Syrjanen K. Implications of the p53 tumor-suppressor 
gene in clinical oncology. J Clin Oncol 1995;13(4):1009-22. 
252. Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, et al. 
Aberrant p53 expression predicts clinical resistance to cisplatin-based 
chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 
1995;55(21):5038-42. 
253. Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, et al. 
A comparative study of p53 gene mutations, protein accumulation, and response 
to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 
1996;56(4):689-93. 
254. Kim JH, Takahashi T, Chiba I, Park JG, Birrer MJ, Roh JK, et al. Occurrence 
of p53 gene abnormalities in gastric carcinoma tumors and cell lines. J Natl 
Cancer Inst 1991;83(13):938-43. 
199 
 
255. Boku N, Chin K, Hosokawa K, Ohtsu A, Tajiri H, Yoshida S, et al. Biological 
markers as a predictor for response and prognosis of unresectable gastric cancer 
patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res 
1998;4(6):1469-74. 
256. Cascinu S, Graziano F, Del Ferro E, Staccioli MP, Ligi M, Carnevali A, et al. 
Expression of p53 protein and resistance to preoperative chemotherapy in locally 
advanced gastric carcinoma. Cancer 1998;83(9):1917-22. 
257. Nagashima F, Boku N, Ohtsu A, Yoshida S, Hasebe T, Ochiai A, et al. 
Biological markers as a predictor for response and prognosis of unresectable 
gastric cancer patients treated with irinotecan and cisplatin. Jpn J Clin Oncol 
2005;35(12):714-9. 
258. Nakata B, Chung KH, Ogawa M, Ogawa Y, Yanagawa K, Muguruma K, et al. 
p53 protein overexpression as a predictor of the response to chemotherapy in 
gastric cancer. Surg Today 1998;28(6):595-8. 
259. Bataille F, Rummele P, Dietmaier W, Gaag D, Klebl F, Reichle A, et al. 
Alterations in p53 predict response to preoperative high dose chemotherapy in 
patients with gastric cancer. Mol Pathol 2003;56(5):286-92. 
260. Forones NM, Carvalho AP, Giannotti-Filho O, Lourenco LG, Oshima CT. Cell 
proliferation and apoptosis in gastric cancer and intestinal metaplasia. Arq 
Gastroenterol 2005;42(1):30-4. 
261. Okumura H, Natsugoe S, Matsumoto M, Mataki Y, Takatori H, Ishigami S, et 
al. The predictive value of p53, p53R2, and p21 for the effect of chemoradiation 
therapy on oesophageal squamous cell carcinoma. Br J Cancer 2005;92(2):284-9. 
262. Sarbia M, Ott N, Puhringer-Oppermann F, Brucher BL. The predictive value of 
molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous 
cell carcinoma of the oesophagus. Br J Cancer 2007;97(10):1404-8. 
263. Akamatsu M, Matsumoto T, Oka K, Yamasaki S, Sonoue H, Kajiyama Y, et al. 
c-erbB-2 oncoprotein expression related to chemoradioresistance in oesophageal 
squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2003;57(5):1323-7. 
264. Gibson MK, Abraham SC, Wu TT, Burtness B, Heitmiller RF, Heath E, et al. 
Epidermal growth factor receptor, p53 mutation, and pathological response 
200 
 
predict survival in patients with locally advanced oesophageal cancer treated with 
preoperative chemoradiotherapy. Clin Cancer Res 2003;9(17):6461-8. 
265. Hamada M, Fujiwara T, Hizuta A, Gochi A, Naomoto Y, Takakura N, et al. 
The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in 
gastric and colorectal cancers. J Cancer Res Clin Oncol 1996;122(6):360-5. 
266. Kinzler KW, Vogelstein B. Cancer therapy meets p53. N Engl J Med 
1994;331(1):49-50. 
267. Duhaylongsod FG, Gottfried MR, Iglehart JD, Vaughn AL, Wolfe WG. The 
significance of c-erb B-2 and p53 immunoreactivity in patients with 
adenocarcinoma of the esophagus. Ann Surg 1995;221(6):677-83; discussion 
683-4. 
268. Seitz JF, Perrier H, Monges G, Giovannini M, Gouvernet J. [Multivariate 
analysis of the prognostic and predictive factors of response to concomitant 
radiochemotherapy in epidermoid cancers of the esophagus. Value of 
immunodetection of protein p53]. Gastroenterol Clin Biol 1995;19(5):465-74. 
269. Xia HH, Talley NJ. Apoptosis in gastric epithelium induced by Helicobacter 
pylori infection: implications in gastric carcinogenesis. Am J Gastroenterol 
2001;96(1):16-26. 
270. Yeh KH, Shun CT, Chen CL, Lin JT, Lee WJ, Lee PH, et al. Overexpression of 
p53 is not associated with drug resistance of gastric cancers to 5-fluorouracil-
based systemic chemotherapy. Hepatogastroenterology 1999;46(25):610-5. 
271. Fondevila C, Metges JP, Fuster J, Grau JJ, Palacin A, Castells A, et al. p53 and 
VEGF expression are independent predictors of tumour recurrence and survival 
following curative resection of gastric cancer. Br J Cancer 2004;90(1):206-15. 
272. Pinto-de-Sousa J, Silva F, David L, Leitao D, Seixas M, Pimenta A, et al. 
Clinicopathological significance and survival influence of p53 protein expression 
in gastric carcinoma. Histopathology 2004;44(4):323-31. 
273. Shimada H, Hoshino T, Okazumi S, Matsubara H, Funami Y, Nabeya Y, et al. 
Expression of angiogenic factors predicts response to chemoradiotherapy and 
prognosis of oesophageal squamous cell carcinoma. Br J Cancer 2002;86(4):552-
7. 
201 
 
274. Giatromanolaki A, Stathopoulos GP, Koukourakis MI, Rigatos S, Vrettou E, 
Kittas C, et al. Angiogenesis and apoptosis-related protein (p53, bcl-2, and bax) 
expression versus response of gastric adenocarcinomas to paclitaxel and 
carboplatin chemotherapy. Am J Clin Oncol 2001;24(3):222-6. 
275. Diez M, Medrano MJ, Gutierrez A, Lopez A, Muguerza JM, Hernandez P, et 
al. P53 protein expression in gastric adenocarcinoma. Negative predictor of 
survival after postoperative adjuvant chemotherapy. Anticancer Res 
2000;20(5C):3929-33. 
276. Kikuyama S, Inada T, Shimizu K, Miyakita M, Ogata Y. p53, bcl-2 and 
thymidine phosphorylase as predictive markers of chemotherapy in patients with 
advanced and recurrent gastric cancer. Anticancer Res 2001;21(3C):2149-53. 
277. Hosaka N, Ichikawa Y, Ishikawa T, Nagashima Y, Kunisaki C, Takahashi M, 
et al. Correlation of immunohistochemical p53 labeling index with inhibition rate 
in chemosensitivity test in gastric and colon cancer. Anticancer Res 
2001;21(1A):229-35. 
278. Ikeguchi M, Saito H, Katano K, Gomyo Y, Tsujitani S, Maeta M, et al. 
Relationship between the long-term effects of intraperitoneal chemotherapy and 
the expression of p53 and p21 in patients with gastric carcinoma at stage IIIa and 
stage IIIb. Int Surg 1997;82(2):170-4. 
279. Berardo MD, Elledge RM, de Moor C, Clark GM, Osborne CK, Allred DC. 
bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer 
1998;82(7):1296-302. 
280. Palazzo JP, Kafka NJ, Grasso L, Chakrani F, Hanau C, Cuesta KH, et al. The 
role of p53, p21WAF1/C1PI, and bcl-2 in radioresistant colorectal carcinoma. 
Hum Pathol 1997;28(10):1189-95. 
281. Saleh HA, Jackson H, Khatib G, Banerjee M. Correlation of bcl-2 oncoprotein 
immunohistochemical expression with proliferation index and histopathologic 
parameters in colorectal neoplasia. Pathol Oncol Res 1999;5(4):273-9. 
282. Lu QL, Abel P, Foster CS, Lalani EN. bcl-2: role in epithelial differentiation 
and oncogenesis. Hum Pathol 1996;27(2):102-10. 
202 
 
283. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat 
Med 1997;3(6):614-20. 
284. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is 
an inner mitochondrial membrane protein that blocks programmed cell death. 
Nature 1990;348(6299):334-6. 
285. Aizawa K, Ueki K, Suzuki S, Yabusaki H, Kanda T, Nishimaki T, et al. 
Apoptosis and Bbcl-2 expression in gastric carcinomas: correlation 
withclinicopathological variables, p53 expression, cell proliferation and 
prognosis. Int J Oncol 1999;14(1):85-91. 
286. Leahy DT, Mulcahy HE, O'Donoghue DP, Parfrey NA. bcl-2 protein 
expression is associated with better prognosis in colorectal cancer. 
Histopathology 1999;35(4):360-7. 
287. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 
1998;281(5381):1322-6. 
288. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and 
oncogenesis. Oncogene 2003;22(53):8590-607. 
289. Cascinu S, Graziano F, Catalano V, Staccioli MP, Rossi MC, Baldelli AM, et 
al. An analysis of p53, BAX and vascular endothelial growth factor expression in 
node-positive rectal cancer. Relationships with tumour recurrence and event-free 
survival of patients treated with adjuvant chemoradiation. Br J Cancer 
2002;86(5):744-9. 
290. Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang HG, Reed JC. 
Immunohistochemical determination of in vivo distribution of Bax, a dominant 
inhibitor of Bcl-2. Am J Pathol 1994;145(6):1323-36. 
291. Smith FM, Reynolds JV, Miller N, Stephens RB, Kennedy MJ. Pathological 
and molecular predictors of the response of rectal cancer to neoadjuvant 
radiochemotherapy. Eur J Surg Oncol 2006;32(1):55-64. 
292. Yin XM, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are 
required for inhibition of apoptosis and heterodimerization with Bax. Nature 
1994;369(6478):321-3. 
203 
 
293. Yunis JJ, Mayer MG, Arnesen MA, Aeppli DP, Oken MM, Frizzera G. bcl-2 
and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J 
Med 1989;320(16):1047-54. 
294. Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, et al. High 
expression of bcl-2 protein in acute myeloid leukemia cells is associated with 
poor response to chemotherapy. Blood 1993;81(11):3091-6. 
295. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, 
et al. Expression of the protooncogene bcl-2 in the prostate and its association 
with emergence of androgen-independent prostate cancer. Cancer Res 
1992;52(24):6940-4. 
296. Bonetti A, Zaninelli M, Leone R, Cetto GL, Pelosi G, Biolo S, et al. bcl-2 but 
not p53 expression is associated with resistance to chemotherapy in advanced 
breast cancer. Clin Cancer Res 1998;4(10):2331-6. 
297. Daidone MG, Veneroni S, Benini E, Tomasic G, Coradini D, Mastore M, et al. 
Biological markers as indicators of response to primary and adjuvant 
chemotherapy in breast cancer. Int J Cancer 1999;84(6):580-6. 
298. Gasparini G, Bevilacqua P, Bonoldi E, Testolin A, Galassi A, Verderio P, et al. 
Predictive and prognostic markers in a series of patients with head and neck 
squamous cell invasive carcinoma treated with concurrent chemoradiation 
therapy. Clin Cancer Res 1995;1(11):1375-83. 
299. Homma A, Furuta Y, Oridate N, Nakano Y, Kohashi G, Yagi K, et al. 
Prognostic significance of clinical parameters and biological markers in patients 
with squamous cell carcinoma of the head and neck treated with concurrent 
chemoradiotherapy. Clin Cancer Res 1999;5(4):801-6. 
300. Costa A, Licitra L, Veneroni S, Daidone MG, Grandi C, Cavina R, et al. 
Biological markers as indicators of pathological response to primary 
chemotherapy in oral-cavity cancers. Int J Cancer 1998;79(6):619-23. 
301. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, 
Niskanen E, et al. Reduced expression of proapoptotic gene BAX is associated 
with poor response rates to combination chemotherapy and shorter survival in 
women with metastatic breast adenocarcinoma. Cancer Res 1995;55(19):4471-8. 
204 
 
302. Tai YT, Lee S, Niloff E, Weisman C, Strobel T, Cannistra SA. BAX protein 
expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol 
1998;16(8):2583-90. 
303. Silvestrini R, Daidone MG, Veneroni S, Benini E, Scarfone G, Zanaboni F, et 
al. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer 
in a prospective randomized treatment protocol. Cancer 1998;82(1):159-67. 
304. Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, et al. 
Immunobiochemical and molecular biologic characterization of the cell 
proliferation-associated nuclear antigen that is defined by monoclonal antibody 
Ki-67. Am J Pathol 1991;138(4):867-73. 
305. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle 
analysis of a cell proliferation-associated human nuclear antigen defined by the 
monoclonal antibody Ki-67. J Immunol 1984;133(4):1710-5. 
306. Xu L, Zhang SM, Wang YP, Zhao FK, Wu DY, Yan X. Relationship between 
DNA ploidy,expression of ki-67 antigen and gastric cancer metastasis. World J 
Gastroenterol 1999;5(1):10-11. 
307. Kakeji Y, Korenaga D, Tsujitani S, Baba H, Anai H, Maehara Y, et al. Gastric 
cancer with p53 overexpression has high potential for metastasising to lymph 
nodes. Br J Cancer 1993;67(3):589-93. 
308. Goishi H, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G, et al. 
Predictive value of cathepsin D and Ki-67 expression at the deepest penetration 
site for lymph node metastases in gastric cancer. Oncol Rep 2000;7(4):713-8. 
309. Kanai T, Konno H, Maruyama K, Baba M, Tanaka T, Maruo Y, et al. p53 
overexpression and proliferative activity do not correlate with lymph node 
metastasis in early gastric cancer. Eur Surg Res 1997;29(1):35-41. 
310. Yonemura Y, Ooyama S, Sugiyama K, Ninomiya I, Kamata T, Yamaguchi A, 
et al. Growth fractions in gastric carcinomas determined with monoclonal 
antibody Ki-67. Cancer 1990;65(5):1130-4. 
311. Kakeji Y, Korenaga D, Tsujitani S, Haraguchi M, Maehara Y, Sugimachi K. 
Predictive value of Ki-67 and argyrophilic nucleolar organizer region staining for 
lymph node metastasis in gastric cancer. Cancer Res 1991;51(13):3503-6. 
205 
 
312. Key G, Becker MH, Baron B, Duchrow M, Schluter C, Flad HD, et al. New Ki-
67-equivalent murine monoclonal antibodies (MIB 1-3) generated against 
bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair 
repetitive elements encoding for the Ki-67 epitope. Lab Invest 1993;68(6):629-
36. 
313. Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J, et al. 
Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 
and MIB 3) detect proliferating cells in microwave-processed formalin-fixed 
paraffin sections. J Pathol 1992;168(4):357-63. 
314. Gerdes J, Becker MH, Key G, Cattoretti G. Immunohistological detection of 
tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed 
tissues. J Pathol 1992;168(1):85-6. 
315. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, 
et al. Tumor vascular permeability factor stimulates endothelial cell growth and 
angiogenesis. J Clin Invest 1989;84(5):1470-8. 
316. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular 
endothelial growth factor is a secreted angiogenic mitogen. Science 
1989;246(4935):1306-9. 
317. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, et al. A 
novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 
(VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. Embo J 
1996;15(7):1751. 
318. Averbach AM, Jacquet P. Strategies to decrease the incidence of intra-
abdominal recurrence in resectable gastric cancer. Br J Surg 1996;83(6):726-33. 
319. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative 
resection for gastric carcinoma. Br J Surg 2000;87(2):236-42. 
320. Rustgi AK. Gastrointestinal cancers : biology, diagnosis, and therapy. 
Philadelphia: Lippincott-Raven, 1995. 
321. Harris AL. Antiangiogenesis for cancer therapy. Lancet 1997;349 Suppl 
2:SII13-5. 
206 
 
322. Gabbert HE, Muller W, Schneiders A, Meier S, Hommel G. The relationship of 
p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 
1995;76(5):720-6. 
323. Maehara Y, Oki E, Abe T, Tokunaga E, Shibahara K, Kakeji Y, et al. 
Overexpression of the heat shock protein HSP70 family and p53 protein and 
prognosis for patients with gastric cancer. Oncology 2000;58(2):144-51. 
324. Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana CD, Ellis LM. 
Significance of vessel count and vascular endothelial growth factor and its 
receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res 
1996;2(10):1679-84. 
325. Witte L, Hicklin DJ, Zhu Z, Pytowski B, Kotanides H, Rockwell P, et al. 
Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-
angiogenic therapeutic strategy. Cancer Metastasis Rev 1998;17(2):155-61. 
326. Duff SE, Li C, Jeziorska M, Kumar S, Saunders MP, Sherlock D, et al. 
Vascular endothelial growth factors C and D and lymphangiogenesis in 
gastrointestinal tract malignancy. Br J Cancer 2003;89(3):426-30. 
327. Takiuchi H, Hirata I, Kawabe S, Egashira Y, Katsu K. Immunohistochemical 
expression of vascular endothelial growth factor can predict response to 5-
fluorouracil and cisplatin in patients with gastric adenocarcinoma. Oncol Rep 
2000;7(4):841-6. 
328. Kabashima A, Maehara Y, Kakeji Y, Sugimachi K. Overexpression of vascular 
endothelial growth factor C is related to lymphogenous metastasis in early gastric 
carcinoma. Oncology 2001;60(2):146-50. 
329. Yonemura Y, Endo Y, Fujita H, Fushida S, Ninomiya I, Bandou E, et al. Role 
of vascular endothelial growth factor C expression in the development of lymph 
node metastasis in gastric cancer. Clin Cancer Res 1999;5(7):1823-9. 
330. Yonemura Y, Fushida S, Bando E, Kinoshita K, Miwa K, Endo Y, et al. 
Lymphangiogenesis and the vascular endothelial growth factor receptor 
(VEGFR)-3 in gastric cancer. Eur J Cancer 2001;37(7):918-23. 
331. Amioka T, Kitadai Y, Tanaka S, Haruma K, Yoshihara M, Yasui W, et al. 
Vascular endothelial growth factor-C expression predicts lymph node metastasis 
207 
 
of human gastric carcinomas invading the submucosa. Eur J Cancer 
2002;38(10):1413-9. 
332. Ichikura T, Tomimatsu S, Ohkura E, Mochizuki H. Prognostic significance of 
the expression of vascular endothelial growth factor (VEGF) and VEGF-C in 
gastric carcinoma. J Surg Oncol 2001;78(2):132-7. 
333. Takahashi A, Kono K, Itakura J, Amemiya H, Feng Tang R, Iizuka H, et al. 
Correlation of vascular endothelial growth factor-C expression with tumor-
infiltrating dendritic cells in gastric cancer. Oncology 2002;62(2):121-7. 
334. Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T. Correlation between 
expression of vascular endothelial growth factor and tumor vascularity, and 
patient outcome in human gastric carcinoma. J Clin Oncol 1997;15(2):826-32. 
335. Tomoda M, Maehara Y, Kakeji Y, Ohno S, Ichiyoshi Y, Sugimachi K. 
Intratumoral neovascularization and growth pattern in early gastric carcinoma. 
Cancer 1999;85(11):2340-6. 
336. Mise M, Arii S, Higashituji H, Furutani M, Niwano M, Harada T, et al. Clinical 
significance of vascular endothelial growth factor and basic fibroblast growth 
factor gene expression in liver tumor. Hepatology 1996;23(3):455-64. 
337. Samoto K, Ikezaki K, Ono M, Shono T, Kohno K, Kuwano M, et al. 
Expression of vascular endothelial growth factor and its possible relation with 
neovascularization in human brain tumors. Cancer Res 1995;55(5):1189-93. 
338. Itakura J, Ishiwata T, Friess H, Fujii H, Matsumoto Y, Buchler MW, et al. 
Enhanced expression of vascular endothelial growth factor in human pancreatic 
cancer correlates with local disease progression. Clin Cancer Res 
1997;3(8):1309-16. 
339. Thiele W, Sleeman JP. Tumor-induced lymphangiogenesis: a target for cancer 
therapy? J Biotechnol 2006;124(1):224-41. 
340. Guidi AJ, Schnitt SJ, Fischer L, Tognazzi K, Harris JR, Dvorak HF, et al. 
Vascular permeability factor (vascular endothelial growth factor) expression and 
angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 
1997;80(10):1945-53. 
208 
 
341. Ling FC, Leimbach N, Baldus SE, Buechel S, Neiss S, Brabender J, et al. HIF-
1alpha mRNA is not associated with histopathological regression following 
neoadjuvant chemoradiation in oesophageal cancer. Anticancer Res 
2006;26(6B):4505-9. 
342. Sohda M, Ishikawa H, Masuda N, Kato H, Miyazaki T, Nakajima M, et al. 
Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a 
useful and sensitive indicator of response to radiation and chemotherapy in 
oesophageal cancer. Int J Cancer 2004;110(6):838-44. 
343. Imdahl A, Bognar G, Schulte-Monting J, Schoffel U, Farthmann EH, Ihling C. 
Predictive factors for response to neoadjuvant therapy in patients with 
oesophageal cancer. Eur J Cardiothorac Surg 2002;21(4):657-63. 
344. Kulke MH, Odze RD, Mueller JD, Wang H, Redston M, Bertagnolli MM. 
Prognostic significance of vascular endothelial growth factor and cyclooxygenase 
2 expression in patients receiving preoperative chemoradiation for oesophageal 
cancer. J Thorac Cardiovasc Surg 2004;127(6):1579-86. 
345. Fukuda H, Takiguchi N, Koda K, Oda K, Seike K, Miyazaki M. Thymidylate 
synthase and dihydropyrimidine dehydrogenase are related to histological effects 
of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric 
cancer patients. Cancer Invest 2006;24(3):235-41. 
346. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory 
mechanisms, and cellular response. Oncologist 2004;9 Suppl 5:4-9. 
347. Wobser M, Siedel C, Schrama D, Brocker EB, Becker JC, Vetter-Kauczok CS. 
Expression pattern of the lymphatic and vascular markers VEGFR-3 and CD31 
does not predict regional lymph node metastasis in cutaneous melanoma. Arch 
Dermatol Res 2006;297(8):352-7. 
348. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 
2004;4(6):448-56. 
349. Lauria R, Perrone F, Carlomagno C, De Laurentiis M, Morabito A, Gallo C, et 
al. The prognostic value of lymphatic and blood vessel invasion in operable 
breast cancer. Cancer 1995;76(10):1772-8. 
209 
 
350. Kato T, Kameoka S, Kimura T, Nishikawa T, Kobayashi M. Blood vessel 
invasion as a predictor of long-term survival for Japanese patients with breast 
cancer. Breast Cancer Res Treat 2002;73(1):1-12. 
351. Jackson DG. Biology of the lymphatic marker LYVE-1 and applications in 
research into lymphatic trafficking and lymphangiogenesis. Apmis 2004;112(7-
8):526-38. 
352. Baluk P, McDonald DM. Markers for microscopic imaging of 
lymphangiogenesis and angiogenesis. Ann N Y Acad Sci 2008;1131:1-12. 
353. Banerji S, Ni J, Wang SX, Clasper S, Su J, Tammi R, et al. LYVE-1, a new 
homologue of the CD44 glycoprotein, is a lymph-specific receptor for 
hyaluronan. J Cell Biol 1999;144(4):789-801. 
354. Al-Rawi MA, Mansel RE, Jiang WG. Molecular and cellular mechanisms of 
lymphangiogenesis. Eur J Surg Oncol 2005;31(2):117-21. 
355. Rodriguez Santiago JM, Munoz E, Marti M, Quintana S, Veloso E, Marco C. 
Metastatic lymph node ratio as a prognostic factor in gastric cancer. Eur J Surg 
Oncol 2005;31(1):59-66. 
356. Giuliani A, Caporale A, Corona M, Di Bari M, Demoro M, Ricciardulli T, et al. 
Lymphadenectomy in gastric cancer: influence on prognosis of lymph node 
count. J Exp Clin Cancer Res 2004;23(2):215-24. 
357. Maehara Y, Orita H, Okuyama T, Moriguchi S, Tsujitani S, Korenaga D, et al. 
Predictors of lymph node metastasis in early gastric cancer. Br J Surg 
1992;79(3):245-7. 
358. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis 
and cancer metastasis. Nat Rev Cancer 2002;2(8):573-83. 
359. Adachi Y, Shiraishi N, Suematsu T, Shiromizu A, Yamaguchi K, Kitano S. 
Most important lymph node information in gastric cancer: multivariate prognostic 
study. Ann Surg Oncol 2000;7(7):503-7. 
360. Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, 
Kriehuber E, et al. Angiosarcomas express mixed endothelial phenotypes of 
blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic 
endothelium. Am J Pathol 1999;154(2):385-94. 
210 
 
361. Wigle JT, Oliver G. Prox1 function is required for the development of the 
murine lymphatic system. Cell 1999;98(6):769-78. 
362. Yokota T, Kunii Y, Saito T, Teshima S, Yamada Y, Iwamoto K, et al. 
Prognostic factors of gastric cancer tumours of less than 2 cm in diameter: 
rationale for limited surgery. Eur J Surg Oncol 2002;28(3):209-13. 
363. Lee HJ, Kim YH, Kim WH, Lee KU, Choe KJ, Kim JP, et al. 
Clinicopathological analysis for recurrence of early gastric cancer. Jpn J Clin 
Oncol 2003;33(5):209-14. 
364. Jackson DG, Prevo R, Clasper S, Banerji S. LYVE-1, the lymphatic system and 
tumor lymphangiogenesis. Trends Immunol 2001;22(6):317-21. 
365. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos C, Gatter KC, 
Harris AL, et al. LYVE-1 immunohistochemical assessment of 
lymphangiogenesis in endometrial and lung cancer. J Clin Pathol 
2005;58(2):202-6. 
366. Mouta Carreira C, Nasser SM, di Tomaso E, Padera TP, Boucher Y, Tomarev 
SI, et al. LYVE-1 is not restricted to the lymph vessels: expression in normal 
liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. 
Cancer Res 2001;61(22):8079-84. 
367. Jackson DG. The lymphatics revisited: new perspectives from the hyaluronan 
receptor LYVE-1. Trends Cardiovasc Med 2003;13(1):1-7. 
368. Prevo R, Banerji S, Ferguson DJ, Clasper S, Jackson DG. Mouse LYVE-1 is an 
endocytic receptor for hyaluronan in lymphatic endothelium. J Biol Chem 
2001;276(22):19420-30. 
369. Fujimoto A, Ishikawa Y, Akishima-Fukasawa Y, Ito K, Akasaka Y, Tamai S, et 
al. Significance of lymphatic invasion on regional lymph node metastasis in early 
gastric cancer using LYVE-1 immunohistochemical analysis. Am J Clin Pathol 
2007;127(1):82-8. 
370. Gao F, Lu YM, Cao ML, Liu YW, He YQ, Wang Y. Expression and 
quantification of LYVE-1 in human colorectal cancer. Clin Exp Med 
2006;6(2):65-71. 
211 
 
371. Charnsangavej C. New imaging modalities for follow-up of colorectal 
carcinoma. Cancer 1993;71(12 Suppl):4236-40. 
372. Dahab GM, Kheriza MM, El-Beltagi HM, Fouda AM, El-Din OA. Digital 
quantification of fibrosis in liver biopsy sections: description of a new method by 
Photoshop software. J Gastroenterol Hepatol 2004;19(1):78-85. 
373. Caballero T, Perez-Milena A, Masseroli M, O'Valle F, Salmeron FJ, Del Moral 
RM, et al. Liver fibrosis assessment with semiquantitative indexes and image 
analysis quantification in sustained-responder and non-responder interferon-
treated patients with chronic hepatitis C. J Hepatol 2001;34(5):740-7. 
374. Masseroli M, Caballero T, O'Valle F, Del Moral RM, Perez-Milena A, Del 
Moral RG. Automatic quantification of liver fibrosis: design and validation of a 
new image analysis method: comparison with semi-quantitative indexes of 
fibrosis. J Hepatol 2000;32(3):453-64. 
375. Baak JPA. Manual of quantitative pathology in cancer diagnosis and 
prognosis: Springer, 1991. 
376. Wu H-S, Einstein AJ. Image analysis in medical microscopy and pathology. 
Trivandrum: Research Signpost, 2007. 
377. Baak JP, Van Dop H, Kurver PH, Hermans J. The value of morphometry to 
classic prognosticators in breast cancer. Cancer 1985;56(2):374-82. 
378. Gratzner HG. Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: A 
new reagent for detection of DNA replication. Science 1982;218(4571):474-5. 
379. Howell WM, Black DA. Controlled silver-staining of nucleolus organizer 
regions with a protective colloidal developer: a 1-step method. Experientia 
1980;36(8):1014-5. 
380. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal 
antibody reactive with a human nuclear antigen associated with cell proliferation. 
Int J Cancer 1983;31(1):13-20. 
381. Polkowski W, Meijer GA, Baak JP, ten Kate FJ, Obertop H, Offerhaus GJ, et 
al. Reproducibility of p53 and Ki-67 immunoquantitation in Barrett's esophagus. 
Anal Quant Cytol Histol 1997;19(3):246-54. 
212 
 
382. Caspersson TO. History of the development of cytophotometry from 1935 to 
the present. Anal Quant Cytol Histol 1987;9(1):2-6. 
383. Lyon HO, Schulte EK, Prento P, Barer MR, Bene MC. Standardized staining 
methods: Feulgen-Rossenbeck reaction for desoxyribonucleic acid and periodic 
acid-Schiff (PAS) procedure. Biotech Histochem 2002;77(3):121-5. 
384. Ris H, Mirsky AE. Quantitative cytochemical determination of 
desoxyribonucleic acid with the Feulgen nucleal reaction. J Gen Physiol 
1949;33(2):125-46. 
385. Swift HH. The desoxyribose nucleic acid content of animal nuclei. Physiol 
Zool 1950;23(3):169-98. 
386. Tolles WE, Horvath WJ, Bostrom RC. A study of the quantitative 
characteristics of exfoliated cells from the female genital tract. II. Suitability of 
quantitative cytological measurements for automatic prescreening. Cancer 
1961;14:455-68. 
387. Prewitt JM, Mendelsohn ML. The analysis of cell images. Ann N Y Acad Sci 
1966;128(3):1035-53. 
388. Mango LJ. Computer-assisted cervical cancer screening using neural networks. 
Cancer Lett 1994;77(2-3):155-62. 
389. ten Kate TK, Belien JA, Smeulders AW, Baak JP. Method for counting mitoses 
by image processing in Feulgen stained breast cancer sections. Cytometry 
1993;14(3):241-50. 
390. Colley M, Kommoss F, Bibbo M, Dytch HE, Franklin WA, Holt JA, et al. 
Assessment of hormone receptors in breast carcinoma by immunocytochemistry 
and image analysis. II. Estrogen receptors. Anal Quant Cytol Histol 
1989;11(5):307-14. 
391. Chevallier M, Guerret S, Chossegros P, Gerard F, Grimaud JA. A histological 
semiquantitative scoring system for evaluation of hepatic fibrosis in needle liver 
biopsy specimens: comparison with morphometric studies. Hepatology 
1994;20(2):349-55. 
392. Duchatelle V, Marcellin P, Giostra E, Bregeaud L, Pouteau M, Boyer N, et al. 
Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months 
213 
 
later in patients with chronic hepatitis C: quantitative assessment by a 
morphometric method. J Hepatol 1998;29(1):20-8. 
393. Kage M, Shimamatu K, Nakashima E, Kojiro M, Inoue O, Yano M. Long-term 
evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitis 
C: morphometric analysis of repeated biopsies. Hepatology 1997;25(4):1028-31. 
394. O'Brien MJ, Keating NM, Elderiny S, Cerda S, Keaveny AP, Afdhal NH, et al. 
An assessment of digital image analysis to measure fibrosis in liver biopsy 
specimens of patients with chronic hepatitis C. Am J Clin Pathol 
2000;114(5):712-8. 
395. Pilette C, Rousselet MC, Bedossa P, Chappard D, Oberti F, Rifflet H, et al. 
Histopathological evaluation of liver fibrosis: quantitative image analysis vs 
semi-quantitative scores. Comparison with serum markers. J Hepatol 
1998;28(3):439-46. 
396. Wright M, Thursz M, Pullen R, Thomas H, Goldin R. Quantitative versus 
morphological assessment of liver fibrosis: semi-quantitative scores are more 
robust than digital image fibrosis area estimation. Liver Int 2003;23(1):28-34. 
397. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J 
Hepatol 1991;13(3):372-4. 
398. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. 
Histological grading and staging of chronic hepatitis. J Hepatol 1995;22(6):696-
9. 
399. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in 
chronic hepatitis C. Hepatology 2003;38(6):1449-57. 
400. Jimenez W, Pares A, Caballeria J, Heredia D, Bruguera M, Torres M, et al. 
Measurement of fibrosis in needle liver biopsies: evaluation of a colorimetric 
method. Hepatology 1985;5(5):815-8. 
401. Auger M, Katz RL, Johnston DA, Sneige N, Ordonez NG, Fritsche H. 
Quantitation of immunocytochemical estrogen and progesterone receptor content 
in fine needle aspirates of breast carcinoma using the SAMBA 4000 image 
analysis system. Anal Quant Cytol Histol 1993;15(4):274-80. 
214 
 
402. Baddoura FK, Cohen C, Unger ER, DeRose PB, Chenggis M. Image analysis 
for quantitation of estrogen receptor in formalin-fixed paraffin-embedded 
sections of breast carcinoma. Mod Pathol 1991;4(1):91-5. 
403. el-Badawy N, Cohen C, Derose PB, Check IJ, Sgoutas D. 
Immunohistochemical progesterone receptor assay. Measurement by image 
analysis. Am J Clin Pathol 1991;96(6):704-10. 
404. Santeusanio G, Mauriello A, Schiaroli S, Anemona L, Spagnoli LG, Scambia 
G, et al. Densitometric and morphometric study of immunocytochemical estrogen 
receptors detection in breast carcinomas. Pathol Res Pract 1992;188(4-5):478-83. 
405. Lopez-De Leon A, Rojkind M. A simple micromethod for collagen and total 
protein determination in formalin-fixed paraffin-embedded sections. J Histochem 
Cytochem 1985;33(8):737-43. 
406. Kockx MM, Muhring J, Knaapen MW, de Meyer GR. RNA synthesis and 
splicing interferes with DNA in situ end labeling techniques used to detect 
apoptosis. Am J Pathol 1998;152(4):885-8. 
407. Gao P, Zhou GY, Zhang QH, Xiang L, Zhang SL, Li C, et al. 
Clinicopathological significance of peritumoral lymphatic vessel density in 
gastric carcinoma. Cancer Lett 2008;263(2):223-30. 
408. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J 
Cell Physiol 2000;182(3):311-22. 
409. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition 
of apoptosis by survivin predicts shorter survival rates in colorectal cancer. 
Cancer Res 1998;58(22):5071-4. 
410. Lu CD, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, 
survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric 
carcinomas. Cancer Res 1998;58(9):1808-12. 
411. Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, et 
al. Expression of survivin correlates with apoptosis, proliferation, and 
angiogenesis during human colorectal tumorigenesis. Cancer 2001;91(11):2026-
32. 
215 
 
412. Sarbia M, Bittinger F, Porschen R, Dutkowski P, Torzewski M, Willers R, et al. 
The prognostic significance of tumour cell proliferation in squamous cell 
carcinomas of the oesophagus. Br J Cancer 1996;74(7):1012-6. 
413. Youssef EM, Matsuda T, Takada N, Osugi H, Higashino M, Kinoshita H, et al. 
Prognostic significance of the MIB-1 proliferation index for patients with 
squamous cell carcinoma of the esophagus. Cancer 1995;76(3):358-66. 
414. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis 
correlates with metastasis in invasive prostate carcinoma. Am J Pathol 
1993;143(2):401-9. 
415. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and 
metastasis--correlation in invasive breast carcinoma. N Engl J Med 
1991;324(1):1-8. 
416. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, et al. 
Quantification of angiogenesis in solid human tumours: an international 
consensus on the methodology and criteria of evaluation. Eur J Cancer 
1996;32A(14):2474-84. 
417. Vermeulen PB, Libura M, Libura J, O'Neill PJ, van Dam P, Van Marck E, et al. 
Influence of investigator experience and microscopic field size on microvessel 
density in node-negative breast carcinoma. Breast Cancer Res Treat 
1997;42(2):165-72. 
418. Nico B, Benagiano V, Mangieri D, Maruotti N, Vacca A, Ribatti D. Evaluation 
of microvascular density in tumors: pro and contra. Histol Histopathol 
2008;23(5):601-7. 
419. Maula SM, Luukkaa M, Grenman R, Jackson D, Jalkanen S, Ristamaki R. 
Intratumoral lymphatics are essential for the metastatic spread and prognosis in 
squamous cell carcinomas of the head and neck region. Cancer Res 
2003;63(8):1920-6. 
420. van der Schaft DW, Pauwels P, Hulsmans S, Zimmermann M, van de Poll-
Franse LV, Griffioen AW. Absence of lymphangiogenesis in ductal breast cancer 
at the primary tumor site. Cancer Lett 2007;254(1):128-36. 
216 
 
421. Shields JD, Borsetti M, Rigby H, Harper SJ, Mortimer PS, Levick JR, et al. 
Lymphatic density and metastatic spread in human malignant melanoma. Br J 
Cancer 2004;90(3):693-700. 
422. Gao P, Zhou GY, Yin G, Liu Y, Liu ZY, Zhang J, et al. Lymphatic vessel 
density as a prognostic indicator for patients with stage I cervical carcinoma. 
Hum Pathol 2006;37(6):719-25. 
423. Haley SM, Osberg JS. Kappa coefficient calculation using multiple ratings per 
subject: a special communication. Phys Ther 1989;69(11):970-4. 
424. Hale CA, Fleiss JL. Interval estimation under two study designs for kappa with 
binary classifications. Biometrics 1993;49(2):523-34. 
425. Landis JR, Koch GG. The measurement of observer agreement for categorical 
data. Biometrics 1977;33(1):159-74. 
426. Macdonald JS. Clinical overview: adjuvant therapy of gastrointestinal cancer. 
Cancer Chemother Pharmacol 2004;54 Suppl 1:S4-11. 
427. Hambraeus GM, Mercke CE, Willen R, Ranstam J, Samuelsson L, Lamm IL, et 
al. Prognostic factors influencing survival in combined radiotherapy and surgery 
of squamous cell carcinoma of the esophagus with special reference to a 
histopathologic grading system. Cancer 1988;62(5):895-904. 
428. Lewinski T, Morysinski T, Pietrow D, Sikora K. Preoperative radiotherapy 
combined with resection of squamous cell carcinoma of the mid-thoracic 
oesophagus. Does a histopathological malignancy grading system assess actual 
survival? Eur J Surg Oncol 1991;17(6):571-4. 
429. Tytgat GN, Bartelink H, Bernards R, Giaccone G, van Lanschot JJ, Offerhaus 
GJ, et al. Cancer of the esophagus and gastric cardia: recent advances. Dis 
Esophagus 2004;17(1):10-26. 
430. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the 
metabolic responses of living systems to pathophysiological stimuli via 
multivariate statistical analysis of biological NMR spectroscopic data. 
Xenobiotica 1999;29(11):1181-9. 
217 
 
431. Vogel SB, Mendenhall WM, Sombeck MD, Marsh R, Woodward ER. 
Downstaging of oesophageal cancer after preoperative radiation and 
chemotherapy. Ann Surg 1995;221(6):685-93; discussion 693-5. 
432. Forastiere AA, Heitmiller RF, Kleinberg L. Multimodality therapy for 
oesophageal cancer. Chest 1997;112(4 Suppl):195S-200S. 
433. Lackey VL, Reagan MT, Smith RA, Anderson WJ. Neoadjuvant therapy of 
squamous cell carcinoma of the esophagus: role of resection and benefit in partial 
responders. Ann Thorac Surg 1989;48(2):218-21. 
434. Urba S. Combined-modality treatment of oesophageal cancer. Oncology 
(Williston Park) 1997;11(9 Suppl 9):63-7. 
435. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, et al. 
Chemoradiotherapy followed by surgery compared with surgery alone in 
squamous-cell cancer of the esophagus. N Engl J Med 1997;337(3):161-7. 
436. Fink U, Stein HJ, Wilke H, Roder JD, Siewert JR. Multimodal treatment for 
squamous cell oesophageal cancer. World J Surg 1995;19(2):198-204. 
437. Keller SM, Ryan LM, Coia LR, Dang P, Vaught DJ, Diggs C, et al. High dose 
chemoradiotherapy followed by esophagectomy for adenocarcinoma of the 
esophagus and gastro-oesophageal junction: results of a phase II study of the 
Eastern Cooperative Oncology Group. Cancer 1998;83(9):1908-16. 
438. Daly LE, Bourke GJ. Interpretation and uses of medical statistics. 5th ed. 
Oxford: Blackwell Scientific, 2000. 
439. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. 
Formulation and application of a numerical scoring system for assessing 
histological activity in asymptomatic chronic active hepatitis. Hepatology 
1981;1(5):431-5. 
440. Ilson DH, Kelsen DP. Combined modality therapy in the treatment of 
oesophageal cancer. Semin Oncol 1994;21(4):493-507. 
441. Malkusch W, Rehn B, Bruch J. Advantages of Sirius Red staining for 
quantitative morphometric collagen measurements in lungs. Exp Lung Res 
1995;21(1):67-77. 
218 
 
442. Lin XZ, Horng MH, Sun YN, Shiesh SC, Chow NH, Guo XZ. Computer 
morphometry for quantitative measurement of liver fibrosis: comparison with 
Knodell's score, colorimetry and conventional description reports. J 
Gastroenterol Hepatol 1998;13(1):75-80. 
443. Blum A, Luedtke H, Ellwanger U, Schwabe R, Rassner G, Garbe C. Digital 
image analysis for diagnosis of cutaneous melanoma. Development of a highly 
effective computer algorithm based on analysis of 837 melanocytic lesions. Br J 
Dermatol 2004;151(5):1029-38. 
444. Puchtler H, Meloan SN, Waldrop FS. Are picro-dye reactions for collagens 
quantitative? Chemical and histochemical considerations. Histochemistry 
1988;88(3-6):243-56. 
445. Junquiera LC, Junqueira LC, Brentani RR. A simple and sensitive method for 
the quantitative estimation of collagen. Anal Biochem 1979;94(1):96-9. 
446. Mun SK, Elsayed AM, Tohme WG, Wu YC. Teleradiology/telepathology 
requirements and implementation. J Med Syst 1995;19(2):153-64. 
447. Rougier P, Mahjoubi M, Lasser P, Ducreux M, Oliveira J, Ychou M, et al. 
Neoadjuvant chemotherapy in locally advanced gastric carcinoma--a phase II trial 
with combined continuous intravenous 5-fluorouracil and bolus cisplatinum. Eur 
J Cancer 1994;30A(9):1269-75. 
448. Cascinu S, Frontini L, Comella G, Barni S, Labianca R, Battelli N, et al. 
Intensive weekly chemotherapy is not effective in advanced pancreatic cancer 
patients: a report from the Italian Group for the Study of Digestive Tract Cancer 
(GISCAD). Br J Cancer 1999;79(3-4):491-4. 
449. Wheater PR, Heath JW, Young B, Burkitt HG. Wheater's functional histology : 
a text and colour atlas. 3rd ed. Edinburgh: Churchill Livingstone, 1993. 
450. Reed JF, 3rd. Homogeneity of kappa statistics in multiple samples. Comput 
Methods Programs Biomed 2000;63(1):43-6. 
451. British Medical Informatics Society. Computer methods and programs in 
biomedicine. [Amsterdam]: Elsevier, 2000. 
219 
 
452. Bankman IN. Handbook of medical imaging processing and analysis. Academic 
Press series in biomedical engineering. San Diego, CA: Academic Press, 
2000:xvi, 901 p. 
453. Bland JM, Altman DG. Cronbach's alpha. BMJ 1997;314(7080):572. 
454. Shavelson RJ. Lee J. Cronbach. Proc Am Philos Soc 2003;147(4):379-85. 
 
  
220 
 
 
 
 
 
 
APPENDIX A:  
HISTOPATHOGOCIAL AND 
IMMUNOHISTOCHEMICAL TECHNIQUES 
USED IN THE THESIS 
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Haematoxylin and Eosin (H&E) 
It is a general tissue demonstration technique 449 performed to distinguish between 
nuclei, cytoplasm and different tissue fibres. In the laboratory at St Mary’s Hospital, 
London, United Kingdom, all routine H&E stains are carried out with the Leica 
automated stainer (Leica Microsystems (UK) Ltd, Bucks, United Kingdom). The 
reagents used are haematoxylin, 1% acid alcohol (1% hydrochloric acid in 70% 
alcohol), Scott’s water and eosin stock solution (10% eosin Y in tap water, diluted to 
1% with tap water). The haematoxylin is supplied pre-manufactured. 
The procedure for manual H&E staining is as follows: 
1. Sections are immersed in water, where the wax is removed first by 
immersing the tissue in Xylene, then alcohol, before placing the tissue in 
water. 
2. Nuclei are stained in Harris haematoxylin for 5 minutes, followed by 
washing in water and differentiating in 1% acid alcohol; 
3. After a good wash in water, the sections are ‘blued’ in Scott’s water. 
4. Sections are washed in water again, and then stained with 1% eosin Y for 5 
minutes; 
5. The slides are washed in water for the last time, dehydrated, cleared and 
mounted. This is done by immersing the slide sequentially in alcohol and 
Xylene, before placing some mountant on the section and then a cover-slip. 
The table below (Table 33) shows the changes which occur in the slides after 
being stained with H&E 
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Structures Colour stained 
Nuclei, keratohyalin, cytoplasmic RNA  Blue  
Some calcium salts, urates, bacteria (weakly)  Blue  
Cytoplasm  Pale pink  
Collagen, reticulin, myelinated nerve fibres, 
amyloid  Pink  
Muscle, keratin, elastic fibres, fibrin, 
fibrinoid  Bright red  
Red blood cells, eosinophil granules  Orange  
Table (32). Colour of structures stained with a haematoxylin and eosin 
 
 
Sirius Red staining 
The principle behind PSR staining is that Sirius Red binds to collagen in a 
stoichiometric manner. Fast Green acts as a counterstain. 0.1% Fast Green is made 
from 0.05 g Fast Green and 50 ml saturated aqueous picric acid. Fast Green is a 
suspected carcinogen, and picric acid is both explosive and toxic. 0.1% Sirius Red is 
made from 0.05 g Sirius Red and 50 ml saturated aqueous picric acid. 
The procedure for PSR staining is automated as follows: 
1. Take sections to water in the same manner as described for H&E staining; 
2. Stain in Fast Green for 2 seconds, then wash in distilled water, followed by 
staining in Sirius Red for 15 minutes; 
3. Blot and dry in a 60 °C oven without washing; 
4. Clear in Xylene and mount. 
 
Techniques used in tumour markers 
Endogenous peroxidase blocking 
This is performed prior to any immunohistochemical staining procedure.  
Endogenous peroxidases if left untreated, will react with the substrate solution 
(hydrogen peroxide and chromogen, e.g. DAB), leading to false positives. Cells 
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containing peroxidase include eosinophils and erythrocytes. The procedure of 
blocking endogenous peroxidase was done as follows: 
1. Two hundred and fifty ml ImmunoStainer Solution (IMS) + 10 ml 30% 
hydrogen peroxide solution are mixed in a dish where the solution is stirred to 
ensure adequate mixing. 
2. The slides are placed into the peroxidase block for 10 minutes, and then washed 
in tap water for 1 minute. 
Pressure cooking 
All the specimens were pressure cooked to unmask the antigen. This is done as 
follows: 
1. Prepare the citrate buffer in the pressure cooker, using distilled water (1980 
ml) + antigen retrieval buffer concentrate (citrate pH 6) (20 mls). Stir the 
solution to mix. 
2. The pressure cooker is heated, and slides are placed into the side-spaced 
metal racks after the mixture reaches boiling point, after which it is closed 
and being cooked at full pressure for 3 minutes. 
3. The cooker is placed into cold water sink, allowing steam to escape. Then, 
cooker is opened, with the addition of cold running water. 
4. The racks are removed and placed into tap water for 1 minute. 
 
Immunohistochemical staining of the used markers in the 
studies 
General processing for all the markers used 
Each antibody and/or protein was well-suited for immunohistochemical staining 
using automated platforms, such as the Dako Autostainer, which was used in the 
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processing. Heat mediated antigen retrieval was carried out prior to the application 
of the antibody. After thermal treatment, allow the racks with buffer and slides to 
cool for 20 - 30 minutes at room temperature. 
p53 staining technique 
This monoclonal rabbit serum antibody was purchased from Dako, United 
Kingdom: P53 antibody (clone 318-6-11; code M3629) and was pre-diluted (1 in 
25). The positive controls were supplied from previous cancers with positive 
staining for every batch processed. The slides were rinsed gently with de-ionized 
water. The tissue sections were kept moist during the treatment as well as during the 
following immunohistochemical staining procedure. The cellular staining pattern is 
nuclear. 
bcl-2 staining technique 
This monoclonal mouse anti-human bcl-2 oncoprotein was purchased from Dako, 
United Kingdom: bcl-2 oncoprotein (clone 124; code M0887), and was pre-diluted 
(1 in 100). The positive controls were supplied from tonsiller tissue with every batch 
stained. The cellular staining pattern is cytoplasmic. 
 
MIB-1 (Ki-67) staining technique 
This monoclonal mouse anti-human agent was purchased from Dako, United 
Kingdom: MIB-1 antigen (clone MIB-1; code M7240), and was pre-diluted (1 in 
100).  The positive controls were supplied from tonsiller tissue with every batch 
stained. Heat mediated antigen retrieval was carried out prior to the application of 
the antibody. The cellular staining pattern is nuclear. 
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VEGF staining technique 
This monoclonal mouse antibody was purchased from Abcam, Cambridge, United 
Kingdom: VEGF antibody (clone VG1; code: ab1316), and was pre-diluted (1 in 
50). The positive controls were supplied from placental tissue with every batch 
stained. Heat mediated antigen retrieval was carried out prior to the application of 
the antibody. The cellular staining pattern is cytoplasmic and/or membranous. 
 
CD-31 staining technique 
This monoclonal mouse antibody, was purchased from Abcam, Cambridge, United 
Kingdom: CD-31 (clone P2B1, code ab24590), and was pre-diluted (1 in 1000). The 
positive controls were supplied from appendicular tissue with every batch stained. 
Heat mediated antigen retrieval was carried out prior to the application of the 
antibody. The cellular staining pattern is membranous. 
 
D-240 (LYVE-1) staining technique 
This mouse monoclonal antibody, was purchased from Abcam, Cambridge, United 
Kingdom: D240 antibody (clone D2-40; code ab77854), and was pre-diluted (1 in 
40). The positive controls were supplied from appendicular tissue with every batch 
stained. The positive controls were supplied from appendicular tissue with every 
batch stained. After thermal treatment, the racks with slides and antibodies are 
incubated for 20 minutes at room temperature. 
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Kappa statistics 
A common example of a situation in which a researcher may want to assess 
agreement on a nominal scale is to determine the presence or absence of some 
disease or condition. This agreement could be determined in situations in which 2 
researchers or clinicians have used the same examination tool or different tools to 
determine the diagnosis. One way of evaluating the agreement between 2 clinicians 
is to calculate overall percentage of agreement (calculated over all paired ratings) or 
effective percentage of agreement (calculated over those paired ratings where at least 
one clinician diagnoses the presence of the disease). Although these calculations 
provide a measure of agreement, neither takes into account the agreement that would 
be expected purely by chance. If clinicians agree purely by chance, they are not 
really "agreeing" at all; only agreement beyond that expected by chance can be 
considered "true" agreement. This has been the main reason that Kappa was taken 
into account in this study, as Kappa is such a measure of "true" agreement 450. It 
indicates the proportion of agreement beyond that expected by chance, that is, the 
achieved beyond-chance agreement as a proportion of the possible beyond-chance 
agreement 438. It takes the form: 
𝑘𝑘 =  𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂 𝑎𝑎𝑎𝑎𝑂𝑂𝑂𝑂𝑂𝑂𝑎𝑎𝑂𝑂𝑎𝑎𝑎𝑎 − 𝐶𝐶ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑂𝑂 𝑎𝑎𝑎𝑎𝑂𝑂𝑂𝑂𝑂𝑂𝑎𝑎𝑂𝑂𝑎𝑎𝑎𝑎1 − 𝐶𝐶ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑂𝑂 𝑎𝑎𝑎𝑎𝑂𝑂𝑂𝑂𝑂𝑂𝑎𝑎𝑂𝑂𝑎𝑎𝑎𝑎  
  
 
Canonical Discriminant analysis 
This type of analysis is closely related to ANOVA (analysis of variance) and 
regression analysis, which also attempts to express one dependent variable as a 
linear combination of other features or measurements. However, the dependent 
variable is a numerical quantity, while for discriminant analysis, it is a categorical 
variable, as the situation here with the classes of Mandard regression system. 
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Discriminant analysis is also closely related to principal component analysis (PCA) 
and factor analysis in that both look for linear combinations of variables which best 
explain the data. Linear discriminant analysis (LDA) explicitly attempts to model 
the difference between the classes of data. PCA on the other hand does not take into 
account any difference in class, and factor analysis builds the feature combinations 
based on differences rather than similarities. Discriminant analysis is also different 
from factor analysis in that it is not an interdependence technique: a distinction 
between independent variables and dependent variables (also called criterion 
variables) must be made 438 451. 
 
Intraclass correlation coefficient and Cronbach’s α statistics 
In statistics, the intraclass correlation (or the intraclass correlation coefficient, 
abbreviated ICC) is a descriptive statistic that can be used when quantitative 
measurements are made of units that are organised into groups. While it is viewed as 
a type of correlation, unlike most other correlation measures it operates on data 
structured as groups, rather than data structured as paired observations. The 
intraclass correlation is commonly used to assess the consistency or reproducibility 
of quantitative measurements made by different observers measuring the same 
quantity 438 452. 
Cronbach's α (alpha) is a statistic that is commonly used as a measure of the internal 
consistency reliability of a psychometric instrument. It was first named as alpha by 
Lee Cronbach in 1951, and this category of the statistical testing would measures 
how well a set of variables or items measures a single, unidimensional latent 
construct 453. 
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Cronbach's alpha will generally increase when the correlations between the items 
increase. For this reason the coefficient is also called the internal consistency or the 
internal consistency reliability of the test. Cronbach's alpha measures how well a set 
of items (or variables) measures a single unidimensional latent construct. When data 
have a multidimensional structure, Cronbach's alpha will usually be low. 
Technically speaking, Cronbach's alpha is considered to be a coefficient of 
reliability (or consistency). Cronbach's alpha can be written as a function of the 
number of test items and the average inter-correlation among the items 454 
 
